



Feidhmeannacht na Seirbhíse Sláinte
Health Service Executive

Primary Care Reimbursement Service

STATISTICAL ANALYSIS OF
CLAIMS AND PAYMENTS 2009

**Feidhmeannacht na Seirbhíse Sláinte
Seirbhís Aisíoca Príomhchúraim**

Bealach amach 5 an M50
An Bóthar Thuaidh
Fionnghlas
Baile Átha Cliath 11

Guthán: (01) 864 7100
Facs: (01) 834 3589

Ríomhphost: pburke.office@hse.ie
Láithreán Gréasáin: www.hse.ie

**Health Service Executive
Primary Care Reimbursement Service**

Exit 5 M50
North Road
Finglas
Dublin 11

Ph: (01) 864 7100
Fax: (01) 834 3589

email: pburke.office@hse.ie
Website: www.hse.ie



Feidhmeannacht na Seirbhíse Sláinte
Health Service Executive

Primary Care Reimbursement Service

STATISTICAL ANALYSIS OF CLAIMS AND PAYMENTS

2009

Contents Summary of Statistical Analysis

Page		Page		Page	
4	Introduction	16	Payments to Dentists	24	Summary of Statistical Information – GMS Scheme
6	Community Based Services – Payment Arrangements	17	Volume of Claims by Dentists	25	Summary of Statistical Information – LTI/DP Schemes
8	Summary Statement of Activity During the Year	18	Payments to Optometrists/Ophthalmologists	26	Fees and Allowances under Capitation Agreement
9	The Year 2009	19	Volume of Treatment by Optometrists/Ophthalmologists	27	Fees and Allowances under Fee-Per-Item Agreement and Fees under the Immunisation Scheme, Health (Amendment) Act 1996 and Methadone Treatment Scheme
10	Number of Agreements	20	Cost Per Person	28	Scale of Fees Payable to Pharmacists
11	Persons Eligible for Services	21	Major Therapeutic Classification of Drugs, Medicines and Appliances – GMS Scheme	29	Scale of Fees Payable to Dentists
12	Payments to Doctors	22	Major Therapeutic Classification of Drugs, Medicines and Appliances – DP Scheme	30	Scale of Fees Payable to Optometrists/Ophthalmologists
13	Volume of Claims by Doctors	23	Major Therapeutic Classification of Drugs, Medicines and Appliances – LTI Scheme		
14	Payments to Pharmacies				
15	Volume of Claims by Pharmacies				

Contents Detailed Statistical Analysis

Page	Table		Page	Table		Page	Table	
34	1	Summary of Statistical Information	60	14	GMS: Visiting Rate Categories for Doctors on Fee-Per-Item of Service	92	19.8	HTD: The Products of the Highest Cost in the Order of their Total Ingredient Cost
35	1.1	Summary of Statistical Information	61	15	GMS: Cost of Medicines by Gender within Age Groups	95	20	GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
36	2	Number of Agreements	63	16	GMS: Number of Prescription Forms and Items	100	20.1	DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
37	3	GMS: Payments to Doctors	64	16.1	GMS: Payment to Pharmacists in Respect of Prescriptions	105	20.2	LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
38	4	GMS: Cost of Prescriptions	65	16.2	GMS: Number of Items on Prescription Forms	110	20.3	HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
39	5	GMS: Cost of Stock Order Forms	66	16.3	DP: Number of Items on Claim Forms	113	21	GMS: Average Payment to Doctors in Panel Ranges
40	6	DTS: Payments to Dentists	67	16.4	LTI: Number of Items on Claim Forms	114	21.1	GMS: Number of Doctors in Payment Ranges
41	7	GMS: Payment per Person	68	17	GMS: Number of Dispensing Doctors and Persons for whom they Dispense	115	22	GMS: Number of Pharmacists in Dispensing Fee Ranges
42	8	GMS: Number of Doctors in Eligible Person Cost Categories	69	18	GMS: Advance Payments to Pharmacists	116	23	DP: Number of Eligible Persons and Number and Cost of Pharmacists Claims
43	9	GMS: Number of Eligible Persons	70	19	Notes on some of the more Commonly Prescribed Products	117	23.1	DP: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
44	9.1	GMS: Number of Eligible Persons by Gender within Age Groups	71	19.1	GMS: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency	118	24	LTI: Number of Eligible Persons and Number and Cost of Pharmacists Claims
46	9.2	GMS: Percentage of Eligible Persons by Mileage Allocation	74	19.2	GMS: The Products of the Highest Cost in the Order of their Total Ingredient Cost	119	24.1	LTI: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
47	9.3	GPVC: Number of Eligible Persons	77	19.3	DP: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency	120	25	EEA: Number and Cost of Pharmacists Claims
48	9.4	GPVC: Number of Eligible Persons by Gender within Age Groups	80	19.4	DP: The Products of the Highest Cost in the Order of their Total Ingredient Cost	121	26	DTS: Number of Treatments
50	10	GMS: Size of Panels of Doctors	83	19.5	LTI: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency	122	26.1	DTS: Number of Dentists in Payment Ranges
51	11	GMS: Payment to Doctors in each Health Service Executive Area	86	19.6	LTI: The Products of The Highest Cost in the Order of their Total Ingredient Cost	123	27	HSE-COS: Number and Cost of Treatments and Cost of Claims
52	12	GMS: Number of Special Type Consultations and Out-of-Hours Claims	89	19.7	HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency	124	27.1	HSE-COS: Number of Optometrists/ Ophthalmologists in Payment Ranges
53	12.1	GMS: Payment to Doctors for Special Type Consultations and Out-of-Hours Claims				125	28	GMS: Investment in General Practice Development
54	13	GMS: Analysis of Special Items of Service						
55	13.1	GMS: Analysis of Special Items of Service by Health Service Executive Area						

Introduction

The Primary Care Reimbursement Service (PCRS) supports the delivery of primary health care by providing reimbursement services to Primary Care Contractors (General Practitioners, Pharmacists, Dentists and Optometrists/Ophthalmologists), for the provision of health services to members of the public in their own community.

In 2009 over 2.69 million people used the services of Primary Care Contractors for which reimbursement was provided by the PCRS. Over 73 million transactions, with an associated expenditure of more than €2.642 billion, were processed by PCRS during the year. With the current national and international economic climate it is anticipated that demand on these services will continue to grow.

The Demand Led Schemes are the state funded General Practitioner, Pharmacy, Dental, Ophthalmic, and other special payments which account for approximately 18% of the HSE's overall budget. The Schemes are – the General Medical Services (GMS) (i.e. Medical Cards/GP Visit Cards), Drugs Payment, Long Term Illness, Dental Treatment Services, European Economic Area, High Tech Drugs, Primary Childhood Immunisation, Health (Amendment) Act 1996, Methadone Treatment and HSE Community Ophthalmic Services.

In November 2009 the PCRS took over executive responsibility for the Demand Led Primary Care Schemes nationally. This new responsibility includes approval, review and reimbursement of all claims for services and refunds and overall responsibility for all associated budgets. While executive responsibility has transferred to PCRS, the transition and streamlining of the Schemes is taking place over a phased period so that the project can be continuously monitored and evaluated, and if required modified to deliver optimal results, for both the patients and the HSE.

Recent Trends

The current economic climate continues to present challenges for service moving forward. Expenditure budgets are being reduced and the number of people on the Live Register continues to grow, with associated increased uptake of the Demand Led Schemes.

Since January 2005 the number of eligible medical card holders has increased by some 322,833. The rate of increase has been particularly acute in this scheme in 2009, with an additional 126,440 eligible persons granted Medical Cards, an increase of 9.35% over 2008. As of 31st December 2009, the total number of eligible Medical Card holders was 1,478,560, which is approximately 35% of the total population. There is also sustained growth in the number of Long Term Illness items claimed in 2009, up 8.02% against 2008.

Expenditure has also continued to grow, up by more than 6.15% from 2008 to 2009 (€2.642 billion compared with €2.489 billion).

Outlook

The sharp growth in numbers eligible for services is expected to continue throughout 2010 and funding to meet this level of demand is not assured, resulting in a challenging environment for service providers in terms of both finance and human resources. Continued focus will be given to driving further efficiencies in order to address these challenges.

The specific Value for Money (VfM) projects set out previously to ensure continued efficiencies have moved apace during 2009 with the major project to centralise the processing of all Medical Cards being one of the primary focuses in this area.

In 2008, the Government introduced a new Medical Card Scheme for persons aged 70 years and over. The processing of applications under the new scheme was centralised to the national office at PCRS in January 2009.

Later on in the year the second phase of the centralisation project commenced. This phase involved transferring the processing of renewals and applications for medical cards from the North West Dublin and Dublin North Central Local Health Offices to the Central Office at the PCRS.

The next phase of the project is to go live and process all new applications in the Central Office from a given date following a consultative process with staff representatives and in line with the recent agreement on pay and reform in the public service. This phase also includes the introduction of a national on-line Medical Card application process. Taking cognisance of the fact that this is a critical change project which must move ahead, there are many benefits accruing in the final phase, e.g. better customer service, full implementation on a given date will provide more clarity to all concerned (Clients, TDs, Primary Care Contractors, HSE staff etc.), will free up staff for redeployment to key frontline services more quickly, and will result in the provision of better Customer Relations Management services to the patient.

In the period since the central office started working on this project, a significant number of patient and staff friendly initiatives have been introduced. As the centralisation process continues, more initiatives will be introduced. The current initiatives will continue to be enhanced as we receive feedback and continue to engage closer with advocacy groups, staff and public representative and primary care contractors to provide improved services to patients in a more efficient way.

Significant progress has been made to date in this national project in providing an improved service to the public at less cost to the State. By the end of 2009 the centralised office at PCRS has, in addition to providing new customer focused initiatives and delivering all of its normal workload, processed over 68,681 Medical Card applications and reviews.

In addition to the changes introduced and the processing and making of payments on a national basis to General Practitioners, Pharmacists, Dentists and Optometrists/Ophthalmologists, the PCRS continues to compile statistics and trend analyses which are provided to customers, the Government, stakeholders, members of the public and other areas within the HSE.

I would like to take this opportunity to once again thank everybody in the organisation for their important individual contribution and commitment, and their team efforts, in the delivery of these vital support services through a year in which significant change management was also taking place.

This dedication and commitment ultimately enables members of the public to access the health services that they need in their own community. I would also like to acknowledge the contribution of the Chief Executive Officer, the Directors and the support of the HSE Board throughout 2009.

The goodwill and co-operation received from all of our customers, General Practitioners, Pharmacists, Dentists and Optometrists/Ophthalmologists, is very much appreciated. I look forward to continuing to build on our success and striving to improve the services to our customers even further.

Patrick Burke

Primary Care Reimbursement Service

Community Based Services – Payment Arrangements

Almost all payments for services provided in the community by General Practitioners, Community Pharmacies, Dentists and Optometrists/Ophthalmologists are made by the Primary Care Reimbursement Service. Payments in the Year 2009 were in excess of €2.642bn. Estimated payments by the Primary Care Reimbursement Service for 2010 are €2.543bn

Claim data is processed and payments are made by the Primary Care Reimbursement Service under the following Schemes/Payment Arrangements:

General Medical Services (GMS)

Persons who are unable without undue hardship to arrange general practitioner medical and surgical services for themselves and their dependants.

Drugs, medicines and appliances supplied under the Scheme are provided through Community Pharmacies. In most cases the Doctor gives a completed prescription form to a person, who takes it to any pharmacy that has an agreement with the Health Service Executive to dispense GMS prescription forms. In rural areas the Doctor may dispense for those persons who opt to have their medicines dispensed by him/her. All GMS claims are processed and paid by the Primary Care Reimbursement Service.

Drugs Payment Scheme (DPS)

Under the Drugs Payment Scheme persons who are ordinarily resident in the State and who do not have a current medical card can benefit – an individual or family has now to pay no more than €100 in a calendar month for approved drugs, medicines and appliances for themselves or their families. In order to benefit under this Scheme a person must register themselves and their dependants with their Local Health Office. Items currently reimbursable under the Drugs Payment Scheme are those listed on the HSE Website. Other items which were reimbursable under the DCS and Refund of Drugs Schemes continue, in certain circumstances, to be reimbursable under the Drugs Payment Scheme. DPS claims are processed and paid by the Primary Care Reimbursement Service.

Long Term Illness Scheme (LTI)

On approval by the Health Service Executive persons who suffer from one or more of a schedule of illnesses are entitled to obtain, without charge, irrespective of income, necessary drugs/medicines and/or appliances under the LTI Scheme. All LTI claims are processed and paid by the Primary Care Reimbursement Service.

Dental Treatment Services Scheme (DTSS)

Under the Dental Treatment Services Scheme GMS eligible adults have access to a range of treatments and clinical procedures comprised of Routine Treatments and Full Upper and Lower Dentures. Routine Treatments are now available for all eligible persons. Dentists may also prescribe a range of medicines to eligible persons. All claims under the DTSS are processed and paid by the Primary Care Reimbursement Service.

European Economic Area (EEA)

Residents from one of the other states of the European Economic Area, with established eligibility, who require emergency general practitioner services while on a temporary visit to the State are entitled to receive from a General Practitioner a GMS prescription form for necessary medication and to have such medication dispensed in a Pharmacy that has entered into an agreement with the Health Service Executive within the State. EEA claims are paid by the Primary Care Reimbursement Service.

High Tech Drugs (HTD)

Arrangements are in place for the supply and dispensing of High Tech medicines through Community Pharmacies. Such medicines are generally only prescribed or initiated in hospital and would include items such as anti-rejection drugs for transplant patients or medicines used in conjunction with chemotherapy or growth hormones. The medicines are purchased by the Health Service Executive and supplied through Community Pharmacies for which Pharmacists are paid a patient care fee: the cost of the medicines and patient care fees are paid by the Primary Care Reimbursement Service.

Primary Childhood Immunisation Scheme

A National Primary Childhood Immunisation Scheme provides for immunisation of the total child population with the aim of eliminating, as far as possible, such conditions as Diphtheria, Polio, Measles, Mumps, Rubella and more recently Meningococcal C Meningitis. Payments under this Scheme to Doctors in the Midland, Mid-Western, Southern and Western HSE Areas are made by the Primary Care Reimbursement Service.

Health (Amendment) Act 1996

Under the Health (Amendment) Act 1996 certain health services are made available without charge to persons who have contracted Hepatitis C directly or indirectly from the use of Human Immunoglobulin - Anti D or the receipt within the State of another blood product or blood transfusion. General Practitioner services, pharmaceutical services, dental services and optometric/ophthalmic services

provided under the Act are paid for by the Primary Care Reimbursement Service.

Methadone Treatment Scheme

Methadone is prescribed and dispensed by Doctors and Pharmacists for approved clients under the Methadone Treatment Scheme – capitation fees payable to participating Doctors and Community Pharmacists and claims by pharmacies for the ingredient cost of the Methadone dispensed and the associated dispensing fees are processed and paid by the Primary Care Reimbursement Service.

Health Services Executive Community Ophthalmic Services Scheme (HSE-COS)

Under the Health Service Executive Community Ophthalmic Services Scheme, adult medical card holders and their dependants are entitled, free of charge, to eye examinations and necessary spectacles/appliances. Claims by Optometrists/Ophthalmologists are paid by the Primary Care Reimbursement Service. Claims for spectacles provided under the Children's Scheme are also paid by the Primary Care Reimbursement Service.

Immunisations for certain GMS Eligible Persons

Agreement was reached between the Department of Health & Children and the Irish Medical Organisation on fee rates to be applied to certain immunisations for GMS eligible persons. The immunisations encompassed by the agreement are:- Pneumococcal, Influenza, Hepatitis B and the combined Pneumococcal/Influenza. The Health

Service Executive facilitated claiming for any of these immunisations by extending the range of codes for 'Special Items of Service'.

General Practitioner Visit Card (GPVC)

Certain people in Ireland who do not qualify for a medical card may apply to the Health Service Executive for a GP Visit Card. GP Visit Cards allow individuals and families who qualify, to visit their General Practitioner for free. All GP claims are processed and paid by the Primary Care Reimbursement Service.


Discretionary Hardship Arrangements

Medical Card patients, for whom Non GMS Reimbursable Items have been prescribed, may make application to the HSE Local Health Office (LHO) for approval to have such items dispensed by a Community Pharmacist. Previously, the LHO reimbursed Community Pharmacists directly in respect of such prescribed items. In July 2009 the payment function for these items transferred to the PCRS.

Summary Statement of Activity During the Year

- Payments in the Year were in excess of €2,642.99m.
- Claim data is processed and payments are made by the PCRS under the following Schemes:
 - General Medical Services (GMS);
 - Drugs Payment (DP);
 - Long Term Illness (LTI);
 - Dental Treatment Services (DTS);
 - European Economic Area (EEA);
 - High Tech Drugs (HTD);
 - Primary Childhood Immunisation;
 - Health (Amendment) Act 1996;
 - Methadone Treatment;
 - Health Service Executive Community Ophthalmic Services (HSE-COS).
- At year end there were more than 3.29m persons registered as being eligible to benefit under the General Medical Services, Drugs Payment, Long Term Illness, Dental Treatment and Health Service Executive Community Ophthalmic Services Schemes.
- More than 94% of eligible GMS persons availed of GP, Pharmaceutical, Dental or Ophthalmic services provided by more than 6,418 Doctors, Pharmacists, Dentists and Optometrists/Ophthalmologists.
- More than 67m prescription items were paid for by the PCRS – an increase of over 2.3m items on 2008.
- Fees and allowances paid to Doctors totalled €499.67m.
- Payments to Pharmacies totalled €1,694.73m:
 - GMS €1,260.24m;
 - DP €263.47m;
 - LTI €139.76m;
 - EEA €1.96m;
 - Patient Care Fees under the HTD Scheme €15.94m;
 - The Health (Amendment) Act 1996, Methadone Treatment Scheme, DTS prescriptions and Pharmacy Training Grants €13.36m.
- Payments to Dentists under the DTS totalled €86.83m.
- Payments to Optometrists/Ophthalmologists under the HSE-COS totalled €23.80m.
- Payments to Wholesalers under the HTD Scheme totalled €315.36m.
- Administration costs in the accounting period of 2009 were €19.72m.
- Claims processed are in respect of services provided in the community and availed of by almost 63.66% of the population.

The Year 2009



- Fees to Doctors include an amount of €9.84m in respect of the Primary Childhood Immunisation Scheme, €0.22m in respect of the Health (Amendment) Act 1996, €6.03m in respect of the Methadone Treatment Scheme.
- Allowances paid to Doctors include an amount of €5.54m paid as superannuation to Retired District Medical Officers and their dependants.
- Payments to Pharmacists include an amount of €1.80m in respect of drugs/medicines dispensed under the Health (Amendment) Act 1996, an amount of €10.56m in respect of the cost of Methadone dispensed under the Methadone Treatment Scheme and an amount of €0.79m in respect of DTS prescriptions.
- Payments to Dentists include an amount of €62,114 in respect of treatments under the Health (Amendment) Act 1996.
- Payments to Optometrists/Ophthalmologists, include an amount of €72,238 in respect of treatments under the Health (Amendment) Act 1996.
- The corresponding figures for 2008 are:-
 - Total of Payments €2,489.38m.
 - Doctors' Fees €338.57m and Doctors' Allowances €136.60m.
 - Pharmacists' Fees and Mark-Up €408.29m, Drugs and Medicines €1,204.96m.
- Payments to Dentists under the DTS Scheme were €65.42m.
- Payments to Optometrists/Ophthalmologists €22.40m.
- Investment in General Practice Development was €4.60m.
- High Tech Drugs Scheme – Payment to Wholesalers €275.39m, Patient Care Fees €15.28m.
- Administration €17.87m.

Number of Agreements

Doctors 2,663	Pharmacists 1,630	Dentists 1,570	Optometrists 555
---------------	-------------------	----------------	------------------

The number of agreements between The Health Service Executive and General Practitioners for the provision of services to GMS persons reflects the policy position agreed between the Department of Health & Children and the Irish Medical Organisation on entry to the GMS. In December 2009 there were 2,663 such agreements.

Number of Agreements as at 31st December 2009

Health Service Executive	Doctors	Pharmacists	Dentists	Optometrists
East Coast Area	283	141	125	41
South West Area	343	203	189	76
Northern Area	298	189	160	50
Midland	151	100	76	46
Mid-Western	234	149	136	45
North Eastern	193	150	103	62
North Western	159	98	78	33
South Eastern	264	181	152	65
Southern	452	251	341	70
Western	286	168	210	67
National	*2,663	#1,630	+ 1,570	555
Corresponding figures for 2008	2,599	1,620	1,349	535

**527 GPs who do not hold GMS agreements and who were registered as providing services under the Primary Childhood Immunisation Scheme, the Health (Amendment) Act 1996, Heartwatch and the Methadone Treatment Scheme at year end are included above.*

#12 Pharmacies who do not hold GMS agreements and who were registered as providing services under non GMS schemes at year end are included above.

+188 Dentists who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.

Persons Eligible for Services

GMS 1,478,560	GPVC 98,325	DP 1,587,448	LTI 127,636
----------------------	--------------------	---------------------	--------------------

Persons who are unable without undue hardship to arrange General Practitioner medical and surgical services plus dental and optometric services for themselves and their dependants are provided with such services free of charge under the GMS Scheme. An eligible person is entitled to select a Doctor of his/her choice, from among those Doctors who have entered into agreements with the Health Service Executive. Drugs, medicines and appliances prescribed by participating Doctors for their GMS patients are provided through Community Pharmacies. Dental and ophthalmic services are provided by Dentists and Optometrists/Ophthalmologists who have contracted with the Health Service Executive. GMS prescription forms may be dispensed in any Pharmacy that has an agreement with the Health Service Executive to dispense GMS prescription forms. In rural areas, where a Doctor has a centre of practice three miles or more from the nearest Community Pharmacy participating in the Scheme, the Doctor dispenses for those persons served from the centre who opt to have

their medicines dispensed by him/her. The number of eligible GMS persons at year end included 44,839 persons who were entitled and had opted to have their medicines dispensed by their GPs.

Under the terms of the Drugs Payment Scheme persons who do not have a medical card may apply for a Drugs Payment Scheme card on an individual or on a family unit basis. Prescribed medicines, which are reimbursable under the GMS, costing in excess of a specified amount per month, currently €100 per family, is claimed by the Pharmacy and is paid by the Primary Care Reimbursement Service.

On approval by the Health Service Executive, persons who suffer from one or more of a schedule of illnesses are entitled to obtain, without charge, irrespective of income, necessary drugs/medicines and/or appliances under the LTI Scheme. The Primary Care Reimbursement Service makes payments on behalf of the Health Service Executive for LTI claims submitted by Pharmacies.

Number of Eligible Persons as at 31st December 2009

Health Service Executive	GMS	GPVC	DP	LTI
Eastern Areas	408,060	18,052	539,188	63,906
Midland	95,925	6,543	101,708	7,453
Mid-Western	131,955	7,718	159,029	8,647
North Eastern	141,500	11,366	147,811	10,241
North Western	117,908	9,157	63,000	7,207
South Eastern	189,845	13,789	149,983	13,602
Southern	220,608	19,882	266,122	9,259
Western	172,759	11,818	160,607	7,321
National	1,478,560	98,325	1,587,448	127,636
% of Population	34.87%	2.32%	37.44%	3.01%
Corresponding figures for 2008	1,352,120	85,546	1,624,413	120,407

GMS – General Medical Services Scheme. **GPVC** – GP Visit Card Scheme. **DP** – Drugs Payment Scheme. **LTI** – Long Term Illness Scheme.

Fees €357.80m

Payments to General Practitioners are categorised as fees and/or allowances. For the majority of GPs who operate under the 1989 agreement the principle fee is the capitation per person which is weighted for gender, age and distance from a Doctor's centre of practice – capitation fees totalled €225,954,778 in 2009 – a decrease of €4,908,112 on 2008. Fees totalling €769,487 were paid to 10 GPs who continue to provide services under the Fee-Per-Item of service agreements.

Apart from 'Out-of-Hours' fees and fees for a range of special services the cost of services provided in normal hours by GPs for GMS persons, including the prescribing of necessary medicines, is encompassed by the capitation fee. All GMS persons can avail of full GP services and in many cases they can benefit from specialist clinics provided by GPs for issues such as Women's Health, Family Planning and Asthma.

In addition to a capitation fee an outside normal hours fee is payable for non routine consultations when an eligible GMS person is seen

Allowances €141.87m

by their GP or another GP acting on his/her behalf from 5pm in the evening to 9am on the following morning (Monday to Friday) and all hours on Saturdays, Sundays and Bank Holidays. The number of 'Out-of-Hours' claims increased to 837,143 in 2009 compared with 817,691 in 2008 – and the cost of such claims increased to €49,507,291 from €46,401,447 in 2008. Special fees are payable for a range of 18 services such as excisions, suturing, vaccinations, catheterization, family planning etc. The most frequent claimed special service in 2009 was Influenza Vaccination (349,890) followed by Excisions (103,183) and E.C.G. treatments (76,757) – there was a total of more than 713,658 special services provided in 2009 – special fees totalling €28,653,853 were paid in 2009.

Annual and Study Leave together with locum, nursing and secretarial support plus other practice support payments account for most of the €141,865,756 allowances paid in the year. The total paid in 2008 was €136,600,570.

Total of Payments to Doctors by Health Service Executive


Health Service Executive	2009
East Coast Area	€30,608,922
South West Area	€55,875,871
Northern Area	€49,996,553
Midland	€33,533,961
Mid-Western	€43,749,789
North Eastern	€45,304,954
North Western	€37,720,543
South Eastern	€61,771,075
Southern	€81,990,163
Western	€59,113,528
National	€499,665,359
Corresponding figure for 2008	€475,174,715

Total Payments accumulated by Regional Health Area	
Dublin North East	€95,301,507
Dublin Mid-Leinster	€120,018,754
South	€143,761,238
West	€140,583,860

The total of payments to Doctors includes payments of: €9,844,411 under the Primary Childhood Immunisation Scheme; €217,499 to Doctors who provided services under the Health (Amendment) Act 1996; Heartwatch €1,538,150; National Cancer Screening Service €15,295,162 and €6,032,984 under the Methadone Treatment Scheme.

Volume of Claims by Doctors

National – Number of Claims – 2009



Number of Claims in each Health Service Executive Area

Health Service Executive	Fee-Per-Item	Special Type	Special Service	Out-of-Hours
East Coast Area	-	11,630	44,013	32,706
South West Area	20,230	34,671	66,827	81,815
Northern Area	3,621	27,793	63,792	45,482
Midland	-	22,184	50,157	68,574
Mid-Western	14,480	25,367	59,184	69,117
North Eastern	-	16,317	58,436	10,169
North Western	-	14,855	59,780	68,358
South Eastern	2,976	22,553	94,588	135,943
Southern	18,325	52,624	117,688	215,184
Western	-	33,890	99,193	109,795
National	59,632	261,884	713,658	837,143
Corresponding figures for 2008	67,083	242,073	679,948	817,691

A majority of Doctors are paid an annual capitation fee for each eligible person – the rate of payment is determined by the age/gender of the person and distance between each person’s residence and the centre of practice of their Doctor-of-Choice. A minority of Doctors (10) who have continued to provide services under the Fee-Per-Item of Service agreement are paid a fee for each Doctor/Patient contact.

A Special Type Consultation (STC) fee is payable when a GMS eligible person is unable to contact their registered Doctor and is seen as an emergency case by another. General Practitioners qualify for payment of ‘special fees’ for the special items of service separately identified under the Capitation agreement and the Fee-Per-Item agreement.

Payments to Pharmacies

GMS €1,260.24m

DP €263.47m

LTI €139.76m

EEA €1.96m

A GMS person who is provided with a properly completed GMS prescription form by his/her GP can choose to have such prescription forms dispensed in any of the Pharmacies who have entered into agreements with the Health Service Executive for the provision of services under Section 59 of the Health Act, 1970.

In 2009 there were 16.3m prescription forms containing over 50m prescription items dispensed at a cost of over €1,260,244,615 i.e. an average cost of €24.56 per dispensed item. More than 94% of all eligible GMS persons were prescribed for in the year. The average cost of medicines per GMS person in 2009 was €907.85.

Payments made to Pharmacies under the GMS and DTS Schemes are inclusive of the ingredient cost of medicines, dispensing fees and VAT.

Under DP, LTI and EEA Schemes Pharmacies are reimbursed the ingredient cost of items dispensed, dispensing fees, mark-up and VAT. For details please see page 28.

The cost of the High Tech Drugs Scheme was €331.29m – at year end there were 53,515 persons registered under this Scheme – Patient Care Fees totalled €15.94m and payments for drugs and medicines totalled €315.36m.

In the year the Health Service Executive processed claims valued at €441.93m on drugs acting on the ‘cardiovascular system’ (GMS €291.07, DP €120.97m and LTI €29.89m). The second highest cost category was drugs acting on the ‘nervous system’ €360.29m (GMS €268.53m, DP €72.28m, LTI €19.48m). The third highest amount paid was for drugs acting on the ‘alimentary tract and metabolism system’ €299.47m (GMS €194.94m, DP €65.56m, LTI €38.97m).

Total of Payments to Pharmacies by Health Service Executive

Health Service Executive	GMS €	DP €	LTI €	*EEA €
East Coast Area	79,438,939	26,567,370	15,830,612	72,098
South Western Area	143,609,194	42,370,859	21,601,891	112,322
Northern Area	142,601,176	38,960,741	23,491,235	73,396
Midland	86,460,595	15,954,793	8,003,509	106,003
Mid-Western	115,957,501	20,067,259	8,608,387	231,847
North Eastern	108,692,171	21,739,038	12,947,603	139,049
North Western	80,798,442	8,722,729	8,994,083	242,507
South Eastern	163,291,281	25,373,805	14,174,555	199,920
Southern	201,087,419	40,040,494	16,577,276	433,731
Western	138,307,897	20,131,101	9,530,021	346,740
National	1,260,244,615	259,928,189	139,759,172	1,957,613
Corresponding figures for 2008	€1,145,291,632	€311,898,446	€137,898,995	€2,245,995

Total Payments accumulated by Regional Health Area

	GMS €	DP €	LTI €	*EEA €
Dublin North East	251,293,347	60,699,779	36,438,838	212,445
Dublin Mid-Leinster	309,508,728	84,893,022	45,436,012	290,423
South	364,378,700	65,414,299	30,751,831	633,651
West	335,063,840	48,921,089	27,132,491	821,094

*EEA – Payment to Pharmacies to cover the cost of GMS prescriptions dispensed for residents from the European Economic Area.


Pharmacies were also paid in respect of the drugs/medicines dispensed under: Health (Amendment) Act 1996 – €1,801,926; Methadone Treatment Scheme – €10,558,156; DTS Scheme – €786,133; Pharmacy Training Grant – €213,110 and Patient Care Fees totalling €15,938,159 under the High Tech Drugs Scheme (Payments to Wholesalers under the High Tech Drugs Scheme amounted to €315,355,866).

Included in the above GMS figures is an amount of €3,684,770 which was paid in respect of non GMS Reimbursable Items dispensed under Discretionary Hardship Arrangements.

In 2009 The National Maternity Hospital was paid €1,118,797 and The Rotunda Hospital was paid €2,427,120 in respect of Fertility Treatment. These figures are not included in the above table.

Volume of Claims by Pharmacies

National – Number of Items – 2009



GMS prescription forms processed for payment in the year totalled 16.3m – the total of prescribed items was more than 50.7m – these accounted for approximately 74.78% of all items paid for by the Primary Care Reimbursement Service in 2009.

Approximately 38.08% of GMS forms contained a single item – more than 19.06% contained 2 items – the average number of items per form was 3.11 (2008 – 3.08).

GMS dispensed items paid for by the Primary Care Reimbursement Service in 2009 increased by more than 2,510,056 – the decrease in the number of DP items was less than 534,913 – the overall increase in the number of pharmacy claims processed by the Primary Care Reimbursement Service in the year was more than 2.3m.

Number of Items in each Health Service Executive Area

Health Service Executive	GMS	DP	LTI	EEA	HTD	*Other
East Coast Area	3,252,646	1,370,170	309,292	3,069	31,387	38,819
South West Area	5,995,036	2,037,467	473,330	5,111	50,400	124,711
Northern Area	5,683,891	1,886,789	428,838	3,509	39,763	108,820
Midland	3,464,279	846,125	172,423	4,609	22,431	18,434
Mid-Western	4,783,532	1,080,867	188,257	10,139	29,475	23,093
North Eastern	4,423,611	1,172,765	265,117	5,407	29,703	23,304
North Western	3,211,631	461,296	184,643	10,878	23,654	7,967
South Eastern	6,546,461	1,421,492	313,172	8,732	39,991	28,683
Southern	8,093,563	2,038,348	328,991	19,539	54,503	36,104
Western	5,267,269	1,057,206	191,298	14,527	36,058	23,366
National	50,721,919	13,372,525	2,855,361	85,520	357,365	433,301
Corresponding figures for 2008	48,211,863	13,907,438	2,643,424	91,822	315,256	395,697

*This group includes: 63,379 claim items in respect of the Health (Amendment) Act 1996; 259,486 items under the Methadone Treatment Scheme and 110,436 prescription items under the DTS Scheme.

GMS – General Medical Services Scheme. **DP** – Drugs Payment Scheme. **LTI** – Long Term Illness Scheme. **EEA** – European Economic Area. **HTD** – High Tech Drugs Scheme. **Other** – Methadone Treatment Scheme, Health (Amendment) Act 1996 and Dental Treatment Services Scheme.

Payments to Dentists

Above the line €60.63m

Dentists were paid a total of €86,772,492 in 2009, in respect of treatments provided for more than 343,067 GMS persons under the DTS Scheme.

The following treatments were available to all eligible GMS persons.

ROUTINE: Routine treatments are categorised as either 'Above the Line' or 'Below the Line';

'Above the Line' treatments are uncomplicated procedures viz. Amalgam; Extractions;

'Below the Line' treatments are advanced procedures viz. Protracted Periodontal; Prosthetics.

Below the line €26.15m

'Below the Line' treatments – prior Health Service Executive approval for a specific course of treatment under this category is required. Full denture treatment is available, with prior Health Service Executive approval, to all edentulous GMS persons over 16 years.

Payments to Dentists in each Health Service Executive Area

Health Service Executive	2009
Eastern Areas	€22,497,276
Midland	€5,611,711
Mid-Western	€7,432,999
North Eastern	€7,990,868
North Western	€4,805,003
South Eastern	€11,598,690
Southern	€15,045,005
Western	€11,790,940
National	€86,772,492
Corresponding figure for 2008	€65,364,364


Total Payments accumulated by Regional Health Area

Dublin North East	€17,146,142
Dublin Mid-Leinster	€18,953,713
South	€26,643,695
West	€24,028,942

Dentists were also paid a total of €62,114 in 2009 in respect of treatments under the Health (Amendment) Act 1996.

Volume of Claims by Dentists

National – Volume of Treatments – 2009



Volume of Treatments by Dentists in each Health Service Executive Area

Health Service Executive	+Above the Line	+Below the Line	No. of persons treated under DTS
Eastern Areas	402,760	29,986	90,772
Midland	89,879	10,060	22,281
Mid-Western	119,984	15,466	30,997
North Eastern	127,435	14,711	30,330
North Western	84,965	6,108	22,219
South Eastern	177,103	23,680	43,678
Southern	258,768	24,635	60,277
Western	178,537	20,521	42,513
National	1,439,431	145,167	343,067
Corresponding figures for 2008	1,084,517	111,428	271,731

ROUTINE – Routine treatments are categorised as either 'Above the Line' or 'Below the Line':

'Above the Line' (ATL) treatments are uncomplicated procedures;

'Below the Line' (BTL) treatments are advanced procedures.

+ The most frequently used ATL service was Amalgam Restoration, which was used by 148,575 patients followed by Oral Examination. In the BTL category the most frequently used service was Prosthetics followed by Protracted Periodontal and Radiographs.

Payments to Optometrists/Ophthalmologists

Under the Health Service Executive Community Ophthalmic Services Scheme, Optometric/Ophthalmic services are provided to adult medical card holders, which include free eye examinations and necessary spectacles/appliances.

Payments in respect of spectacles provided under the Children's Scheme are also made by the Primary Care Reimbursement Service on behalf of the majority of Health Service Executive Areas.

Payments in respect of eye examinations and necessary spectacles/appliances are provided under the Teenager's Scheme for eligible medical card holders on behalf of certain Health Service Executive Areas.

In the 12-month period to the end of December 2009 claims were received on behalf of 238,844 GMS persons for 564,606 treatments costing €22,184,541.

Eye examinations by Optometrists/Ophthalmologists totalled 242,336; complete spectacles (distance, reading and bi-focals) provided under the Scheme totalled 322,270. The balance of treatments included replacement lenses and frames, tinted lenses, prisms and contact lenses. A breakdown of treatments and payments in each Health Service Executive Area is shown hereunder.

Payments to Optometrists/Ophthalmologists in each Health Service Executive Area


Health Service Executive	2009
Eastern Areas	€6,204,743
Midland	€1,647,247
Mid-Western	€2,111,555
North Eastern	€1,553,308
North Western	€1,638,602
South Eastern	€3,247,259
Southern	€3,464,502
Western	€2,317,325
National	€22,184,541
Corresponding figure for 2008	€20,997,766

Total Payments accumulated by Regional Health Area	
Dublin North East	€3,508,064
Dublin Mid-Leinster	€5,897,233
South	€6,711,762
West	€6,067,482

Opticians were also paid in respect of: Health (Amendment) Act 1996 €72,238; Optical services for Teenagers €195,744; Optical services for Children €1,348,185.

Volume of Treatments by Optometrists/Ophthalmologists

National – Volume of Treatments – 2009




Volume of Treatments by Optometrists/Ophthalmologists in each Health Service Executive Area

Health Service Executive	Eye Exams	Appliances	Volume of Treatments	No. of Persons Treated
Eastern Areas	67,626	84,744	152,370	65,184
Midland	17,461	23,092	40,553	16,678
Mid-Western	22,435	31,870	54,305	22,793
North Eastern	16,870	23,483	40,353	17,517
North Western	19,122	24,898	44,020	19,413
South Eastern	34,548	50,731	85,279	36,115
Southern	38,894	48,732	87,626	35,941
Western	25,380	34,720	60,100	25,203
National	242,336	322,270	564,606	238,844
Corresponding figures for 2008	225,403	304,879	530,282	222,567

Cost per Person

National 2009



Cost per Person in each Health Service Executive Area

Health Service Executive	GMS			LTI	DP	DTS	HSE-COS
	Doctor Cost €	Pharmacy Cost €	Total Cost €	Pharmacy Cost €	Net Cost Per Claimant €	Per Person Treated €	Per Adult Treated €
Eastern Areas	334.39	896.72	1,231.11	2,243.64	442.50	247.84	95.16
Midland	349.89	943.28	1,293.17	2,010.43	377.56	251.86	98.77
Mid-Western	331.55	936.25	1,267.80	1,855.26	349.58	239.80	92.64
North Eastern	320.18	884.91	1,205.09	2,173.88	358.62	263.46	88.67
North Western	319.92	787.19	1,107.11	2,212.57	349.37	216.23	84.41
South Eastern	325.38	908.98	1,234.36	2,020.89	364.80	265.55	89.91
Southern	371.65	975.65	1,347.30	2,100.78	383.07	249.60	96.39
Western	342.17	900.00	1,242.17	1,894.64	335.73	277.35	91.95
National	€337.94	€907.85	€1,245.79	€2,126.23	€391.97	€252.93	€92.88
Corresponding figures for 2008	€352.67	€932.63	€1,285.30	€2,191.17	€453.61	€240.55	€94.34


The Doctor cost above does not include superannuation paid to retired DMOs.

The above table shows the actual cost per person in respect of those who availed of services under each Scheme in 2009.

Medical and pharmaceutical services delivered to GMS persons decreased in cost from €1,285.30 in 2008 to €1,245.79 in 2009 a decrease of €39.51 per person – the cost of medical services per person decreased in cost from €352.67 in 2008 to €337.94 a decrease of 4.18% – the cost per person of pharmaceutical services decreased from €932.63 in 2008 to €907.85 in 2009 a decrease of 2.66%.

Major Therapeutic Classification of Drugs, Medicines and Appliances – General Medical Services Scheme


National 2009



Major Therapeutic Classification	€m	%
A Alimentary Tract and Metabolism	194.94	15.47
B Blood and Blood Forming Organs	56.99	4.52
C Cardiovascular System	291.07	23.10
D Dermatologicals	23.29	1.85
G Genito Urinary System and Sex Hormones	48.13	3.82
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins	13.46	1.07
J Anti-infectives for Systemic Use	40.27	3.19
L Antineoplastic and Immunomodulating Agents	11.32	0.90
M Musculo-Skeletal System	72.75	5.77
N Nervous System	268.53	21.31
P Antiparasitic Products, Insecticides and Repellents	1.02	0.08
R Respiratory System	117.19	9.30
S Sensory Organs	22.85	1.81
V Clinical Nutritional Products	44.13	3.50
Diagnostic Products	22.25	1.77
Ostomy Appliances	13.26	1.05
Urinary Appliances	7.02	0.56
Needles/Syringes/Lancets	5.24	0.41
Other Therapeutic Products	2.66	0.21
Dressings	1.65	0.13
Allergens	0.00	0.00
Miscellaneous	2.23	0.18
Total	€1,260.25m	100%

Major Therapeutic Classification of Drugs, Medicines and Appliances – Drugs Payment Scheme

National 2009




Major Therapeutic Classification	€m	%
A Alimentary Tract and Metabolism	65.56	14.52
B Blood and Blood Forming Organs	17.06	3.78
C Cardiovascular System	120.97	26.78
D Dermatologicals	16.48	3.65
G Genito Urinary System and Sex Hormones	27.16	6.01
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins	4.67	1.03
J Anti-infectives for Systemic Use	17.04	3.77
L Antineoplastic and Immunomodulating Agents	6.52	1.44
M Musculo-Skeletal System	27.50	6.09
N Nervous System	72.28	16.00
P Antiparasitic Products, Insecticides and Repellents	1.62	0.36
R Respiratory System	50.67	11.22
S Sensory Organs	5.75	1.27
V Clinical Nutritional Products	8.15	1.80
Ostomy Appliances	5.46	1.21
Urinary Appliances	1.89	0.42
Diagnostic Products	1.33	0.29
Dressings	0.37	0.08
Needles/Syringes/Lancets	0.34	0.08
Other Therapeutic Products	0.45	0.10
Allergens	0.10	0.02
Miscellaneous	0.34	0.08
Total	€451.71m	100%

Note: The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.

Major Therapeutic Classification of Drugs, Medicines and Appliances – Long Term Illness Scheme

National 2009



Major Therapeutic Classification	€m	%
A Alimentary Tract and Metabolism	38.97	27.88
B Blood and Blood Forming Organs	3.41	2.44
C Cardiovascular System	29.89	21.38
D Dermatologicals	0.15	0.11
G Genito Urinary System and Sex Hormones	1.61	1.15
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins	0.81	0.58
J Anti-infectives for Systemic Use	1.87	1.34
L Antineoplastic and Immunomodulating Agents	0.08	0.06
M Musculo-Skeletal System	0.64	0.46
N Nervous System	19.48	13.94
P Antiparasitic Products, Insecticides and Repellents	0.00	0.00
R Respiratory System	0.67	0.48
S Sensory Organs	0.30	0.21
V Diagnostic Products	25.27	18.09
Clinical Nutritional Products	6.58	4.71
Needles/Syringes/Lancets/Swabs	7.42	5.31
Urinary Appliances	1.23	0.88
Nutritional/Ancillary Devices	0.58	0.41
Dressings	0.22	0.16
Ostomy Appliances	0.18	0.13
Other Therapeutic Products	0.09	0.06
Miscellaneous	0.31	0.22
Total	€139.76m	100%

Summary of Statistical Information relating to the GMS Scheme for each of the five years 2005-2009

	2009	2008	2007	2006	2005
Number of Eligible Persons in December	1,478,560	1,352,120	1,276,178	1,221,695	1,155,727
Doctors	(000's)	(000's)	(000's)	(000's)	(000's)
Total Payments	€466,737	€459,476	€427,418	€391,029	€403,071
Doctors' Payment per Person	€337.94	€352.67	€349.03	€314.85	€343.35
Pharmacies	(000's)	(000's)	(000's)	(000's)	(000's)
Total Cost of Prescriptions	€1,245,935	€1,129,494	€1,032,178	€924,995	€816,304
Ingredient Cost	€962,305	€881,425	€824,323	€743,943	€653,251
Dispensing Fee	€257,968	€225,697	€188,163	€163,537	€147,860
VAT	€25,662	€22,372	€19,692	€17,516	€15,193
Number of Forms	16,333	15,648	14,780	13,932	13,227
Number of Items	50,722	48,212	44,358	40,569	37,428
Cost per Form	€76.28	€72.18	€69.84	€66.39	€61.71
Cost per Item	€24.56	€23.43	€23.27	€22.80	€21.81
Ingredient Cost per Item	€18.97	€18.28	€18.58	€18.34	€17.45
Items per Form	3.11	3.08	3.00	2.91	2.83
	(000's)	(000's)	(000's)	(000's)	(000's)
Total Cost of Stock Orders	€14,309	€15,797	€16,231	€15,230	€15,139
Ingredient Cost	€11,044	€12,188	€12,559	€11,777	€11,714
Pharmacy Fees	€2,761	€3,047	€3,140	€2,944	€2,927
VAT	€504	€562	€532	€509	€498
	(000's)	(000's)	(000's)	(000's)	(000's)
Overall Cost of Medicines	€1,260,244	€1,145,292	€1,048,409	€940,225	€831,443
*Pharmacy Payment per Person	€907.85	€932.63	€856.14	€809.04	€750.04
	(000's)	(000's)	(000's)	(000's)	(000's)
Overall Payments	€1,726,981	€1,604,768	€1,475,827	€1,331,254	€1,234,514
*Overall Payment per Person	€1,245.79	€1,285.30	€1,205.17	€1,123.89	€1,093.39

Doctors' payment per person is exclusive of superannuation paid to retired DMOs.

* These figures are based on the actual number of persons who availed of services.

Summary of Statistical Information relating to the LTI /DP Schemes for each of the five years 2005-2009

	2009	2008	2007	2006	2005
LTI Scheme					
Number of Eligible Persons in December	127,636	120,407	112,580	106,307	99,280
*Number of Claimants	65,731	62,934	59,040	53,082	53,006
	(000's)	(000's)	(000's)	(000's)	(000's)
Number of Items	2,855	2,643	2,353	2,165	1,929
Total Cost	€139,759	€137,899	€124,458	€115,461	€100,547
Cost per Item	€48.95	€52.17	€52.90	€53.32	€52.12
*Cost per Claimant	€2,126.23	€2,191.17	€2,108.03	€2,175.15	€1,896.89
DP Scheme					
Number of Eligible Persons in December	1,587,448	1,624,413	1,583,738	1,525,657	1,478,650
*Number of Claimants	663,127	687,587	667,782	597,835	526,052
	(000's)	(000's)	(000's)	(000's)	(000's)
Number of Items	13,373	13,907	13,430	11,872	10,582
Gross Cost	€451,707	€506,806	€491,186	€442,924	€388,021
Net Cost	€259,928	€311,898	€307,334	€283,108	€244,486
Gross Cost per Item	€33.78	€36.44	€36.57	€37.31	€36.67
*Net Cost per Claimant	€391.97	€453.61	€460.23	€473.56	€464.76

* These figures are based on the actual number of persons who availed of services under each Scheme.

Fees and Allowances under Capitation Agreement as at 31st December 2009

Ages	Up to 3 Miles		3-5 Miles		5-7 Miles		7-10 Miles		Over 10 Miles	
	Male €	Female €	Male €	Female €	Male €	Female €	Male €	Female €	Male €	Female €
Under 5 years	76.98	75.09	81.07	79.19	87.11	85.27	93.09	91.25	100.48	98.63
5-15	44.68	45.19	46.38	46.88	48.87	49.43	51.29	51.81	54.33	54.80
16-44	57.03	93.26	59.23	95.46	62.49	98.70	65.68	101.37	69.60	105.81
45-64	113.91	125.17	119.19	130.45	126.98	138.21	134.65	145.93	144.22	155.43
65-69	120.00	133.87	134.67	148.56	156.46	170.34	177.85	191.75	204.46	218.37

Above rates inclusive of supplementary Out-of-Hours Fee.

The Capitation rate is €280.31 per annum for persons aged 70 years and over in the community issued with a medical card.

A Capitation rate of €896.07 per annum will apply to anyone aged 70 years and over in a private nursing home (approved by the Health Service Executive) for continuous periods in excess of five weeks.

* Special Items of Service.

- (i) Excisions/Cryotherapy/ Diathermy of Skin Lesions.
- (ii) Suturing of Cuts and Lacerations.
- (iii) Draining of Hydroceles.
- (iv) Treatment and Plugging of Dental and Nasal Haemorrhages.
- (v) Recognised Vein Treatment.
- (vi) ECG Tests and their Interpretation.
- (vii) Instruction in the fitting of a Diaphragm.
- (viii) Removal of Adherent Foreign Bodies from the Conjunctival Surface of the Eye.
- (ix) Removal of Lodged or Impacted Foreign Bodies from the Ear, Nose and Throat.
- (x) Nebuliser Treatment in the case of Acute Asthmatic Attack.
- (xi) Bladder Catheterization.
- (xii) Attendance at case conferences (in cases where such are convened by the HSE).
- (xiii) Advice and Fitting of a Diaphragm.
- (xiv) Counselling and Fitting of an IUCD.
- (xv) Pneumococcal Vaccination.
- (xvi) Influenza Vaccination.
- (xvii) Pneumococcal/Influenza Vaccination.
- (xviii) Hepatitis B Vaccination.

Out-of-Hours Payment	
Surgery	€46.59
Domiciliary	
Up to 3 miles	€46.59
3-5 miles	€62.17
5-7 miles	€69.98
7-10 miles	€77.68
Over 10 miles	€93.24
Additional Fee	€36.37

*Special Items of Service	
(i) to (ix)	€29.14
(x) and (xi)	€43.73
(xii)	€72.88
(xiii)	€49.05
(xiv)	€78.49
(xv) and (xvi)	€42.75
(xvii)	€64.12
(xviii)	€154.13
+ Mileage	

Temporary Residents	
Surgery	€46.59
Domiciliary	
Up to 3 miles	€46.59
3-5 miles	€62.17
5-7 miles	€69.98
7-10 miles	€77.68
Over 10 miles	€93.24
Rural Dispensing Fee	€15.41
Fee for Second Medical Opinion	€31.09

Practice Payments for Rural Areas	
Rural Practice Allowance	
Per Annum	€19,055.31

Practice Support	
Allowance for Practice Secretary up to a maximum Per Annum of	€25,591.70
Allowance for Practice Nurse up to a maximum Per Annum of	€40,215.55
Allowance for Practice Manager up to a maximum Per Annum of	€32,903.63

Contributions to Locum Expenses (Subject to the conditions of the Agreement)	
Annual Leave	Up to a maximum of €1,622.39 per week
Sick Leave	Up to a maximum of €1,622.39 per week
Study Leave	
Adoptive Leave	Up to a maximum of €231.77 per day
Maternity Leave	
Paternity Leave	

Contributions to Medical Indemnity Insurance	
Calculation of contribution is related to GMS panel numbers and net premium.	

Asylum Seekers	
A one off superannuable registration fee of €179.25 per relevant patient will be paid to Doctors in respect of each such patient on their GMS Scheme panels.	

Fees and Allowances under the Fee-Per-Item Agreement and Fees under the Immunisation Scheme, Health (Amendment) Act 1996 and Methadone Treatment Scheme as at 31st December 2009

Surgery Consultations		
Day	Normal Hours	€12.83
Late	Outside Normal Hours other than (Night)	€18.25
Night	Midnight to 8.00 a.m.	€36.09
Domiciliary Consultations		
Day	Normal Hours	
	Urban	€18.93
	Up to 3 miles	€18.93
	3-5 miles	€24.79
	5-7 miles	€33.30
	7-10 miles	€41.76
Late	Over 10 miles	€52.22
	Outside Normal Hours	
	Urban	€24.79
	Up to 3 miles	€24.79
	3-5 miles	€32.08
	5-7 miles	€41.76
Night	7-10 miles	€55.48
	Over 10 miles	€65.05
	Midnight to 8.00 a.m.	
	Urban	€48.61
	Up to 3 miles	€48.61
	3-5 miles	€62.49
5-7 miles	€79.05	
7-10 miles	€88.20	
Over 10 miles	€95.75	

Emergency Fee/EEA Fee (Additional to Standard Fee)	
Dispensing Fee	€15.26
Rural Practitioner's Allowance	
Per Annum	€8,276.04
Locum and Practice Expense Allowance	
Per Annum	€1,611.12
Sessional Rate – Homes for the Aged	
Per 3 Hour Session	€85.99
* Special Items of Service	
(i) to (vii)	€26.36
(viii) and (ix)	€42.75
(x)	€64.12
(xi)	€154.13
Immunisation Fees	
(i) Registration of child with a GP	€40.84
(ii) Complete course of immunisation against PT/DT, Hib, Polio and MMR	€136.08
(iii) 95% uptake bonus	€65.54
Health (Amendment) Act 1996	
Surgery Fee	€35.87
Domiciliary Fee	€47.31
Methadone Treatment Scheme	
Level 1 Contractor	€159.97
Level 2 Contractor	€176.43

- * Special Items of Service.
- (i) Excisions/Cryotherapy/ Diathermy of Skin Lesions.
 - (ii) Suturing of Cuts and Lacerations.
 - (iii) Draining of Hydroceles.
 - (iv) Treatment and Plugging of Dental and Nasal Haemorrhages.
 - (v) Recognised Vein Treatment.
 - (vi) ECG Tests and their Interpretation.
 - (vii) Instruction in the fitting of a Diaphragm.
 - (viii) Pneumococcal Vaccination.
 - (ix) Influenza Vaccination.
 - (x) Pneumococcal/Influenza Vaccination.
 - (xi) Hepatitis B Vaccination.

Scale of Fees Payable to Participating Pharmacists as at 31st December 2009

GMS Scheme	€
*Fee-Per-Item	
- for each of the first 1,667 items dispensed by the Community Pharmacy Contractor in a month	5.00
- for each of the next 833 items dispensed by the Community Pharmacy Contractor in that month	4.50
- for each other item dispensed by the Community Pharmacy Contractor in that month	3.50
Extemporaneous Fee	6.53
Extemporaneous dispensing and compounding of	
- Powders	19.60
- Ointments and Creams	13.07
Non-Dispensing – exercise of professional judgement	3.27
Phased Dispensing – each part of phased dispensing	3.27
<i>*A Fee-Per-Item is also payable on prescription forms issued by Dentists under the DTS Scheme.</i>	
Supplies to Dispensing Doctors	
Pharmacies supplying Dispensing Doctors are reimbursed on the basis of the reimbursement price with the addition of 25% on cost.	
DP/LTI/EEA Schemes and Health (Amendment) Act 1996	
<p>*The Fee-Per-Item structure shown for the GMS Scheme above includes the items dispensed in these four Schemes. Reimbursement of ingredient cost plus 20% mark-up on ingredient cost plus Fee-Per-Item. 20% mark-up on Incontinence products and Dressings under DP Scheme, 50% mark-up on all other Non Drug Items.</p> <p>Extemporaneously dispensed preparations are reimbursed according to Statutory Instrument S.I. No. 249 of 2009. In the case of the Drugs Payment Scheme the PCRS makes payments to Pharmacies in respect of authorised Patients whose monthly costs of prescribed drugs and medicines are in excess of the specified monthly amount (currently €100) payable to the Pharmacy by an individual or family.</p>	
High Tech Medicines Scheme	
Patient Care Fee: €62.03 per month.	
Methadone Treatment Scheme	
Patient Care Fee: Up to a Maximum of €62.00 per month.	

Scale of Fees Payable under the Dental Treatment Services Scheme as at 31st December 2009

Treatment Type	Routine €
Oral Examination	33.00
Prophylaxis	31.00
Restoration (Amalgam)	50.06
Restoration (Composite) 6 anterior teeth only	51.88
Exodontics (Extraction under local anaesthetic)	39.50
Surgical Extraction – Maximum 3 units:	
Fee payable for each 15 minute unit	35.00
Maximum	105.00
1st Stage Endodontic Treatment (Anterior teeth only)	57.30
Denture Repairs	
1st Item of Repair	47.86
Each Subsequent Item	15.34
Maximum	78.54
Apicectomy/Amputation of Roots	* Dentist Estimate
Endodontics (Anterior teeth only)	* Dentist Estimate
Protracted Periodontal Treatment	* Dentist Estimate
Radiographs	
1 Film	24.70
2 or more Films	37.40
Panoramic	41.45
Miscellaneous	
(e.g. Abscess, Haemorrhage, Dressings etc.)	22.65
Prosthetics	
Full Upper or Lower Denture (Other than Edentulous Persons)	326.22
Partial Upper or Lower Acrylic Denture	239.27
Complete Upper or Lower Reline	130.59
Complete Upper and Lower Reline	217.38
Full Upper and Lower Denture (Edentulous Persons Only)	478.74

* Dentist Estimates are subject to agreement between a Dentist and the Health Service Executive Area.

Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme

As at 31st December 2009	€		€
Examinations		Single Vision Lens (1) (Plastic) Distance	26.84 (H)
Eye Examination Ophthalmic Optician	22.51	Single Vision Lenses (2) (Plastic) Distance	53.67 (H)
Eye Examination Ophthalmologist/ Ophthalmic Medical Practitioner	25.55	Single Vision Lens (1) (Plastic) Reading	26.84 (H)
Medical Eye Examination by Ophthalmologist	51.11	Single Vision Lenses (2) (Plastic) Reading	53.67 (H)
Eye Examination for Contact Lenses (Grant)	68.44 (H)	Additional Specification for Lenses to All Spectacle Types	
Eye Examination Ophthalmic (Dilation)	45.03	Special grant towards additional specification for lens (1) – applies to all spectacle types	81.81 (H)
Appliances		Special grant towards additional specification for lenses (2) – applies to all spectacle types	163.62 (H)
Single Vision Complete Appliances		Other Items – Single Vision	
Spectacles – Distance	42.07	Lenticular Lens (1 Surface)	11.64
Spectacles – Reading	42.07	Lenticular Lenses (2 Surfaces)	23.28
Spectacles – Uncollected	29.32	Lenticular Lenses (3 Surfaces)	34.92
Contact Lenses (Pair)	42.07	Lenticular Lenses (4 Surfaces)	46.56
Contact Lenses Standard or Disposable per pair (Grant)	64.34 (H)	Tinted Lens (1)	7.43
Single Vision Spectacles – with Glass Lenses Distance	122.18 (H)	Tinted Lenses (2)	14.87
Single Vision Spectacles – with Glass Lenses Reading	122.18 (H)	Tinted Lenses (3)	22.30
Single Vision Spectacles – with Plastic Lenses Distance	131.27 (H)	Tinted Lenses (4)	29.74
Single Vision Spectacles – with Plastic Lenses Reading	131.27 (H)	Prism (1)	6.30
Single Vision Lenses to Own Frame		Prisms (2)	12.60
Replacement Distance Lens (1) to own frame	16.35	Prisms (3)	18.90
Replacement Distance Lenses (2) to own frame	32.71	Prisms (4)	25.20
Replacement Reading Lens (1) to own frame	16.35	Prisms (5)	31.50
Replacement Reading Lenses (2) to own frame	32.71	Prisms (6)	37.80
Single Vision Lenses to Non-Standard Frame		Prisms (7)	44.10
Single Vision Lens (1) (Glass) Distance	23.54 (H)	Prisms (8)	50.40
Single Vision Lenses (2) (Glass) Distance	47.10 (H)	Dioptric powers higher than 8.00 (1) Lens	6.17
Single Vision Lens (1) (Glass) Reading	23.54 (H)	Dioptric powers higher than 8.00 (2) Lenses	12.34
Single Vision Lenses (2) (Glass) Reading	47.10 (H)	Dioptric powers higher than 8.00 (3) Lenses	18.52

(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.

Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme *continued*

As at 31st December 2009	€		€	
Dioptric powers higher than 8.00 (4) Lenses	24.69		Bifocal Lenses (2) to Non-Standard Frames	95.78 (H)
Anti-Reflective Coating on Plastic Lens (1)	18.14 (H)		Varifocal Lens (1) (Grant)	94.82 (H)
Anti-Reflective Coating on Plastic Lenses (2)	36.28 (H)		Varifocal Lenses (2) (Grant)	189.64 (H)
Dioptric powers higher than 6.00 (Plastic) (1) Lens	15.43			
Dioptric powers higher than 6.00 (Plastic) (2) Lenses	30.86		Other Items – Bifocals	
Dioptric powers higher than 6.00 (Plastic) (3) Lenses	46.29		Sphere over 6.00 and up to 9.00 extra charge (1) Lens	4.17
Dioptric powers higher than 6.00 (Plastic) (4) Lenses	61.72		Sphere over 6.00 and up to 9.00 extra charge (2) Lenses	8.33
Plastic Lens (1) for children as prescribed	4.70		Sphere over 9.00 extra charge (1) Lens	9.26
Plastic Lenses (2) for children as prescribed	9.39		Sphere over 9.00 extra charge (2) Lenses	18.52
Plastic Lens (1) Adult	4.55 (H)		Tinted Lens (1)	8.21
Plastic Lenses (2) Adult	9.10 (H)		Tinted Lenses (2)	16.42
			Prism (1)	8.76
Bifocals			Prisms (2)	17.51
Spectacles Bifocal Complete	83.70			
Fused Bifocal Spectacles	163.01 (H)		Repairs	
Varifocals Spectacles – Glass or Plastic	250.80 (H)		Replacement Frame to own lenses	12.16
			Replacement Front to own lenses	5.83
Bifocal Lenses			Replacement Side (1) to own frame	2.45
Replacement Bifocal Lens (1) to own frame	37.21		Replacement Sides (2) to own frame	4.90
Replacement Bifocal Lenses (2) to own frame	74.42		Complete New Frames	90.60 (H)
Bifocal Lens (1) To Non-Standard Frames	47.89 (H)			

(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.



DETAILED STATISTICAL ANALYSIS
OF CLAIMS AND PAYMENTS 2009

Table I GMS: Summary of Statistical Information for each of the Five Years 2005-2009

Year ended December:-	2009	2008	2007	2006	2005	Year ended December:-	2009	2008	2007	2006	2005
Number of Eligible Persons in December	1,478,560	1,352,120	1,276,178	1,221,695	1,155,727	Number of Doctor Contracts	2,663	2,599	2,347	2,315	2,257
						Number of Pharmacist Contracts	1,630	1,620	1,587	1,530	1,430
DOCTORS	(000's)	(000's)	(000's)	(000's)	(000's)		(000's)	(000's)	(000's)	(000's)	(000's)
Total Payments	€466,737	€459,476	€427,418	€391,029	€403,071	Total Cost of Stock Orders	€14,309	€15,797	€16,231	€15,230	€15,139
Doctors' Payment per Person	€337.94	€352.67	€349.03	€314.85	€343.35	Ingredient Cost	€11,044	€12,188	€12,559	€11,777	€11,714
						Pharmacy Fees	€2,761	€3,047	€3,140	€2,944	€2,927
						VAT	€504	€562	€532	€509	€498
PHARMACIES											
Total Cost of Prescriptions	€1,245,935	€1,129,494	€1,032,178	€924,995	€816,304	Overall Cost of Medicines	€1,260,244	€1,145,292	€1,048,409	€940,225	€831,443
Ingredient Cost	€962,305	€881,425	€824,323	€743,943	€653,251	*Pharmacy Payment per Person	€907.85	€932.63	€856.14	€809.04	€750.04
Dispensing Fee	€257,968	€225,697	€188,163	€163,537	€147,860						
VAT	€25,662	€22,372	€19,692	€17,516	€15,193						
Number of Forms	16,333	15,648	14,780	13,932	13,227						
Number of Items	50,722	48,212	44,358	40,569	37,428	Overall Payments	€1,726,981	€1,604,768	€1,475,827	€1,331,254	€1,234,514
Cost per Form	€76.28	€72.18	€69.84	€66.39	€61.71	*Overall Payment per Person	€1,245.79	€1,285.30	€1,205.17	€1,123.89	€1,093.39
Cost per Item	€24.56	€23.43	€23.27	€22.80	€21.81						
Ingredient Cost per Item	€18.97	€18.28	€18.58	€18.34	€17.45						
Items per Form	3.11	3.08	3.00	2.91	2.83						

Note: Doctors payment per person is exclusive of superannuation paid to retired DMOs.

* These figures are based on the actual number of persons who availed of services.

Table I.1 LTI/DP: Summary of Statistical Information for each of the Five Years 2005-2009

Year ended December:-	2009	2008	2007	2006	2005	Year ended December:-	2009	2008	2007	2006	2005
LTI Scheme						DP Scheme					
Number of Eligible Persons in December	127,636	120,407	112,580	106,307	99,280	Number of Eligible Persons in December	1,587,448	1,624,413	1,583,738	1,525,657	1,478,650
*Number of Claimants	65,731	62,934	59,040	53,082	53,006	*Number of Claimants	663,127	687,587	667,782	597,835	526,052
	(000's)	(000's)	(000's)	(000's)	(000's)		(000's)	(000's)	(000's)	(000's)	(000's)
Number of Items	2,855	2,643	2,353	2,165	1,929	Number of Items	13,373	13,907	13,430	11,872	10,582
Total Cost	€139,759	€137,899	€124,458	€115,461	€100,547	Gross Cost	€451,707	€506,806	€491,186	€442,924	€388,021
Cost per Item	€48.95	€52.17	€52.90	€53.32	€52.12	Net Cost	€259,928	€311,898	€307,334	€283,108	€244,486
*Cost per Claimant	€2,126.23	€2,191.17	€2,108.03	€2,175.15	€1,896.89	Gross Cost per Item	€33.78	€36.44	€36.57	€37.31	€36.67
						*Net Cost per Claimant	€391.97	€453.61	€460.23	€473.56	€464.76

* These figures are based on the actual number of persons who availed of services under each Scheme.

Table 2 Number of Agreements

Health Service Executive	Doctors		Pharmacists		Dentists		Optometrists	
	2009	2008	2009	2008	2009	2008	2009	2008
East Coast Area	283	277	141	136	125	86	41	38
South Western Area	343	330	203	213	189	172	76	75
Northern Area	298	280	189	188	160	130	50	50
Midland	151	152	100	97	76	72	46	43
Mid-Western	234	233	149	148	136	124	45	43
North Eastern	193	180	150	150	103	94	62	60
North Western	159	156	98	96	78	69	33	32
South Eastern	264	268	181	179	152	117	65	61
Southern	452	441	251	244	341	310	70	66
Western	286	282	168	169	210	175	67	67
NATIONAL	2,663	2,599	1,630	1,620	1,570	1,349	555	535

- Note: (i) Where Doctors have panel numbers drawn from more than one HSE Area, the Area wherein the majority of such persons reside is deemed to be the Doctors HSE Area.
- (ii) 527 Doctors who do not have agreements under the GMS Scheme and who provide services under the Primary Childhood Immunisation Scheme, the Health (Amendment) Act 1996, Heartwatch, Palliative Care and the Methadone Treatment Scheme are included in the above.
- (iii) 188 Dentists (188 – 2008) who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.
- (iv) 12 Pharmacies who do not hold GMS agreements and who were registered as providing non GMS Schemes at year-end are included above.
- (v) Above figures relate to the position as at 31st December 2009.

Table 3 GMS: Payments to Doctors

		2009	2008
		€	€
FEES	- Item of Service Contract	769,487	1,064,036
	- Capitation	225,954,778	230,862,890
	- Special Claims/Services	44,124,618	39,556,736
	- Out-of-Hours	49,507,291	46,401,447
	- Dispensing	2,285,357	2,323,010
	- Asylum Seekers	846,494	1,001,801
	- GP Visit Cards	1,383,375	1,665,580
ALLOWANCES	- Annual Leave	10,437,384	10,111,378
	- Locum and Practice Expenses	12,643	13,696
	- Sick Leave	2,223,277	1,804,395
	- Maternity Leave/Paternity Leave	1,351,647	1,387,015
	- Rural Practice	3,761,836	3,862,778
	- Secretarial/Nursing	74,616,329	70,292,878
	- Study Leave	1,785,347	1,890,919
	- Medical Indemnity Insurance	2,816,513	2,668,269
	- Rostering/Out-of-Hours	12,511,152	11,898,090
	- Practice Development	4,353,527	4,363,099
	- Practice Support Grant	2,671,843	2,667,629
	- IMO Agreements:		
	One-in-one rotas	-	-
	Third year Trainees	-	-
Trainer Grants	-	-	
SALARIES	- Former District Medical Officers	1,696,801	1,548,323
	- Benefits to retired DMOs and their dependants	5,537,300	5,727,599
SUPERANNUATION FUND	- Contribution	23,627,456	24,092,101
TOTAL		€472,274,455	€465,203,669

Table 4 GMS: Cost of Prescriptions

Health Service Executive	Ingredient Cost		Dispensing Fee		VAT		Total	
	2009 €	2008 €	2009 €	2008 €	2009 €	2008 €	2009 €	2008 €
East Coast Area	60,233,490	59,039,119	17,422,789	16,095,744	1,613,143	1,523,298	79,269,422	76,658,161
South Western Area	110,468,331	101,636,757	29,933,769	26,417,902	3,075,991	2,705,566	143,478,091	130,760,225
Northern Area	110,257,084	101,677,847	29,238,738	25,432,421	2,900,229	2,560,661	142,396,051	129,670,929
Midland	66,313,109	60,241,590	17,708,193	15,508,514	1,834,861	1,559,590	85,856,163	77,309,694
Mid-Western	88,610,101	80,950,093	23,931,783	20,817,988	2,319,769	2,023,333	114,861,653	103,791,414
North Eastern	82,676,183	75,055,457	22,385,331	19,304,583	2,249,767	1,911,417	107,311,281	96,271,457
North Western	61,038,782	55,745,729	16,259,762	14,134,176	1,592,292	1,363,908	78,890,836	71,243,813
South Eastern	122,874,913	109,403,268	33,699,763	29,069,409	3,396,313	2,896,205	159,970,989	141,368,882
Southern	155,975,463	142,678,310	40,611,288	35,409,200	3,997,631	3,503,316	200,584,382	181,590,826
Western	103,857,704	94,996,907	26,776,671	23,507,378	2,681,780	2,324,559	133,316,155	120,828,844
National	€962,305,160	€881,425,077	€257,968,087	€225,697,315	€25,661,776	€22,371,853	€1,245,935,023	€1,129,494,245

Note: Cost of medicines supplied by pharmacies to Dispensing Doctors is given in Table 5.

Table 5 GMS: Cost of Stock Order Forms

Health Service Executive	Ingredient Cost		* Pharmacy Fee		VAT		Total	
	2009 €	2008 €	2009 €	2008 €	2009 €	2008 €	2009 €	2008 €
East Coast Area	111,493	155,246	28,126	38,804	29,898	35,469	169,517	229,519
South Western Area	86,341	102,702	21,594	25,675	23,168	26,880	131,103	155,257
Northern Area	137,431	188,907	34,367	47,226	33,327	44,629	205,125	280,762
Midland	463,139	492,476	115,809	123,117	25,484	27,408	604,432	643,001
Mid-Western	841,912	884,368	210,536	221,089	43,400	46,573	1,095,848	1,152,030
North Eastern	1,063,718	1,235,735	265,943	308,936	51,229	59,548	1,380,890	1,604,219
North Western	1,481,938	1,699,269	370,489	424,821	55,179	59,445	1,907,606	2,183,535
South Eastern	2,579,326	2,974,977	644,769	743,642	96,197	101,842	3,320,292	3,820,461
Southern	358,812	408,970	89,737	102,231	54,488	64,342	503,037	575,543
Western	3,919,974	4,045,697	979,988	1,011,405	91,780	95,958	4,991,742	5,153,060
National	€11,044,084	€12,188,347	€2,761,358	€3,046,946	€504,150	€562,094	€14,309,592	€15,797,387

Note: (i) Stock Order Forms are provided by HSE Areas for the use of Dispensing Doctors to obtain Medicines and Appliances from Community Pharmacies for dispensing to persons who are entitled to be dispensed to.

(ii) * Pharmacies are reimbursed for stock order items on the basis of the reimbursement price, with the addition of 25% on cost.

(iii) The above figures include needles, syringes and dressings which are available for Doctors use.

Table 6 DTS: Payments to Dentists

Health Service Executive	Above the Line		Below the Line		Total	
	2009 €	2008 €	2009 €	2008 €	2009 €	2008 €
Eastern Areas	16,981,125	12,567,717	5,516,151	4,580,574	22,497,276	17,148,291
Midland	3,748,497	2,746,567	1,863,214	1,441,222	5,611,711	4,187,789
Mid-Western	4,980,966	3,876,098	2,452,033	1,864,581	7,432,999	5,740,679
North Eastern	5,502,224	3,981,584	2,488,644	1,983,307	7,990,868	5,964,891
North Western	3,456,832	2,501,120	1,348,171	1,045,002	4,805,003	3,546,122
South Eastern	7,467,429	5,308,001	4,131,261	2,895,519	11,598,690	8,203,520
Southern	10,821,398	8,657,154	4,223,607	3,344,182	15,045,005	12,001,336
Western	7,667,247	5,514,157	4,123,693	3,057,579	11,790,940	8,571,736
National	€60,625,718	€45,152,398	€26,146,774	€20,211,966	€86,772,492	€65,364,364

Note: Dentists were also paid a total €62,114 in 2009 (€56,233 in 2008) in respect of fees under Health (Amendment) Act 1996.

Table 7 GMS: Payment per Person

Health Service Executive	2009			2008		
	Doctors €	Pharmacies €	Total €	Doctors €	Pharmacies €	Total €
Eastern Areas	334.39	896.72	1,231.11	347.76	910.92	1,258.68
Midland	349.89	943.28	1,293.17	362.76	1,010.94	1,373.70
Mid-Western	331.55	936.25	1,267.80	342.08	954.60	1,296.68
North Eastern	320.18	884.91	1,205.09	343.48	926.64	1,270.12
North Western	319.92	787.19	1,107.11	326.17	779.35	1,105.52
South Eastern	325.38	908.98	1,234.36	347.16	951.02	1,298.18
Southern	371.65	975.65	1,347.30	385.80	993.09	1,378.89
Western	342.17	900.00	1,242.17	356.29	938.34	1,294.63
National	€337.94	€907.85	€1,245.79	€352.67	€932.63	€1,285.30

Note: The payment per person is inclusive of total payments to Doctors (Table 3) excluding superannuation benefits to retired DMOs and their dependants and total payments to pharmacies (Tables 4 and 5) in respect of the actual cost per person who availed of services.

Table 8 GMS: Number of Doctors in Eligible Person Cost Categories

2009 (2008 in brackets)

Number of Doctors with an annual cost per eligible person of:-										
Health Service Executive	Up to €300	€301-€350	€351-€400	€401-€450	€451-€500	€501-€550	€551-€600	€601-€650	€651-€700	€701 & Over
Eastern Areas	156 (62)	3 (6)	3 (3)	4 (7)	5 (8)	11 (10)	18 (13)	12 (8)	13 (15)	540 (516)
Midland	18 (14)	- (-)	- (1)	1 (1)	- (1)	3 (-)	- (3)	2 (3)	2 (2)	103 (101)
Mid-Western	21 (11)	1 (1)	- (1)	1 (1)	1 (-)	1 (1)	1 (1)	5 (3)	4 (-)	168 (163)
North Eastern	17 (1)	- (1)	1 (-)	4 (3)	1 (3)	4 (2)	- (3)	5 (7)	13 (3)	128 (126)
North Western	9 (2)	- (1)	- (1)	2 (-)	2 (3)	6 (3)	3 (3)	2 (3)	6 (5)	115 (112)
South Eastern	27 (5)	2 (2)	- (2)	3 (-)	3 (2)	2 (3)	4 (3)	4 (3)	4 (2)	203 (205)
Southern	48 (29)	2 (1)	2 (2)	4 (4)	5 (2)	4 (1)	3 (2)	7 (8)	4 (6)	336 (324)
Western	28 (14)	1 (-)	1 (1)	3 (5)	5 (2)	2 (3)	4 (4)	6 (3)	5 (4)	206 (202)
National	324 (138)	9 (12)	7 (11)	22 (21)	22 (21)	33 (23)	33 (32)	43 (38)	51 (37)	1799 (1749)

Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from this table.

(ii) The annual cost per eligible person is the total payment for the Doctor and the total prescribing/dispensing costs in respect of the number of persons on the panel as at December 2009.

(iii) Doctors payment is exclusive of superannuation paid to retired DMOs.

Table 9 GMS: Number of Eligible Persons

Health Service Executive	Number of persons (including dependants) and % of population* eligible in		Health Service Executive	Number of persons (including dependants) and % of population* eligible in	
	December 2009			December 2009	
	No.	%		No.	%
HSE DUBLIN MID-LEINSTER			HSE WEST		
Dublin South	23,102	0.54	Galway	87,377	2.06
Dublin South East	17,156	0.40	Mayo	58,776	1.39
Dublin South City	29,124	0.69	Roscommon	26,606	0.63
Dublin South West	53,260	1.26	Donegal	81,199	1.91
Dublin West	48,258	1.14	Sligo / Leitrim	36,709	0.87
Kildare / West Wicklow	53,325	1.26	Clare	42,563	1.00
Wicklow	34,356	0.81	North Tipperary / East Limerick	26,393	0.62
Laois / Offaly	52,067	1.23	Limerick	62,999	1.49
Longford / Westmeath	43,858	1.03	TOTAL HSE WEST	422,622	9.97
TOTAL HSE DUBLIN MID-LEINSTER	354,506	8.36			
			HSE SOUTH		
HSE DUBLIN NORTH EAST			Cork South Lee	51,629	1.22
Dublin North West	52,521	1.24	Cork North Lee	65,050	1.53
North Central Dublin	37,776	0.89	West Cork	20,466	0.48
North Dublin	59,182	1.40	Kerry	51,040	1.20
Cavan / Monaghan	47,645	1.12	North Cork	32,423	0.77
Louth	47,594	1.12	Carlow / Kilkenny	49,599	1.17
Meath	46,261	1.09	Waterford	48,285	1.14
TOTAL HSE DUBLIN NORTH EAST	290,979	6.86	South Tipperary	35,894	0.85
			Wexford	56,067	1.32
			TOTAL HSE SOUTH	410,453	9.68
			NATIONAL	1,478,560	34.87

Note: *The figures show the number of eligible persons for each Local Health Office. The 2006 Census is used to calculate the percentage. The most recent Official C.S.O. estimate of national population as at October 2006 is 4,239,848.

Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups

Health Service Executive	Age Classification																	
	As at December 2009																	
	Under 5 Years			5-11 Years			12-15 Years			16-24 Years			25-34 Years			35-44 Years		
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Eastern Areas	14,544	15,426	29,970	22,006	23,510	45,516	10,206	10,733	20,939	18,760	14,524	33,284	26,253	16,841	43,094	24,033	18,989	43,022
Midland	3,645	3,835	7,480	5,334	5,580	10,914	2,594	2,710	5,304	4,685	3,863	8,548	6,048	4,554	10,602	5,782	5,037	10,819
Mid-Western	4,335	4,548	8,883	6,514	6,645	13,159	3,257	3,357	6,614	6,550	5,752	12,302	8,120	6,364	14,484	7,560	6,652	14,212
North Eastern	5,367	5,598	10,965	7,896	8,271	16,167	3,775	4,034	7,809	7,236	6,213	13,449	9,218	6,972	16,190	8,640	7,668	16,308
North Western	3,897	4,151	8,048	5,829	6,286	12,115	3,033	3,405	6,438	6,231	5,695	11,926	6,875	5,755	12,630	6,958	6,348	13,306
South Eastern	6,306	6,749	13,055	9,329	9,847	19,176	4,652	5,036	9,688	10,043	8,749	18,792	11,783	9,615	21,398	11,028	9,937	20,965
Southern	7,163	7,380	14,543	9,983	10,852	20,835	5,026	5,335	10,361	9,848	8,836	18,684	13,550	10,697	24,247	12,388	11,206	23,594
Western	5,519	5,844	11,363	8,218	8,862	17,080	4,355	4,520	8,875	9,019	7,979	16,998	10,135	8,365	18,500	9,980	9,009	18,989
National	50,776	53,531	104,307	75,109	79,853	154,962	36,898	39,130	76,028	72,372	61,611	133,983	91,982	69,163	161,145	86,369	74,846	161,215
% of Eligible Persons	3.43%	3.62%	7.05%	5.08%	5.40%	10.48%	2.50%	2.65%	5.14%	4.89%	4.17%	9.06%	6.22%	4.68%	10.90%	5.84%	5.06%	10.90%

Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups continued

Health Service Executive	Age Classification																	
	As at December 2009																	
	45-54 Years			55-64 Years			65-69 Years			70-74 Years			75 Years and Over			All		
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Eastern Areas	17,787	15,532	33,319	19,055	15,434	34,489	11,720	8,010	19,730	19,888	16,303	36,191	42,717	25,789	68,506	226,969	181,091	408,060
Midland	4,428	4,181	8,609	4,736	4,144	8,880	2,601	2,011	4,612	3,524	3,286	6,810	7,674	5,673	13,347	51,051	44,874	95,925
Mid-Western	6,100	5,914	12,014	6,930	6,250	13,180	4,009	3,226	7,235	5,284	4,990	10,274	11,620	7,978	19,598	70,279	61,676	131,955
North Eastern	6,257	5,987	12,244	6,588	6,009	12,597	3,624	2,922	6,546	5,049	4,780	9,829	11,583	7,813	19,396	75,233	66,267	141,500
North Western	5,798	5,653	11,451	6,386	6,144	12,530	3,194	2,978	6,172	3,846	3,790	7,636	9,019	6,637	15,656	61,066	56,842	117,908
South Eastern	9,030	8,675	17,705	9,875	9,026	18,901	5,510	4,617	10,127	7,224	6,793	14,017	15,183	10,838	26,021	99,963	89,882	189,845
Southern	10,572	9,856	20,428	11,640	10,601	22,241	6,960	5,422	12,382	9,529	8,651	18,180	21,178	13,935	35,113	117,837	102,771	220,608
Western	8,468	8,348	16,816	8,927	9,004	17,931	4,839	4,273	9,112	6,006	6,016	12,022	14,576	10,497	25,073	90,042	82,717	172,759
National	68,440	64,146	132,586	74,137	66,612	140,749	42,457	33,459	75,916	60,350	54,609	114,959	133,550	89,160	222,710	792,440	686,120	1,478,560
% of Eligible Persons	4.63%	4.34%	8.97%	5.01%	4.51%	9.52%	2.87%	2.26%	5.13%	4.08%	3.69%	7.78%	9.03%	6.03%	15.06%	53.60%	46.40%	100.00%

Table 9.2 GMS: Percentage of Eligible Persons by Mileage Allocation

Health Service Executive	Mileage Classification														
	As at December 2009														
	Up to 3 Miles			3-5 Miles			5-7 Miles			7-10 Miles			Over 10 Miles		
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Eastern Areas	49.37	39.11	88.48	3.29	2.74	6.03	1.78	1.47	3.25	0.68	0.62	1.30	0.49	0.45	0.94
Midland	33.86	29.72	63.58	5.83	5.26	11.09	11.01	9.40	20.41	2.47	2.35	4.82	0.05	0.05	0.10
Mid-Western	35.34	30.96	66.30	6.37	5.56	11.93	10.33	9.13	19.46	0.96	0.84	1.80	0.26	0.25	0.51
North Eastern	34.39	30.15	64.54	7.03	6.25	13.28	10.84	9.69	20.53	0.77	0.63	1.40	0.14	0.11	0.25
North Western	25.95	23.91	49.86	8.85	8.45	17.30	12.52	11.81	24.33	3.32	2.96	6.28	1.16	1.07	2.23
South Eastern	34.56	30.95	65.51	5.83	5.23	11.06	10.91	10.09	21.00	1.12	0.90	2.02	0.23	0.18	0.41
Southern	34.83	30.21	65.04	6.31	5.52	11.83	9.44	8.24	17.68	1.70	1.57	3.27	1.13	1.05	2.18
Western	28.29	25.19	53.48	7.53	7.13	14.66	11.35	10.82	22.17	3.58	3.41	6.99	1.36	1.34	2.70
National	37.28	31.70	68.98	5.80	5.19	10.99	8.30	7.49	15.79	1.59	1.44	3.03	0.63	0.58	1.21

Table 9.3 GPVC: Number of Eligible Persons

Health Service Executive	Number of persons (including dependants) and % of population* eligible in		Health Service Executive	Number of persons (including dependants) and % of population* eligible in	
	December 2009			December 2009	
	No.	%		No.	%
HSE DUBLIN MID-LEINSTER			HSE WEST		
Dublin South	1,017	0.02	Galway	6,733	0.16
Dublin South East	756	0.02	Mayo	3,355	0.08
Dublin South City	720	0.02	Roscommon	1,730	0.04
Dublin South West	2,307	0.05	Donegal	6,260	0.15
Dublin West	2,959	0.07	Sligo / Leitrim	2,897	0.07
Kildare / West Wicklow	2,927	0.07	Clare	2,287	0.05
Wicklow	2,017	0.05	North Tipperary / East Limerick	1,671	0.04
Laois / Offaly	3,520	0.08	Limerick	3,760	0.09
Longford / Westmeath	3,023	0.07	TOTAL HSE WEST	28,693	0.69
TOTAL HSE DUBLIN MID-LEINSTER	19,246	0.45			
HSE DUBLIN NORTH EAST			HSE SOUTH		
Dublin North West	2,076	0.05	Cork South Lee	4,718	0.11
North Central Dublin	1,017	0.02	Cork North Lee	5,840	0.14
North Dublin	2,256	0.05	West Cork	1,891	0.04
Cavan / Monaghan	3,828	0.09	Kerry	3,999	0.09
Louth	3,379	0.08	North Cork	3,434	0.08
Meath	4,159	0.10	Carlow / Kilkenny	4,033	0.10
TOTAL HSE DUBLIN NORTH EAST	16,715	0.39	Waterford	3,109	0.07
			South Tipperary	2,375	0.06
			Wexford	4,272	0.10
			TOTAL HSE SOUTH	33,671	0.79
			NATIONAL	98,325	2.32

Note: * The figures show the number of eligible persons for each Local Health Office. The 2006 Census is used to calculate the percentage. The most recent Official C.S.O. estimate of national population as at October 2006 is 4,239,848.

Table 9.4 GPVC: Number of Eligible Persons by Gender within Age Groups

Health Service Executive	Age Classification																	
	As at December 2009																	
	Under 5 Years			5-11 Years			12-15 Years			16-24 Years			25-34 Years			35-44 years		
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Eastern Areas	910	968	1,878	1,416	1,437	2,853	625	634	1,259	945	532	1,477	1,552	854	2,406	1,810	1,469	3,279
Midland	391	397	788	535	541	1,076	273	275	548	324	197	521	654	457	1,111	598	544	1,142
Mid-Western	430	409	839	544	605	1,149	310	294	604	507	346	853	768	499	1,267	688	681	1,369
North Eastern	645	696	1,341	910	967	1,877	365	412	777	582	432	1,014	1,039	685	1,724	1,151	1,024	2,175
North Western	416	425	841	667	672	1,339	386	332	718	604	410	1,014	743	509	1,252	821	711	1,532
South Eastern	702	745	1,447	999	1,031	2,030	504	486	990	841	544	1,385	1,456	889	2,345	1,316	1,125	2,441
Southern	1,088	1,068	2,156	1,435	1,506	2,941	709	726	1,435	1,069	730	1,799	1,876	1,223	3,099	1,888	1,713	3,601
Western	588	656	1,244	855	901	1,756	399	389	788	633	424	1,057	1,148	751	1,899	1,159	1,037	2,196

National	5,170	5,364	10,534	7,361	7,660	15,021	3,571	3,548	7,119	5,505	3,615	9,120	9,236	5,867	15,103	9,431	8,304	17,735
% of Eligible Persons	5.26%	5.46%	10.71%	7.49%	7.79%	15.28%	3.63%	3.61%	7.24%	5.60%	3.68%	9.28%	9.39%	5.97%	15.36%	9.59%	8.45%	18.04%

Table 9.4 GPVC: Number of Eligible Persons by Gender within Age Groups continued

Health Service Executive	Age Classification																	
	As at December 2009																	
	45-54 Years			55-64 Years			65-69 Years			70-74 Years			75 Years and over			All		
	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total	Female	Male	Total
Eastern Areas	1,216	909	2,125	971	749	1,720	474	506	980	27	38	65	5	4	9	9,951	8,100	18,051
Midland	371	369	740	239	224	463	65	83	148	2	3	5	-	1	1	3,452	3,091	6,543
Mid-Western	455	437	892	283	252	535	83	107	190	9	10	19	1	-	1	4,078	3,640	7,718
North Eastern	646	584	1,230	451	405	856	156	193	349	10	13	23	-	-	-	5,955	5,411	11,366
North Western	628	631	1,259	443	472	915	115	164	279	2	6	8	-	-	-	4,825	4,332	9,157
South Eastern	931	776	1,707	599	515	1,114	125	200	325	3	2	5	-	-	-	7,476	6,313	13,789
Southern	1,298	1,088	2,386	987	816	1,803	265	359	624	18	19	37	2	-	2	10,635	9,248	19,883
Western	790	752	1,542	510	467	977	134	196	330	10	15	25	4	-	4	6,230	5,588	11,818

National	6,335	5,546	11,881	4,483	3,900	8,383	1,417	1,808	3,225	81	106	187	12	5	17	52,602	45,723	98,325
% of Eligible Persons	6.44%	5.64%	12.08%	4.56%	3.97%	8.53%	1.44%	1.84%	3.28%	0.08%	0.11%	0.19%	0.01%	0.01%	0.02%	53.50%	46.50%	100%

Table 10 GMS: Size of Panels of Doctors

As at December 2009 (2008 in brackets)

Health Service Executive	Number of Doctors with panels of:-											
	Up to 250		251-500		501-1,000		1,001-1,500		1,501-2,000		2,001-2,500	
East Coast Area	55	(52)	51	(52)	59	(59)	11	(12)	-		-	
South Western Area	40	(43)	37	(43)	100	(94)	46	(44)	21	(11)	3	(3)
Northern Area	34	(43)	43	(43)	69	(64)	45	(39)	11	(16)	3	(1)
Midland	9	(15)	14	(14)	45	(49)	35	(29)	12	(9)	-	
Mid-Western	23	(23)	36	(34)	83	(87)	32	(30)	12	(9)	1	(-)
North Eastern	10	(9)	16	(25)	71	(82)	51	(38)	11	(6)	3	(-)
North Western	10	(14)	23	(19)	50	(54)	39	(39)	15	(11)	3	(1)
South Eastern	14	(19)	24	(37)	120	(123)	56	(46)	19	(11)	1	(-)
Southern	84	(81)	61	(69)	155	(153)	63	(51)	10	(6)	3	(2)
Western	30	(27)	45	(51)	108	(105)	51	(50)	9	(3)	1	(-)
National	309	(326)	350	(387)	860	(870)	429	(378)	120	(82)	18	(7)

Table 11 GMS: Payments to Doctors in each Health Service Executive Area

Health Service Executive	2009 €	2008 €
East Coast Area	28,086,765	33,415,983
South Western Area	50,599,550	49,876,623
Northern Area	45,733,538	45,340,172
Midland	30,794,005	29,655,724
Mid-Western	40,618,410	39,960,511
North Eastern	43,156,720	40,648,365
North Western	36,550,156	35,215,976
South Eastern	59,744,270	57,301,388
Southern	76,157,054	74,791,102
Western	55,296,686	53,270,226
National	€466,737,154	€459,476,070

Table 12 GMS: Number of Special Type Consultations and Out-of-Hours Claims

Health Service Executive	No. of Temporary Resident Claims		No. of EEA Visitor Claims		No. of Emergency Claims		Second Medical Opinion Claims		No. of Out-of-Hours Claims		Total No. of Claims	
	2009	2008	2009	2008	2009	2008	2009	2008	2009	2008	2009	2008
East Coast Area	6,254	5,171	2,573	2,709	2,797	2,703	6	2	32,706	32,499	44,336	43,084
South Western Area	16,546	12,989	5,174	5,624	12,937	5,874	14	5	81,815	76,582	116,486	101,074
Northern Area	11,307	9,548	2,394	2,126	14,092	12,978	-	1	45,482	57,153	73,275	81,806
Midland	17,254	17,144	2,533	2,815	2,388	1,973	9	20	68,574	59,160	90,758	81,112
Mid-Western	14,843	17,824	5,340	5,797	4,540	4,311	644	604	69,117	62,598	94,484	91,134
North Eastern *	11,966	8,127	2,428	2,603	1,904	1,205	19	21	10,169	10,816	26,486	22,772
North Western	5,463	4,994	7,238	7,628	2,084	2,098	70	29	68,358	67,143	83,213	81,892
South Eastern	15,013	13,472	4,676	5,470	2,830	2,677	34	3	135,943	131,423	158,496	153,045
Southern	34,170	30,771	12,277	14,129	5,165	4,716	1,012	1,065	215,184	211,209	267,808	261,890
Western	17,798	16,976	8,381	9,303	7,560	6,415	151	153	109,795	109,108	143,685	141,955
National	150,614	137,016	53,014	58,204	56,297	44,950	1,959	1,903	837,143	817,691	1,099,027	1,059,764

Note: * HSE North Eastern Area figures do not include statistics from North East Doc.

Table 12.1 GMS: Payment to Doctors for Special Type Consultations and Out-of-Hours Claims

Health Service Executive	Cost of Temporary Resident Claims		Cost of EEA Visitor Claims		Cost of Emergency Claims		Cost of Second Medical Opinion Claims		Cost of Out-of-Hours Claims		Total Cost of Claims	
	2009 €	2008 €	2009 €	2008 €	2009 €	2008 €	2009 €	2008 €	2009 €	2008 €	2009 €	2008 €
East Coast Area	312,097	268,168	124,816	131,518	134,897	131,948	192	64	1,610,238	1,609,440	2,182,240	2,141,138
South Western Area	865,291	672,489	253,212	273,483	684,341	286,003	457	169	4,104,053	3,906,532	5,907,354	5,138,676
Northern Area	553,250	471,211	116,882	103,469	677,326	628,943	-	32	2,223,675	2,805,082	3,571,133	4,008,737
Midland	849,597	845,260	123,449	137,443	115,819	96,749	291	651	3,502,092	3,067,637	4,591,248	4,147,740
Mid-Western	743,035	914,879	259,478	282,457	226,722	212,198	20,883	19,558	3,531,354	3,241,233	4,781,472	4,670,325
North Eastern*	594,459	405,081	118,280	126,660	94,913	63,496	610	680	515,104	560,033	1,323,366	1,155,950
North Western	271,337	247,296	353,272	371,894	102,791	103,637	2,319	935	3,497,795	3,469,448	4,227,514	4,193,210
South Eastern	737,735	671,017	227,003	266,116	137,081	130,685	1,138	96	6,695,156	6,537,206	7,798,113	7,605,120
Southern	1,793,957	1,692,984	599,846	689,782	278,383	240,269	32,851	34,509	10,821,508	10,769,581	13,526,545	13,427,125
Western	902,781	873,555	408,267	453,281	367,017	314,143	4,989	4,945	5,585,294	5,619,175	7,268,348	7,265,099
National	7,623,539	7,061,940	2,584,505	2,836,103	2,819,290	2,208,071	63,730	61,639	42,086,269	41,585,367	55,177,333	53,753,120

Note: * HSE North Eastern Area figures do not include statistics from North East Doc.

Table 13 GMS: Analysis of Special Items of Service

Type of Service		Number of Claims		Cost of Claims	
		2009	2008	2009 €	2008 €
(i)	Excisions/Cryotherapy/Diathermy: Skin Lesions	103,183	94,419	3,336,932	2,866,090
(ii)	Suturing: Cuts and Lacerations	36,416	34,425	1,178,427	1,045,166
(iii)	Hydroceles: Draining of	1,378	1,309	43,880	39,760
(iv)	Haemorrhages: Dental/Nasal	2,427	2,196	78,640	66,744
(v)	Veins: Recognised treatment	4,499	4,287	145,061	130,529
(vi)	ECG: Tests and interpretation	76,757	72,249	2,480,452	2,195,068
(vii)	Diaphragm: Instruction in the fitting of	1,186	1,157	38,754	35,102
(viii)	Eye: Removal of adherent foreign body	9,580	9,790	310,301	296,882
(ix)	Ear/Nose/Throat: Removal of foreign body	28,774	27,237	929,154	826,994
(x)	Nebuliser: Treatment in the case of acute asthmatic attack	50,945	53,715	2,334,488	2,454,626
(xi)	Bladder: Catheterization	6,877	6,366	316,521	290,315
(xii)	Case Conference: Convened by HSE	834	631	59,826	48,156
(xiii)	Diaphragm: Advice and fitting of	743	722	37,765	36,893
(xiv)	IUCD: Counselling and fitting of	10,006	8,638	790,666	706,981
(xv)	Pneumococcal: Vaccination	14,588	16,307	625,251	671,109
(xvi)	Influenza: Vaccination	349,890	329,030	14,961,300	13,481,357
(xvii)	Pneumococcal/Influenza: Vaccination	13,482	17,021	863,658	1,047,577
(xviii)	Hepatitis B: Vaccination	2,093	449	122,777	66,096
National		713,658	679,948	€28,653,853	€26,305,445

Table 13.1 GMS: Analysis of Special Items of Service by HSE Area

Type of Service		East Coast Area		South Western Area	
		Number of Claims	Cost of Claims €	Number of Claims	Cost of Claims €
(i)	Excisions/Cryotherapy/Diathermy: Skin Lesions	6,993	226,581	9,553	309,065
(ii)	Suturing: Cuts and Lacerations	1,345	43,627	2,321	75,137
(iii)	Hydroceles: Draining of	64	2,156	78	2,499
(iv)	Haemorrhages: Dental/Nasal	57	1,877	126	4,131
(v)	Veins: Recognised treatment	32	942	395	12,796
(vi)	ECG: Tests and interpretation	3,758	122,350	4,802	155,872
(vii)	Diaphragm: Instruction in the fitting of	19	690	233	7,639
(viii)	Eye: Removal of adherent foreign body	225	7,306	937	30,265
(ix)	Ear/Nose/Throat: Removal of foreign body	1,521	49,470	2,760	88,707
(x)	Nebuliser: Treatment in the case of acute asthmatic attack	1,407	64,770	4,017	183,742
(xi)	Bladder: Catheterization	189	8,681	253	11,631
(xii)	Case Conference: Convened by HSE	11	778	12	818
(xiii)	Diaphragm: Advice and fitting of	27	1,391	88	4,480
(xiv)	IUCD: Counselling and fitting of	585	46,174	1,081	85,691
(xv)	Pneumococcal: Vaccination	939	40,414	1,611	68,983
(xvi)	Influenza: Vaccination	25,556	1,094,091	36,893	1,577,192
(xvii)	Pneumococcal/Influenza: Vaccination	1,202	76,983	1,458	93,460
(xviii)	Hepatitis B: Vaccination	83	4,668	209	11,766
Total		44,013	€1,792,949	66,827	€2,723,874

Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued

Type of Service		Mid-Western		North Eastern	
		Number of Claims	Cost of Claims €	Number of Claims	Cost of Claims €
(i)	Excisions/Cryotherapy/Diathermy: Skin Lesions	6,587	212,833	8,594	277,484
(ii)	Suturing: Cuts and Lacerations	2,942	94,776	2,820	90,802
(iii)	Hydroceles: Draining of	118	3,773	51	1,611
(iv)	Haemorrhages: Dental/Nasal	120	3,886	70	2,281
(v)	Veins: Recognised treatment	161	4,981	1,319	42,317
(vi)	ECG: Tests and interpretation	5,538	178,697	5,630	181,605
(vii)	Diaphragm: Instruction in the fitting of	66	2,089	65	2,210
(viii)	Eye: Removal of adherent foreign body	451	14,742	397	12,748
(ix)	Ear/Nose/Throat: Removal of foreign body	2,272	73,152	2,318	73,993
(x)	Nebuliser: Treatment in the case of acute asthmatic attack	4,213	191,911	3,837	176,082
(xi)	Bladder: Catheterization	655	30,031	446	20,467
(xii)	Case Conference: Convened by HSE	50	3,589	11	852
(xiii)	Diaphragm: Advice and fitting of	114	5,620	68	3,483
(xiv)	IUCD: Counselling and fitting of	650	51,260	892	69,764
(xv)	Pneumococcal: Vaccination	1,101	47,210	1,131	48,638
(xvi)	Influenza: Vaccination	32,701	1,399,339	29,369	1,256,620
(xvii)	Pneumococcal/Influenza: Vaccination	1,284	82,164	1,295	82,933
(xviii)	Hepatitis B: Vaccination	161	9,700	123	6,936
Total		59,184	€2,409,753	58,436	€2,350,826

Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued

Type of Service		Northern Area		Midland	
		Number of Claims	Cost of Claims €	Number of Claims	Cost of Claims €
(i)	Excisions/Cryotherapy/Diathermy: Skin Lesions	7,985	259,823	6,625	213,471
(ii)	Suturing: Cuts and Lacerations	2,454	79,598	3,462	111,176
(iii)	Hydroceles: Draining of	38	1,178	51	1,641
(iv)	Haemorrhages: Dental/Nasal	66	2,016	916	29,596
(v)	Veins: Recognised treatment	31	988	953	30,542
(vi)	ECG: Tests and interpretation	5,231	169,054	6,374	204,432
(vii)	Diaphragm: Instruction in the fitting of	44	1,350	39	1,216
(viii)	Eye: Removal of adherent foreign body	472	15,633	959	30,965
(ix)	Ear/Nose/Throat: Removal of foreign body	2,606	84,701	2,440	78,020
(x)	Nebuliser: Treatment in the case of acute asthmatic attack	1,806	82,939	4,584	211,043
(xi)	Bladder: Catheterization	137	6,356	593	27,416
(xii)	Case Conference: Convened by HSE	15	1,129	13	956
(xiii)	Diaphragm: Advice and fitting of	57	2,911	43	2,174
(xiv)	IUCD: Counselling and fitting of	1,107	87,537	849	66,821
(xv)	Pneumococcal: Vaccination	2,013	86,310	764	32,712
(xvi)	Influenza: Vaccination	38,117	1,629,632	20,547	878,946
(xvii)	Pneumococcal/Influenza: Vaccination	1,257	80,561	871	55,798
(xviii)	Hepatitis B: Vaccination	356	20,632	74	3,802
Total		63,792	€2,612,348	50,157	€1,980,727

Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued

Type of Service		North Western		South Eastern	
		Number of Claims	Cost of Claims €	Number of Claims	Cost of Claims €
(i)	Excisions/Cryotherapy/Diathermy: Skin Lesions	8,550	276,070	13,072	422,863
(ii)	Suturing: Cuts and Lacerations	3,327	108,274	5,671	184,029
(iii)	Hydroceles: Draining of	175	5,676	111	3,536
(iv)	Haemorrhages: Dental/Nasal	140	4,658	204	6,562
(v)	Veins: Recognised treatment	10	307	530	17,802
(vi)	ECG: Tests and interpretation	9,920	321,208	12,062	390,182
(vii)	Diaphragm: Instruction in the fitting of	248	7,993	104	3,575
(viii)	Eye: Removal of adherent foreign body	804	26,034	1,104	34,578
(ix)	Ear/Nose/Throat: Removal of foreign body	2,130	68,872	3,314	108,828
(x)	Nebuliser: Treatment in the case of acute asthmatic attack	5,328	244,910	6,965	319,135
(xi)	Bladder: Catheterization	1,106	50,891	1,037	47,791
(xii)	Case Conference: Convened by HSE	35	2,542	74	3,982
(xiii)	Diaphragm: Advice and fitting of	42	2,128	113	5,789
(xiv)	IUCD: Counselling and fitting of	773	61,100	1,649	130,680
(xv)	Pneumococcal: Vaccination	1,033	44,305	1,880	80,472
(xvi)	Influenza: Vaccination	25,030	1,070,165	44,727	1,912,169
(xvii)	Pneumococcal/Influenza: Vaccination	943	60,437	1,812	116,182
(xviii)	Hepatitis B: Vaccination	186	10,511	159	12,462
Total		59,780	€2,366,081	94,588	€3,800,617

Table 13.1 GMS: Analysis of Special Items of Service by HSE Area continued

Type of Service		Southern		Western	
		Number of Claims	Cost of Claims €	Number of Claims	Cost of Claims €
(i)	Excisions/Cryotherapy/Diathermy: Skin Lesions	17,565	566,842	17,659	571,900
(ii)	Suturing: Cuts and Lacerations	6,504	209,440	5,570	181,568
(iii)	Hydroceles: Draining of	358	11,065	334	10,745
(iv)	Haemorrhages: Dental/Nasal	283	9,103	445	14,530
(v)	Veins: Recognised treatment	629	20,197	439	14,189
(vi)	ECG: Tests and interpretation	10,635	343,193	12,807	413,859
(vii)	Diaphragm: Instruction in the fitting of	132	4,389	236	7,603
(viii)	Eye: Removal of adherent foreign body	2,878	94,049	1,353	43,981
(ix)	Ear/Nose/Throat: Removal of foreign body	5,112	165,277	4,301	138,134
(x)	Nebuliser: Treatment in the case of acute asthmatic attack	8,118	369,172	10,670	490,784
(xi)	Bladder: Catheterization	1,296	59,699	1,165	53,558
(xii)	Case Conference: Convened by HSE	56	4,198	557	40,982
(xiii)	Diaphragm: Advice and fitting of	84	4,307	107	5,482
(xiv)	IUCD: Counselling and fitting of	1,682	132,760	738	58,879
(xv)	Pneumococcal: Vaccination	2,119	90,786	1,997	85,421
(xvi)	Influenza: Vaccination	57,714	2,467,108	39,236	1,676,038
(xvii)	Pneumococcal/Influenza: Vaccination	2,044	131,009	1,316	84,131
(xviii)	Hepatitis B: Vaccination	479	27,981	263	14,319
Total		117,688	€4,710,575	99,193	€3,906,103

Table 14 GMS: Visiting Rate Categories for Doctors on Fee-Per-Item of Service

NATIONAL 2009 (2008 in brackets)									
Doctors with panels of:-	Visiting Rate:-*								
	4-4.9	5-5.9	6-6.9	7-7.9	8-8.9	9-9.9	10-10.9	11-11.9	12 and Over
100-249	-	-	- (1)	-	-	-	-	-	-
250-499	1 (-)	-	1 (-)	-	-	- (2)	-	-	-
500-999	-	2 (-)	-	- (1)	-	-	-	-	-
1,000-1,499	-	-	- (1)	1 (-)	-	-	-	-	- (1)
Over 1,500	-	-	-	-	-	1 (-)	1 (1)	-	-
TOTAL	1 (-)	2 (-)	1 (2)	1 (1)	- (-)	1 (2)	1 (1)	- (-)	- (1)

Note: (i) The overall visiting rate in 2009 of the Doctors who continued on a Fee-Per-Item of service contract was 8.26 (Surgery: 8.13 Domiciliary: 0.13), (2008 – Total: 9.59 Surgery: 9.28 Domiciliary: 0.31).

(ii) Only Doctors with panels of 100 persons or over are included in the above table.

(iii) * Visiting Rate is the total number of consultations divided by the total number of persons on panel.

Table 15 GMS: Cost of Medicines by Gender within Age Groups

Health Service Executive	Age Classification																	
	Under 5 Years			5-11 Years			12-15 Years			16-24 Years			25-34 Years			35-44 Years		
	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €
Eastern Areas	97.26	118.45	108.16	72.20	83.12	77.84	90.69	94.02	92.40	255.39	198.33	230.49	363.08	348.43	357.35	541.04	500.30	523.05
Midland	110.25	112.87	111.59	91.47	98.11	94.87	100.62	92.83	96.64	299.80	228.83	267.73	404.35	368.65	389.01	624.06	524.32	577.62
Mid-Western	131.84	137.90	134.94	105.59	126.98	116.39	110.82	168.90	140.30	284.82	234.24	261.17	403.30	391.06	397.92	593.97	561.50	578.77
North Eastern	83.24	103.90	93.79	75.34	83.23	79.38	82.66	89.24	86.06	237.96	176.64	209.63	311.99	291.97	303.37	431.52	403.56	418.38
North Western	72.92	89.30	81.37	63.35	82.84	73.46	74.21	84.81	79.81	191.79	157.58	175.45	294.00	246.18	272.21	414.24	381.97	398.85
South Eastern	101.47	109.31	105.52	76.19	100.09	88.46	92.76	119.01	106.40	260.34	207.21	235.60	349.30	353.35	351.12	544.17	491.94	519.42
Southern	120.13	148.16	134.35	101.97	120.32	111.53	151.61	128.17	138.25	299.18	253.95	277.79	406.38	400.28	403.69	604.81	570.16	588.36
Western	107.08	115.82	111.58	78.27	90.63	84.68	87.52	95.78	91.73	238.56	201.28	221.06	356.50	328.53	343.85	498.68	472.87	486.44
National	€102.61	€118.58	€110.80	€81.22	€95.79	€88.73	€95.06	€107.14	€101.28	€258.26	€207.26	€234.81	€362.95	€345.78	€355.58	€534.71	€493.46	€515.56
% of National Average	12.04%	13.91%	13.00%	9.53%	11.24%	10.41%	11.15%	12.57%	11.88%	30.30%	24.32%	27.55%	42.58%	40.57%	41.72%	62.73%	57.89%	60.49%

Table 15 GMS: Cost of Medicines by Gender within Age Groups continued

Health Service Executive	Age Classification																	
	45-54 Years			55-64 Years			65-69 Years			70-74 Years			75 Years & Over			Total		
	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €	Female €	Male €	Total €
Eastern Areas	988.74	903.66	949.08	1,423.46	1,392.79	1,409.74	1,660.55	1,789.16	1,712.77	1,686.90	1,626.12	1,659.52	2,043.28	1,985.41	2,021.50	952.81	831.71	899.07
Midland	1,065.61	968.35	1,018.37	1,637.68	1,544.42	1,594.16	1,747.43	1,907.08	1,817.04	1,915.24	1,869.37	1,893.11	2,347.11	2,218.73	2,292.55	987.05	879.11	936.55
Mid-Western	982.01	910.95	947.03	1,453.12	1,377.72	1,417.36	1,570.64	1,562.60	1,567.06	1,628.68	1,568.85	1,599.63	1,922.20	1,910.95	1,917.62	918.48	838.61	881.15
North Eastern	811.91	760.44	786.74	1,267.30	1,245.87	1,257.08	1,480.21	1,547.98	1,510.46	1,665.63	1,590.14	1,628.92	1,950.04	1,919.43	1,937.71	790.48	709.52	752.56
North Western	650.96	642.06	646.57	1,093.18	1,040.23	1,067.21	1,342.37	1,327.47	1,335.18	1,427.49	1,426.02	1,426.76	1,774.98	1,697.60	1,742.17	712.65	643.27	679.20
South Eastern	975.12	888.37	932.61	1,390.21	1,347.22	1,369.68	1,620.17	1,645.32	1,631.63	1,688.25	1,639.30	1,664.52	2,014.60	1,972.45	1,997.04	887.91	805.47	848.88
Southern	1,018.94	934.93	978.41	1,486.77	1,430.80	1,460.09	1,620.96	1,698.55	1,654.94	1,686.39	1,669.57	1,678.38	1,872.67	1,888.89	1,879.11	963.39	879.19	924.17
Western	827.11	758.71	793.15	1,202.49	1,135.96	1,169.08	1,376.84	1,419.37	1,396.78	1,560.01	1,512.84	1,536.41	1,919.37	1,835.12	1,884.09	822.99	743.72	785.04
National	€931.20	€856.00	€894.82	€1,376.49	€1,320.20	€1,349.85	€1,573.99	€1,630.49	€1,598.89	€1,664.28	€1,614.53	€1,640.65	€1,980.27	€1,932.22	€1,961.04	€896.71	€801.11	€852.35
% of National Average	109.25%	100.43%	104.98%	161.49%	154.89%	158.37%	184.66%	191.29%	187.59%	195.26%	189.42%	192.49%	232.33%	226.69%	230.07%	105.20%	93.99%	100.00%

Table 16 GMS: Number of Prescription Forms and Items

Health Service Executive	Number of Forms		Number of Items		Items per Form	
	2009	2008	2009	2008	2009	2008
East Coast Area	993,022	1,017,824	3,252,646	3,313,978	3.28	3.26
South Western Area	1,884,323	1,811,548	5,995,036	5,710,301	3.18	3.15
Northern Area	1,720,016	1,653,006	5,683,891	5,386,385	3.30	3.26
Midland	1,112,330	1,049,184	3,464,279	3,263,230	3.11	3.11
Mid-Western	1,528,655	1,467,904	4,783,532	4,543,217	3.13	3.10
North Eastern	1,438,637	1,357,289	4,423,611	4,151,331	3.07	3.06
North Western	1,145,110	1,101,717	3,211,631	3,051,204	2.80	2.77
South Eastern	2,124,830	1,988,249	6,546,461	6,090,929	3.08	3.06
Southern	2,610,466	2,509,295	8,093,563	7,682,044	3.10	3.06
Western	1,775,985	1,692,464	5,267,269	5,019,244	2.97	2.97
National	16,333,374	15,648,480	50,721,919	48,211,863	3.11	3.08

Table 16.1 GMS: Payment to Pharmacists in Respect of Prescriptions

Health Service Executive	Cost		Cost per Form		Cost per Item		Ingredient Cost per Item	
	2009 €	2008 €	2009 €	2008 €	2009 €	2008 €	2009 €	2008 €
East Coast Area	79,269,422	76,658,161	79.83	75.32	24.37	23.13	18.52	17.82
South Western Area	143,478,091	130,760,225	82.79	72.18	25.05	22.90	19.40	17.80
Northern Area	142,396,051	129,670,929	76.14	78.45	23.93	24.07	18.43	18.88
Midland	85,856,163	77,309,694	77.19	73.69	24.78	23.69	19.14	18.46
Mid-Western	114,861,653	103,791,414	75.14	70.71	24.01	22.85	18.52	17.82
North Eastern	107,311,281	96,271,457	74.59	70.93	24.26	23.19	18.69	18.08
North Western	78,890,836	71,243,813	68.89	64.67	24.56	23.35	19.01	18.27
South Eastern	159,970,989	141,368,882	75.29	71.10	24.44	23.21	18.77	17.96
Southern	200,584,382	181,590,826	76.84	72.37	24.78	23.64	19.27	18.57
Western	133,316,155	120,828,844	75.07	71.39	25.31	24.07	19.72	18.93
National	€1,245,935,023	€1,129,494,245	€76.28	€72.18	€24.56	€23.43	€18.97	€18.28

Table 16.2 GMS: Number of Items on Prescription Forms

Prescription forms having:-	2009		2008	
	No. of Forms	% of Total	No. of Forms	% of Total
One Item	6,260,489	38.08	5,906,955	37.71
Two Items	3,133,752	19.06	3,014,358	19.25
Three Items	1,788,810	10.88	1,736,950	11.09
Four Items	1,230,428	7.48	1,200,360	7.66
Five Items	993,697	6.04	965,800	6.17
Six Items	912,282	5.55	889,444	5.68
Seven Items	981,195	5.97	964,431	6.16
Eight or more Items	1,140,953	6.94	984,059	6.28

Table 16.3 DP: Number of Items on Claim Forms

Claim forms having:-	2009		2008	
	No. of Forms	% of Total	No. of Forms	% of Total
One Item	2,004,397	40.84	2,372,535	43.38
Two Items	993,484	20.24	1,155,396	21.13
Three Items	616,005	12.55	680,676	12.44
Four Items	430,221	8.77	447,136	8.18
Five Items	301,242	6.14	297,116	5.43
Six Items	202,985	4.14	192,925	3.53
Seven Items	132,144	2.69	122,229	2.23
Eight or more Items	227,500	4.63	201,026	3.68

Table 16.4 LTI: Number of Items on Claim Forms

Claim forms having:-	2009		2008	
	No. of Forms	% of Total	No. of Forms	% of Total
One Item	305,806	33.97	306,096	35.20
Two Items	154,991	17.21	155,502	17.88
Three Items	107,973	11.99	105,346	12.11
Four Items	92,888	10.32	87,855	10.10
Five Items	78,834	8.76	73,169	8.42
Six Items	60,763	6.75	54,981	6.32
Seven Items	41,885	4.65	37,240	4.28
Eight or more Items	57,202	6.35	49,471	5.69

Table 17 GMS: Number of Dispensing Doctors* and Persons for whom they Dispense

Health Service Executive	2009		2008	
	No. of Doctors	No. of Persons	No. of Doctors	No. of Persons
Eastern Areas	-	-	-	-
Midland	8	4,450	8	4,552
Mid-Western	11	2,572	10	2,844
North Eastern	5	1,414	5	1,350
North Western	31	12,053	31	12,372
South Eastern	19	7,667	20	7,714
Southern	11	1,544	11	1,516
Western	32	15,139	32	14,030
National	117	44,839	117	44,378

Note: * In rural areas where a Doctor has a centre of practice 3 miles or more from the nearest Community Pharmacy the Doctor dispenses for persons served from that centre who opt to be dispensed to. The Doctor is paid a dispensing fee for each such person. A Doctor's medicine requirements are obtained on a Stock Order from a Community Pharmacy – the stock ordered is approved in advance by a HSE Area.

Table 18 GMS: Advance Payments to Pharmacists

Health Service Executive	Amount Advanced to Pharmacists as at 31st December:-	
	2009 €	2008 €
Eastern	3,362,872	3,384,618
Midland	809,506	816,960
Mid-Western	1,054,886	1,115,195
North Eastern	1,345,799	1,355,407
North Western	1,100,378	1,129,687
South Eastern	1,666,976	1,736,620
Southern	1,920,544	1,969,626
Western	1,592,977	1,690,724
National	€12,853,938	€13,198,837

Table 19 GMS: Notes on Some of the More Commonly Prescribed Products

<p>AMOXICILLIN AMOXICILLIN AND ENZYME INHIBITOR</p>	<p>Amoxicillin, alone or potentiated by an inhibitor of bacterial enzymes is a broad spectrum Penicillin antibiotic indicated for the treatment of a wide range of infections.</p>	<p>BECLOMETASONE</p>	<p>Beclometasone is a potent steroid having an anti-inflammatory action within the lungs. It is used mainly by inhalation for the treatment of bronchial asthma.</p>
<p>SALBUTAMOL</p>	<p>Salbutamol is a beta-adrenergic stimulant used mainly in the treatment of chronic asthma and chronic bronchitis.</p>	<p>AMLODIPINE</p>	<p>Amlodipine is a calcium – channel blocker (similar to nifedipine) with peripheral and coronary vasodilator properties. It is given by mouth in the management of hypertension and of angina pectoris.</p>
<p>DICLOFENAC</p>	<p>Diclofenac is a Non-Steroidal Anti-inflammatory Drug (NSAID) mainly used to treat pain and inflammation associated with muscular conditions and rheumatoid arthritis.</p>	<p>ACETYLSALICYLIC ACID - ASPIRIN</p>	<p>Acetylsalicylic Acid-Aspirin has anti-inflammatory and additionally analgesic and antipyretic (body temperature lowering) action. Acetylsalicylic Acid-Aspirin also has action against thrombosis or clot formation by inhibition of platelet cell aggregation in the blood.</p>
<p>ATORVASTATIN AND PRAVASTATIN</p>	<p>Atorvastatin and Pravastatin are indicated, in combination with dietary measures, for lowering cholesterol levels.</p>	<p>ATENOLOL</p>	<p>Atenolol is a beta blocker. Members of this class of drugs are used in the treatment of hypertension, angina pectoris and cardiac arrhythmias.</p>
<p>FUROSEMIDE FUROSEMIDE WITH POTASSIUM SPARING DIURETICS</p>	<p>The diuretic Furosemide, alone or in combination with potassium – sparing diuretics, is used to treat hypertension.</p>	<p>OMEPRAZOLE LANSOPRAZOLE</p>	<p>Omeprazole and Lansoprazole are proton pump inhibitors which prevent secretion of gastric acid. They are used in the treatment of reflux oesophagitis and peptic ulceration.</p>

Table 19.1 GMS:The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
1	Acetylsalicylic Acid-Aspirin (Antithrombotic)	2,543,938	5.02	5,532,028	0.57
2	Atorvastatin	1,706,372	3.36	70,800,434	7.27
3	Levothyroxine Sodium	974,211	1.92	1,864,262	0.19
4	Calcium, Combinations	898,419	1.77	7,303,320	0.75
5	Paracetamol	869,518	1.71	1,127,559	0.12
6	Bisoprolol	861,809	1.70	6,856,504	0.70
7	Salbutamol (Inhaled)	855,724	1.69	4,582,589	0.47
8	Amlodipine	775,614	1.53	10,303,977	1.06
9	Ramipril	715,103	1.41	7,396,800	0.76
10	Esomeprazole	688,570	1.36	30,645,624	3.15
11	Warfarin	677,398	1.34	1,685,742	0.17
12	Amoxicillin and Enzyme Inhibitor	676,616	1.33	5,808,315	0.60
13	Lansoprazole	668,620	1.32	24,535,582	2.52
14	Omeprazole	613,217	1.21	22,776,338	2.34
15	Furosemide	609,987	1.20	634,260	0.07
16	Clinical Nutritional Products	553,149	1.09	41,382,430	4.25
17	Diclofenac (Systemic)	546,302	1.08	5,647,663	0.58
18	Perindopril	530,925	1.05	10,680,222	1.10
19	Pravastatin	511,563	1.01	14,203,093	1.46
20	Metformin	495,350	0.98	1,738,430	0.18
21	Zopiclone	492,141	0.97	3,500,795	0.36
22	Diazepam	484,814	0.96	496,483	0.05
23	Prednisolone (Systemic)	474,136	0.93	1,747,898	0.18
24	Rosuvastatin	468,619	0.92	13,876,445	1.43
25	Atenolol	461,321	0.91	2,258,362	0.23
26	Salmeterol and other drugs for obstructive airway diseases	440,067	0.87	31,646,309	3.25
27	Pantoprazole	427,325	0.84	13,354,807	1.37
28	Diagnostic Products	425,437	0.84	16,387,335	1.68
29	Alprazolam	399,798	0.79	1,011,278	0.10
30	Bendroflumethiazide	390,063	0.77	613,389	0.06
31	Amoxicillin	381,979	0.75	1,473,515	0.15
32	Zolpidem	375,896	0.74	1,699,259	0.17
33	Escitalopram	368,346	0.73	11,431,492	1.17
34	Paracetamol Combs. excl. Psycholeptics	363,064	0.72	2,401,407	0.25
35	Codeine, Combs excl. Psycholeptics	349,172	0.69	3,065,687	0.31

Table 19.1 GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
36	Clopidogrel	348,614	0.69	18,998,563	1.95
37	Diclofenac (Topical)	329,475	0.65	2,017,589	0.21
38	Gliclazide	323,960	0.64	3,153,663	0.32
39	Lactulose	321,390	0.63	1,375,688	0.14
40	Alendronic Acid	319,955	0.63	10,708,256	1.10
41	Tramadol	318,039	0.63	3,795,162	0.39
42	Ferrous Fumarate	313,904	0.62	576,014	0.06
43	Carbocisteine	309,255	0.61	1,167,977	0.12
44	Folic Acid	306,310	0.60	294,058	0.03
45	Artificial tears and other indifferent preparations	294,267	0.58	1,706,462	0.18
46	Venlafaxine	288,438	0.57	10,533,483	1.08
47	Doxazosin	288,041	0.57	8,469,086	0.87
48	Tiotropium Bromide	280,345	0.55	14,282,459	1.47
49	Alginic Acid	277,924	0.55	1,605,719	0.16
50	Citalopram	271,792	0.54	5,002,090	0.51
51	Beclometasone (Inhaled)	270,526	0.53	4,989,137	0.51
52	Domperidone	264,949	0.52	1,026,364	0.11
53	Glucosamine	262,931	0.52	6,461,137	0.66
54	Digoxin	255,203	0.50	215,827	0.02
55	Clarithromycin	238,508	0.47	4,206,028	0.43
56	Needles/Syringes/Lancets	230,613	0.45	3,065,677	0.31
57	Macrogol combinations	228,431	0.45	3,726,191	0.38
58	Lisinopril	227,405	0.45	2,499,061	0.26
59	Ibuprofen	219,017	0.43	630,582	0.06
60	Isosorbide Mononitrate	214,132	0.42	2,479,507	0.25
61	Drospirenone and Estrogen	207,599	0.41	1,494,744	0.15
62	Pregabalin	205,776	0.41	18,953,727	1.95
63	Bendroflumethiazide and Potassium	204,434	0.40	724,031	0.07
64	Furosemide and Potassium-Sparing Agents	201,610	0.40	832,892	0.09
65	Temazepam	200,706	0.40	418,493	0.04
66	Valsartan	200,351	0.39	4,784,821	0.49
67	Tamsulosin	196,762	0.39	5,512,832	0.57
68	Allopurinol	195,508	0.39	955,978	0.10
69	Lercanidipine	192,352	0.38	2,992,465	0.31
70	Mirtazapine	186,066	0.37	4,127,061	0.42

Table 19.1 GMS:The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
71	Formoterol and other drugs for obstructive airway diseases	182,896	0.36	10,752,860	1.10
72	Olanzapine	180,955	0.36	20,827,127	2.14
73	Flurazepam	178,165	0.35	778,239	0.08
74	Losartan	177,148	0.35	4,870,209	0.50
75	Simvastatin	175,008	0.35	4,284,057	0.44
76	Nebivolol	170,890	0.34	2,491,412	0.26
77	Amitriptyline	165,518	0.33	149,647	0.02
78	Risedronic Acid	162,789	0.32	5,967,470	0.61
79	Betahistine	162,763	0.32	1,742,642	0.18
80	Sodium Valproate	162,583	0.32	1,794,629	0.18
81	Mefenamic Acid	161,631	0.32	640,915	0.07
82	Betamethasone (Topical)	160,125	0.32	739,493	0.08
83	Flucloxacillin	153,310	0.30	1,268,490	0.13
84	Metoprolol	149,672	0.30	314,966	0.03
85	Tolterodine	149,190	0.29	6,989,654	0.72
86	Quetiapine	148,026	0.29	9,098,226	0.93
87	Glyceryl Trinitrate	147,425	0.29	1,465,935	0.15
88	Other Emollients and Protectives	146,583	0.29	364,014	0.04
89	Latanoprost	144,185	0.28	3,648,466	0.37
90	Valsartan and Diuretics	136,862	0.27	3,642,901	0.37
91	Montelukast	136,287	0.27	5,321,158	0.55
92	Rabeprazole	135,812	0.27	4,337,875	0.45
93	Fluoxetine	135,275	0.27	3,078,761	0.32
94	Levonorgestrel and Estrogen (Fixed Comb. Contraceptive)	135,084	0.27	501,337	0.05
95	Sertraline	134,374	0.26	4,300,656	0.44
96	Cefaclor	131,082	0.26	988,307	0.10
97	Carbamazepine	130,731	0.26	955,261	0.10
98	Risperidone	129,810	0.26	8,482,197	0.87
99	Salbutamol and other drugs for obstructive airway diseases	126,375	0.25	6,576,100	0.68
100	Hypromellose	125,560	0.25	805,471	0.08
	Total	36,605,285	72.22%	€651,430,932	66.88%

Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
1	Atorvastatin	70,800,434	7.27	1,706,372	3.36
2	Clinical Nutritional Products	41,382,430	4.25	553,149	1.09
3	Salmeterol and other drugs for obstructive airway diseases	31,646,309	3.25	440,067	0.87
4	Esomeprazole	30,645,624	3.15	688,570	1.36
5	Lansoprazole	24,535,582	2.52	668,620	1.32
6	Omeprazole	22,776,338	2.34	613,217	1.21
7	Olanzapine	20,827,127	2.14	180,955	0.36
8	Clopidogrel	18,998,563	1.95	348,614	0.69
9	Pregabalin	18,953,727	1.95	205,776	0.41
10	Diagnostic Products	16,387,335	1.68	425,437	0.84
11	Tiotropium Bromide	14,282,459	1.47	280,345	0.55
12	Pravastatin	14,203,093	1.46	511,563	1.01
13	Rosuvastatin	13,876,445	1.43	468,619	0.92
14	Pantoprazole	13,354,807	1.37	427,325	0.84
15	Ostomy Requisites	12,619,818	1.30	122,742	0.24
16	Escitalopram	11,431,492	1.17	368,346	0.73
17	Donepezil	10,860,158	1.12	112,976	0.22
18	Formoterol and other drugs for obstructive airway diseases	10,752,860	1.10	182,896	0.36
19	Alendronic Acid	10,708,256	1.10	319,955	0.63
20	Perindopril	10,680,222	1.10	530,925	1.05
21	Venlafaxine	10,533,483	1.08	288,438	0.57
22	Amlodipine	10,303,977	1.06	775,614	1.53
23	Quetiapine	9,098,226	0.93	148,026	0.29
24	Risperidone	8,482,197	0.87	129,810	0.26
25	Doxazosin	8,469,086	0.87	288,041	0.57
26	Fentanyl	8,402,617	0.86	57,306	0.11
27	Ramipril	7,396,800	0.76	715,103	1.41
28	Calcium, Combinations	7,303,320	0.75	898,419	1.77
29	Tolterodine	6,989,654	0.72	149,190	0.29
30	Bisoprolol	6,856,504	0.70	861,809	1.70
31	Urinary Appliances	6,670,509	0.69	70,783	0.14
32	Salbutamol and other drugs for obstructive airway diseases	6,576,100	0.68	126,375	0.25
33	Glucosamine	6,461,137	0.66	262,931	0.52
34	Lamotrigine	6,230,181	0.64	110,309	0.22
35	Risedronic Acid	5,967,470	0.61	162,789	0.32

Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
36	Budesonide (Inhaled)	5,931,549	0.61	73,066	0.14
37	Amoxicillin and Enzyme Inhibitor	5,808,315	0.60	676,616	1.33
38	Diclofenac (Systemic)	5,647,663	0.58	546,302	1.08
39	Acetylsalicylic Acid-Aspirin (Antithrombotic)	5,532,028	0.57	2,543,938	5.02
40	Tamsulosin	5,512,832	0.57	196,762	0.39
41	Montelukast	5,321,158	0.55	136,287	0.27
42	Simvastatin and Ezetimibe	5,123,994	0.53	93,389	0.18
43	Citalopram	5,002,090	0.51	271,792	0.54
44	Beclometasone (Inhaled)	4,989,137	0.51	270,526	0.53
45	Losartan	4,870,209	0.50	177,148	0.35
46	Valsartan	4,784,821	0.49	200,351	0.39
47	Levetiracetam	4,776,320	0.49	50,964	0.10
48	Salbutamol (Inhaled)	4,582,589	0.47	855,724	1.69
49	Memantine	4,516,315	0.46	46,468	0.09
50	Buprenorphine	4,358,311	0.45	72,558	0.14
51	Rabeprazole	4,337,875	0.45	135,812	0.27
52	Sertraline	4,300,656	0.44	134,374	0.26
53	Simvastatin	4,284,057	0.44	175,008	0.35
54	Anastrozole	4,234,429	0.44	39,573	0.08
55	Clarithromycin	4,206,028	0.43	238,508	0.47
56	Mirtazapine	4,127,061	0.42	186,066	0.37
57	Gabapentin	4,111,893	0.42	82,425	0.16
58	Nicotine	4,065,655	0.42	122,746	0.24
59	Insulin Glargine, Long Acting	4,054,967	0.42	51,737	0.10
60	Etoricoxib	4,052,328	0.42	124,928	0.25
61	Aripiprazole	3,807,726	0.39	21,194	0.04
62	Tramadol	3,795,162	0.39	318,039	0.63
63	Macrogol, Combinations	3,726,191	0.38	228,431	0.45
64	Latanoprost	3,648,466	0.37	144,185	0.28
65	Valsartan and Diuretics	3,642,901	0.37	136,862	0.27
66	Varenicline	3,559,612	0.37	45,259	0.09
67	Ezetimibe	3,546,845	0.36	86,139	0.17
68	Zopiclone	3,500,795	0.36	492,141	0.97
69	Mesalazine	3,483,699	0.36	51,240	0.10
70	Alendronic Acid, Combinations	3,452,932	0.35	98,214	0.19

Table 19.2 GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
71	Duloxetine	3,215,869	0.33	82,609	0.16
72	Gliclazide	3,153,663	0.32	323,960	0.64
73	Insulin Aspart, Fast Acting	3,102,759	0.32	48,529	0.10
74	Fluoxetine	3,078,761	0.32	135,275	0.27
75	Codeine Combs. excl. Psycholeptics	3,065,687	0.31	349,172	0.69
76	Needles/Syringes/Lancets	3,065,677	0.31	230,613	0.45
77	Sildenafil	3,004,298	0.31	92,095	0.18
78	Lercanidipine	2,992,465	0.31	192,352	0.38
79	Telmisartan	2,974,997	0.31	118,818	0.23
80	Oxycodone	2,902,925	0.30	77,612	0.15
81	Fluticasone (Inhaled)	2,843,927	0.29	48,495	0.10
82	Orlistat	2,834,373	0.29	43,534	0.09
83	Ibandronic Acid	2,770,811	0.28	83,638	0.16
84	Solifenacin	2,743,127	0.28	52,998	0.10
85	Calcipotriol, Combinations	2,731,892	0.28	31,399	0.06
86	Insulin Detemir, Long Acting	2,645,764	0.27	30,009	0.06
87	Tinzaparin	2,638,922	0.27	11,194	0.02
88	Timolol, Combinations	2,532,828	0.26	85,647	0.17
89	Lisinopril	2,499,061	0.26	227,405	0.45
90	Nebivolol	2,491,412	0.26	170,890	0.34
91	Isosorbide Mononitrate	2,479,507	0.25	214,132	0.42
92	Ranitidine	2,465,606	0.25	117,116	0.23
93	Paroxetine	2,454,341	0.25	110,091	0.22
94	Omega-3-triglycerides	2,445,312	0.25	87,453	0.17
95	Paracetamol Combs. excl. Psycholeptics	2,401,407	0.25	363,064	0.72
96	Candesartan	2,364,328	0.24	98,037	0.19
97	Alfuzosin	2,299,393	0.24	76,825	0.15
98	Strontium Ranelate	2,269,421	0.23	48,234	0.10
99	Atenolol	2,258,362	0.23	461,321	0.91
100	Losartan and Diuretics	2,230,767	0.23	72,185	0.14
	Total	€771,118,611	79.19%	27,410,886	54.04%

Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
1	Acetylsalicylic Acid-Aspirin (Antithrombotic)	678,884	5.08	1,487,184	0.52
2	Atorvastatin	620,468	4.64	25,690,138	8.96
3	Levothyroxine Sodium	334,499	2.50	649,269	0.23
4	Salbutamol (Inhaled)	281,051	2.10	1,328,871	0.46
5	Esomeprazole	264,083	1.97	11,759,753	4.10
6	Rosuvastatin	262,873	1.97	7,624,316	2.66
7	Bisoprolol	245,196	1.83	1,896,662	0.66
8	Calcium, Combinations	243,582	1.82	2,033,110	0.71
9	Diclofenac (Systemic)	223,253	1.67	2,429,004	0.85
10	Amlodipine	215,177	1.61	2,758,218	0.96
11	Amoxicillin and Enzyme Inhibitor	187,961	1.41	1,628,488	0.57
12	Omeprazole	176,244	1.32	6,579,690	2.29
13	Salmeterol and other drugs for obstructive airway diseases	172,611	1.29	11,559,155	4.03
14	Lansoprazole	170,503	1.28	6,629,745	2.31
15	Ramipril	169,155	1.26	1,747,212	0.61
16	Perindopril	162,989	1.22	3,281,226	1.14
17	Prednisolone (Systemic)	148,635	1.11	621,795	0.22
18	Atenolol	127,115	0.95	600,376	0.21
19	Escitalopram	123,888	0.93	3,952,971	1.38
20	Pravastatin	123,030	0.92	3,425,036	1.19
21	Venlafaxine	117,870	0.88	4,358,108	1.52
22	Clinical Nutritional Products	117,302	0.88	5,119,042	1.78
23	Pantoprazole	112,633	0.84	3,558,223	1.24
24	Warfarin	111,687	0.84	274,048	0.10
25	Zopiclone	104,380	0.78	741,334	0.26
26	Formoterol and other drugs for obstructive airway diseases	103,917	0.78	5,964,413	2.08
27	Clopidogrel	102,952	0.77	5,497,417	1.92
28	Glucosamine	101,475	0.76	2,456,869	0.86
29	Clarithromycin	99,784	0.75	1,862,140	0.65
30	Montelukast	96,152	0.72	3,696,647	1.29
31	Zolpidem	95,823	0.72	449,209	0.16
32	Alprazolam	93,390	0.70	226,441	0.08
33	Bendroflumethiazide	86,502	0.65	131,639	0.05
34	Paracetamol	84,719	0.63	108,461	0.04
35	Codeine Combs. excl. Psycholeptics	79,426	0.59	662,049	0.23

Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
36	Folic Acid	79,245	0.59	75,435	0.03
37	Doxazosin	77,571	0.58	2,265,141	0.79
38	Valsartan	76,586	0.57	1,768,281	0.62
39	Beclometasone (Inhaled)	76,116	0.57	1,327,992	0.46
40	Paracetamol Combs. excl. Psycholeptics	75,786	0.57	543,172	0.19
41	Diazepam	74,493	0.56	53,116	0.02
42	Amoxicillin	73,347	0.55	332,623	0.12
43	Alendronic Acid	72,966	0.55	2,406,296	0.84
44	Citalopram	69,572	0.52	1,300,900	0.45
45	Nebivolol	69,248	0.52	1,007,848	0.35
46	Tramadol	67,601	0.51	790,858	0.28
47	Allopurinol	66,278	0.50	352,572	0.12
48	Valsartan and Diuretics	64,770	0.48	1,674,267	0.58
49	Drospirenone and Estrogen	64,057	0.48	451,762	0.16
50	Diclofenac (Topical)	62,318	0.47	410,667	0.14
51	Pregabalin	62,036	0.46	5,566,197	1.94
52	Losartan	58,977	0.44	1,579,669	0.55
53	Simvastatin and Ezetimibe	58,414	0.44	3,094,750	1.08
54	Lisinopril	57,849	0.43	620,480	0.22
55	Omega-3-triglycerides	56,526	0.42	1,610,900	0.56
56	Domperidone	55,010	0.41	210,270	0.07
57	Etoricoxib	53,536	0.40	1,709,481	0.60
58	Amitriptyline	51,239	0.38	64,877	0.02
59	Alginic Acid	51,165	0.38	308,865	0.11
60	Mometasone	50,916	0.38	777,254	0.27
61	Telmisartan	50,853	0.38	1,234,819	0.43
62	Artificial tears and other indifferent preparations	50,558	0.38	373,034	0.13
63	Ezetimibe	50,402	0.38	1,997,274	0.70
64	Furosemide	49,523	0.37	58,894	0.02
65	Methotrexate	49,092	0.37	431,651	0.15
66	Tiotropium Bromide	48,441	0.36	2,377,466	0.83
67	Fluticasone (Nasal)	48,333	0.36	496,824	0.17
68	Cetirizine	47,989	0.36	317,826	0.11
69	Mefenamic Acid	47,537	0.36	168,102	0.06
70	Lercanidipine	46,826	0.35	719,868	0.25

Table 19.3 DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
71	Tadalafil	46,685	0.35	1,370,135	0.48
72	Simvastatin	45,707	0.34	1,110,107	0.39
73	Sertraline	45,099	0.34	1,482,479	0.52
74	Risedronic Acid	45,070	0.34	1,582,359	0.55
75	Mesalazine	44,979	0.34	3,604,461	1.26
76	Betamethasone (Topical)	44,740	0.33	216,808	0.08
77	Bendroflumethazide and Potassium	43,918	0.33	149,854	0.05
78	Olmesartan Medoxomil	43,794	0.33	912,730	0.32
79	Fluoxetine	43,174	0.32	1,021,534	0.36
80	Estradiol	42,883	0.32	431,377	0.15
81	Carbocisteine	41,958	0.31	161,248	0.06
82	Olanzapine	40,711	0.30	3,598,191	1.25
83	Sildenafil	38,601	0.29	1,186,917	0.41
84	Ostomy Requisites	38,497	0.29	3,520,075	1.23
85	Tamsulosin	38,375	0.29	1,052,452	0.37
86	Lithium	37,651	0.28	80,991	0.03
87	Candesartan	37,544	0.28	867,418	0.30
88	Paroxetine	36,409	0.27	782,246	0.27
89	Desloratadine	36,020	0.27	400,808	0.14
90	Duloxetine	34,358	0.26	1,363,685	0.48
91	Metformin	34,195	0.26	105,743	0.04
92	Losartan and Diuretics	34,028	0.25	1,009,327	0.35
93	Ibandronic Acid	33,985	0.25	1,071,579	0.37
94	Metoprolol	33,980	0.25	71,415	0.02
95	Ibuprofen	33,688	0.25	124,751	0.04
96	Flucloxacillin	33,578	0.25	283,360	0.10
97	Bromazepam	32,884	0.25	168,499	0.06
98	Cefaclor	32,715	0.24	257,902	0.09
99	Meloxicam	32,368	0.24	311,683	0.11
100	Antifungal Combs. (Topical)	32,292	0.24	111,379	0.04
	Total	9,714,271	72.66%	€199,679,203	69.66%

Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
1	Atorvastatin	25,690,138	8.96	620,468	4.64
2	Esomeprazole	11,759,753	4.10	264,083	1.97
3	Salmeterol and other drugs for obstructive airway diseases	11,559,155	4.03	172,611	1.29
4	Rosuvastatin	7,624,316	2.66	262,873	1.97
5	Lansoprazole	6,629,745	2.31	170,503	1.28
6	Omeprazole	6,579,690	2.29	176,244	1.32
7	Formoterol and other drugs for obstructive airway diseases	5,964,413	2.08	103,917	0.78
8	Pregabalin	5,566,197	1.94	62,036	0.46
9	Clopidogrel	5,497,417	1.92	102,952	0.77
10	Clinical Nutritional Products	5,119,042	1.78	117,302	0.88
11	Venlafaxine	4,358,108	1.52	117,870	0.88
12	Escitalopram	3,952,971	1.38	123,888	0.93
13	Montelukast	3,696,647	1.29	96,152	0.72
14	Mesalazine	3,604,461	1.26	44,979	0.34
15	Olanzapine	3,598,191	1.25	40,711	0.30
16	Pantoprazole	3,558,223	1.24	112,633	0.84
17	Ostomy Requisites	3,520,075	1.23	38,497	0.29
18	Pravastatin	3,425,036	1.19	123,030	0.92
19	Perindopril	3,281,226	1.14	162,989	1.22
20	Simvastatin and Ezetimibe	3,094,750	1.08	58,414	0.44
21	Amlodipine	2,758,218	0.96	215,177	1.61
22	Glucosamine	2,456,869	0.86	101,475	0.76
23	Diclofenac (Systemic)	2,429,004	0.85	223,253	1.67
24	Alendronic Acid	2,406,296	0.84	72,966	0.55
25	Tiotropium Bromide	2,377,466	0.83	48,441	0.36
26	Doxazosin	2,265,141	0.79	77,571	0.58
27	Calcipotriol, Combinations	2,236,169	0.78	22,580	0.17
28	Follitropin Beta	2,178,992	0.76	2,530	0.02
29	Calcium, Combinations	2,033,110	0.71	243,582	1.82
30	Ezetimibe	1,997,274	0.70	50,402	0.38
31	Bisoprolol	1,896,662	0.66	245,196	1.83
32	Clarithromycin	1,862,140	0.65	99,784	0.75
33	Plastic IUCD with Progestogens	1,816,938	0.63	14,771	0.11
34	Valsartan	1,768,281	0.62	76,586	0.57
35	Varenicline	1,767,000	0.62	22,605	0.17

Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
36	Ramipril	1,747,212	0.61	169,155	1.26
37	Etoricoxib	1,709,481	0.60	53,536	0.40
38	Valsartan and Diuretics	1,674,267	0.58	64,770	0.48
39	Quetiapine	1,635,068	0.57	25,789	0.19
40	Amoxicillin and Enzyme Inhibitor	1,628,488	0.57	187,961	1.41
41	Omega-3-triglycerides	1,610,900	0.56	56,526	0.42
42	Anastrozole	1,595,470	0.56	15,274	0.11
43	Risedronic Acid	1,582,359	0.55	45,070	0.34
44	Losartan	1,579,669	0.55	58,977	0.44
45	Acetylsalicylic Acid-Aspirin (Antithrombotic)	1,487,184	0.52	678,884	5.08
46	Sertraline	1,482,479	0.52	45,099	0.34
47	Orlistat	1,404,045	0.49	21,948	0.16
48	Tadalafil	1,370,135	0.48	46,685	0.35
49	Duloxetine	1,363,685	0.48	34,358	0.26
50	Salbutamol (Inhaled)	1,328,871	0.46	281,051	2.10
51	Beclometasone (Inhaled)	1,327,992	0.46	76,116	0.57
52	Citalopram	1,300,900	0.45	69,572	0.52
53	Fentanyl	1,279,272	0.45	6,774	0.05
54	Lamotrigine	1,245,751	0.43	27,729	0.21
55	Telmisartan	1,234,819	0.43	50,853	0.38
56	Urinary Requisites	1,219,839	0.43	9,936	0.07
57	Sumatriptan	1,207,104	0.42	20,821	0.16
58	Sibutramine	1,188,996	0.41	18,933	0.14
59	Sildenafil	1,186,917	0.41	38,601	0.29
60	Isotretinoin	1,164,364	0.41	17,643	0.13
61	Famciclovir	1,127,500	0.39	8,255	0.06
62	Gabapentin	1,121,004	0.39	21,025	0.16
63	Simvastatin	1,110,107	0.39	45,707	0.34
64	Fluticasone (Inhaled)	1,108,250	0.39	28,847	0.22
65	Ibandronic Acid	1,071,579	0.37	33,985	0.25
66	Tamsulosin	1,052,452	0.37	38,375	0.29
67	Tolterodine	1,028,220	0.36	22,431	0.17
68	Fluoxetine	1,021,534	0.36	43,174	0.32
69	Alendronic Acid, Combinations	1,015,713	0.35	30,245	0.23
70	Losartan and Diuretics	1,009,327	0.35	34,028	0.25

Table 19.4 DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
71	Nebivolol	1,007,848	0.35	69,248	0.52
72	Rabeprazole	994,835	0.35	31,072	0.23
73	Progesterone	993,908	0.35	10,216	0.08
74	Strontium Ranelate	984,980	0.34	21,445	0.16
75	Proguanil, Combinations	967,015	0.34	13,699	0.10
76	Olmesartan Medoxomil	912,730	0.32	43,794	0.33
77	Budesonide (Inhaled)	905,467	0.32	20,952	0.16
78	Tinzaparin	893,403	0.31	4,924	0.04
79	Candesartan	867,418	0.30	37,544	0.28
80	Tramadol	790,858	0.28	67,601	0.51
81	Paroxetine	782,246	0.27	36,409	0.27
82	Zolmitriptan	780,155	0.27	17,382	0.13
83	Mometasone	777,254	0.27	50,916	0.38
84	Risperidone	763,715	0.27	14,665	0.11
85	Telmisartan and Diuretics	744,515	0.26	28,867	0.22
86	Zopiclone	741,334	0.26	104,380	0.78
87	Fumaric Acid Derivatives, Combinations	740,563	0.26	1,217	0.01
88	Azathioprine	735,032	0.26	26,476	0.20
89	Lercanidipine	719,868	0.25	46,826	0.35
90	Calcipotriol	704,395	0.25	16,081	0.12
91	Solifenacin	687,280	0.24	13,650	0.10
92	Mirtazapine	686,680	0.24	31,377	0.23
93	Diagnostic Products	678,454	0.24	19,379	0.14
94	Terbinafine (Systemic)	677,756	0.24	18,093	0.14
95	Lignocaine (Local Anaesthetic)	671,269	0.23	3,067	0.02
96	Codeine Combs. excl. Psycholeptics	662,049	0.23	79,426	0.59
97	Levothyroxine Sodium	649,269	0.23	334,499	2.50
98	Aripiprazole	642,906	0.22	4,062	0.03
99	Prednisolone (Systemic)	621,795	0.22	148,635	1.11
100	Letrozole	621,283	0.22	7,040	0.05
	Total	€229,956,347	80.22%	8,240,146	61.63%

Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
1	Diagnostic Products	289,982	10.16	13,136,530	15.59
2	Acetylsalicylic Acid-Aspirin (Antithrombotic)	255,278	8.94	565,709	0.67
3	Metformin	245,005	8.58	937,288	1.11
4	Atorvastatin	180,569	6.32	7,342,973	8.71
5	Needles/Syringes/Lancets	158,723	5.56	3,678,602	4.36
6	Gliclazide	130,613	4.57	1,310,664	1.56
7	Ramipril	85,984	3.01	911,882	1.08
8	Insulin Aspart, Fast Acting	84,666	2.97	5,135,135	6.09
9	Perindopril	64,473	2.26	1,368,143	1.62
10	Amlodipine	54,326	1.90	746,739	0.89
11	Insulin Glargine, Long Acting	50,939	1.78	3,882,445	4.61
12	Sodium Valproate	49,614	1.74	602,262	0.71
13	Rosuvastatin	48,265	1.69	1,412,882	1.68
14	Lamotrigine	47,037	1.65	3,156,186	3.74
15	Carbamazepine	42,620	1.49	370,020	0.44
16	Bisoprolol	40,196	1.41	318,581	0.38
17	Clinical Nutritional Products	34,323	1.20	4,287,817	5.09
18	Insulin Detemir, Long Acting	34,231	1.20	2,875,991	3.41
19	Pravastatin	29,043	1.02	814,243	0.97
20	Levetiracetam	25,866	0.91	2,468,283	2.93
21	Doxazosin	24,964	0.87	799,451	0.95
22	Lisinopril	22,841	0.80	261,353	0.31
23	Atenolol	22,270	0.78	111,341	0.13
24	Phenytoin	21,537	0.75	144,250	0.17
25	Levothyroxine Sodium	20,174	0.71	43,081	0.05
26	Losartan	18,770	0.66	537,466	0.64
27	Clopidogrel	16,982	0.59	908,408	1.08
28	Valsartan	16,847	0.59	400,952	0.48
29	Sitagliptin	16,576	0.58	774,885	0.92
30	Folic Acid	16,354	0.57	19,246	0.02
31	Bendrofluazide	13,795	0.48	20,534	0.02
32	Furosemide	12,655	0.44	16,783	0.02
33	Lercanidipine	12,552	0.44	198,009	0.23
34	Insulin Aspart, Comb. Intermediate/Fast Acting	11,997	0.42	853,759	1.01
35	Simvastatin	11,922	0.42	295,018	0.35

Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
36	Nebivolol	11,195	0.39	175,927	0.21
37	Valsartan and Diuretics	10,182	0.36	274,908	0.33
38	Warfarin	10,044	0.35	25,982	0.03
39	Glimepiride	10,027	0.35	81,663	0.10
40	Insulin (Human), Comb. Intermediate/Fast Acting	10,017	0.35	537,061	0.64
41	Metformin and Rosiglitazone	9,798	0.34	539,912	0.64
42	Tadalafil	9,473	0.33	278,048	0.33
43	Telmisartan	9,372	0.33	234,899	0.28
44	Insulin Lispro, Fast Acting	9,356	0.33	558,132	0.66
45	Sildenafil	9,274	0.32	287,304	0.34
46	Insulin (Human), Intermediate Acting	9,273	0.32	338,507	0.40
47	Simvastatin and Ezetimibe	9,046	0.32	490,476	0.58
48	Rosiglitazone	8,683	0.30	492,037	0.58
49	Phenobarbital	8,655	0.30	40,998	0.05
50	Candesartan	8,588	0.30	208,465	0.25
51	Topiramate	8,294	0.29	596,148	0.71
52	Ezetimibe	8,290	0.29	332,489	0.39
53	Pancreatic Enzymes	7,875	0.28	861,894	1.02
54	Glucagon	7,606	0.27	218,679	0.26
55	Levodopa and Decarboxylase Inhibitor	7,514	0.26	133,049	0.16
56	Olmesartan Medoxomil	7,123	0.25	153,773	0.18
57	Omega-3-triglycerides	6,990	0.24	213,503	0.25
58	Urinary Appliances	6,850	0.24	790,351	0.94
59	Indapamide	6,668	0.23	41,200	0.05
60	Metformin and Sitagliptin	6,645	0.23	337,017	0.40
61	Omeprazole	6,524	0.23	257,618	0.31
62	Metoprolol	6,122	0.21	14,025	0.02
63	Calcium, Combinations	6,061	0.21	52,028	0.06
64	Lansoprazole	5,828	0.20	224,329	0.27
65	Lisinopril and Diuretics	5,674	0.20	70,526	0.08
66	Irbesartan	5,631	0.20	144,205	0.17
67	Exenatide	5,582	0.20	603,212	0.72
68	Pioglitazone	5,409	0.19	294,993	0.35
69	Fenofibrate	5,394	0.19	114,144	0.14
70	Esomeprazole	5,367	0.19	234,442	0.28

Table 19.5 LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
71	Oxcarbazepine	5,340	0.19	170,411	0.20
72	Losartan and Diuretics	5,271	0.18	165,211	0.20
73	Pregabalin	5,230	0.18	522,755	0.62
74	Diltiazem	4,884	0.17	76,845	0.09
75	Gabapentin	4,791	0.17	312,603	0.37
76	Baclofen	4,730	0.17	59,361	0.07
77	Enalapril	4,690	0.16	55,336	0.07
78	Salbutamol (Inhaled)	4,654	0.16	34,969	0.04
79	Insulin (Human), Fast Acting	4,531	0.16	130,922	0.16
80	Bendroflumethazide and potassium	4,525	0.16	14,807	0.02
81	Insulin Glulisine, Fast Acting	4,420	0.15	220,611	0.26
82	Telmisartan and Diuretics	4,011	0.14	106,848	0.13
83	Allopurinol	3,637	0.13	22,009	0.03
84	Evening Primrose Oil (Naudicelle)	3,629	0.13	94,484	0.11
85	Clobazam	3,501	0.12	19,143	0.02
86	Levodopa Decarboxylase Inhibitor and COMT Inhibitor	3,493	0.12	404,604	0.48
87	Isosorbide Mononitrate	3,492	0.12	39,500	0.05
88	Quinapril	3,484	0.12	44,924	0.05
89	Ropinirole	3,401	0.12	421,653	0.50
90	Selegiline	3,276	0.11	106,665	0.13
91	Pramipexole	3,176	0.11	547,224	0.65
92	Diazepam	3,114	0.11	11,043	0.01
93	Atenolol with other Diuretics	3,113	0.11	22,001	0.03
94	Nifedipine	3,106	0.11	44,820	0.05
95	Paracetamol	3,093	0.11	8,725	0.01
96	Clonazepam	3,038	0.11	63,823	0.08
97	Captopril	3,002	0.11	47,463	0.06
98	Amoxicillin and Enzyme Inhibitor	2,995	0.10	31,786	0.04
99	Pantoprazole	2,949	0.10	91,984	0.11
100	Amitriptyline	2,938	0.10	6,233	0.01
	Total	2,601,933	91.08%	€74,857,618	88.85%

Table 19.6 LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
1	Diagnostic Products	13,136,530	15.59	289,982	10.16
2	Atorvastatin	7,342,973	8.71	180,569	6.32
3	Insulin Aspart, Fast Acting	5,135,135	6.09	84,666	2.97
4	Clinical Nutritional Products	4,287,817	5.09	34,323	1.20
5	Insulin Glargine, Long Acting	3,882,445	4.61	50,939	1.78
6	Needles/Syringes/Lancets	3,678,602	4.36	158,723	5.56
7	Lamotrigine	3,156,186	3.74	47,037	1.65
8	Insulin Detemir, Long Acting	2,875,991	3.41	34,231	1.20
9	Levetiracetam	2,468,283	2.93	25,866	0.91
10	Rosuvastatin	1,412,882	1.68	48,265	1.69
11	Perindopril	1,368,143	1.62	64,473	2.26
12	Gliclazide	1,310,664	1.56	130,613	4.57
13	Metformin	937,288	1.11	245,005	8.58
14	Ramipril	911,882	1.08	85,984	3.01
15	Clopidogrel	908,408	1.08	16,982	0.59
16	Pancreatic Enzymes	861,894	1.02	7,875	0.28
17	Insulin Aspart, Comb. Intermediate/Fast Acting	853,759	1.01	11,997	0.42
18	Pravastatin	814,243	0.97	29,043	1.02
19	Doxazosin	799,451	0.95	24,964	0.87
20	Urinary Requisites	790,351	0.94	6,850	0.24
21	Sitagliptin	774,885	0.92	16,576	0.58
22	Amlodipine	746,739	0.89	54,326	1.90
23	Apomorphine	690,561	0.82	873	0.03
24	Exenatide	603,212	0.72	5,582	0.20
25	Sodium Valproate	602,262	0.71	49,614	1.74
26	Topiramate	596,148	0.71	8,294	0.29
27	Acetylsalicylic Acid-Aspirin (Antithrombotic)	565,709	0.67	255,278	8.94
28	Insulin Lispro, Fast Acting	558,132	0.66	9,356	0.33
29	Pramipexole	547,224	0.65	3,176	0.11
30	Metformin and Rosiglitazone	539,912	0.64	9,798	0.34
31	Losartan	537,466	0.64	18,770	0.66
32	Insulin (Human), Comb. Intermediate/Fast Acting	537,061	0.64	10,017	0.35
33	Pregabalin	522,755	0.62	5,230	0.18
34	Rosiglitazone	492,037	0.58	8,683	0.30
35	Simvastatin and Ezetimibe	490,476	0.58	9,046	0.32

Table 19.6 LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
36	Ropinirole	421,653	0.50	3,401	0.12
37	Levodopa, Decarboxylase Inhibitor and COMT Inhibitor	404,604	0.48	3,493	0.12
38	Valsartan	400,952	0.48	16,847	0.59
39	Carbamazepine	370,020	0.44	42,620	1.49
40	Colistin Parenteral	360,389	0.43	2,343	0.08
41	Insulin (Human), Intermediate Acting	338,507	0.40	9,273	0.32
42	Metformin and Sitagliptin	337,017	0.40	6,645	0.23
43	Ezetimibe	332,489	0.39	8,290	0.29
44	Nutritional/Ancillary Devices	329,525	0.39	2,230	0.08
45	Bisoprolol	318,581	0.38	40,196	1.41
46	Gabapentin	312,603	0.37	4,791	0.17
47	Zonisamide	306,145	0.36	2,802	0.10
48	Simvastatin	295,018	0.35	11,922	0.42
49	Pioglitazone	294,993	0.35	5,409	0.19
50	Sildenafil	287,304	0.34	9,274	0.32
51	Tadalafil	278,048	0.33	9,473	0.33
52	Valsartan and Diuretics	274,908	0.33	10,182	0.36
53	Rasagiline	262,240	0.31	2,515	0.09
54	Lisinopril	261,353	0.31	22,841	0.80
55	Rotigotine	258,031	0.31	1,490	0.05
56	Omeprazole	257,618	0.31	6,524	0.23
57	Telmisartan	234,899	0.28	9,372	0.33
58	Esomeprazole	234,442	0.28	5,367	0.19
59	Other Alimentary Tract/Metabolism Products	234,427	0.28	1,697	0.06
60	Lansoprazole	224,329	0.27	5,828	0.20
61	Insulin Glulisine, Fast Acting	220,611	0.26	4,420	0.15
62	Glucagon	218,679	0.26	7,606	0.27
63	Meropenem	214,727	0.25	124	0.00
64	Omega-3-triglycerides	213,503	0.25	6,990	0.24
65	Candesartan	208,465	0.25	8,588	0.30
66	Lercanidipine	198,009	0.23	12,552	0.44
67	Orlistat	186,029	0.22	2,924	0.10
68	Nebivolol	175,927	0.21	11,195	0.39
69	Oxcarbazepine	170,411	0.20	5,340	0.19
70	Losartan and Diuretics	165,211	0.20	5,271	0.18

Table 19.6 LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
71	Azithromycin	164,388	0.20	2,564	0.09
72	Modafinil	154,304	0.18	880	0.03
73	Olmesartan Medoxomil	153,773	0.18	7,123	0.25
74	Desmopressin	150,290	0.18	2,161	0.08
75	Phenytoin	144,250	0.17	21,537	0.75
76	Irbesartan	144,205	0.17	5,631	0.20
77	Tizanidine	143,683	0.17	1,421	0.05
78	Levodopa and Decarboxylase Inhibitor	133,049	0.16	7,514	0.26
79	Multivitamins and Trace Elements	131,866	0.16	2,258	0.08
80	Insulin (Human), Fast Acting	130,922	0.16	4,531	0.16
81	Salmeterol and other drugs for obstructive airway diseases	125,368	0.15	1,708	0.06
82	Dressings	115,545	0.14	2,107	0.07
83	Ostomy Requisites	115,441	0.14	1,236	0.04
84	Fenofibrate	114,144	0.14	5,394	0.19
85	Atenolol	111,341	0.13	22,270	0.78
86	Tolterodine	110,896	0.13	2,358	0.08
87	Telmisartan and Diuretics	106,848	0.13	4,011	0.14
88	Selegiline	106,665	0.13	3,276	0.11
89	Metformin and Pioglitazone	101,081	0.12	1,996	0.07
90	Midazolam	96,819	0.11	1,754	0.06
91	Evening Primrose Oil (Naudicelle)	94,484	0.11	3,629	0.13
92	Pantoprazole	91,984	0.11	2,949	0.10
93	Levocarnitine	89,361	0.11	272	0.01
94	Melatonin	87,409	0.10	987	0.03
95	Glimepiride	81,663	0.10	10,027	0.35
96	Candesartan and Diuretics	77,297	0.09	2,660	0.09
97	Diltiazem	76,845	0.09	4,884	0.17
98	Valsartan and Amlodipine	76,612	0.09	2,576	0.09
99	Ceftazidime	74,858	0.09	125	0.00
100	Vardenafil	70,543	0.08	2,254	0.08
	Total	€78,715,107	93.42%	2,484,934	86.98%

Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
1	Adalimumab	33,726	9.12	46,250,835	16.54
2	Etanercept	33,436	9.05	38,064,481	13.61
3	Tacrolimus	26,352	7.13	7,150,988	2.56
4	Mycophenolic Acid	25,738	6.96	5,512,786	1.97
5	Bicalutamide	23,777	6.43	2,060,709	0.74
6	Ciclosporin	18,599	5.03	2,191,614	0.78
7	Darbepoetin alfa	16,842	4.56	8,047,667	2.88
8	Interferon beta-1a	14,143	3.83	16,380,502	5.86
9	Erythropoietin	13,990	3.78	10,132,560	3.62
10	Triptorelin	13,806	3.73	5,005,534	1.79
11	Leuprorelin	11,504	3.11	5,594,792	2.00
12	Pegfilgrastim	11,005	2.98	13,704,084	4.90
13	Teriparatide	10,390	2.81	4,752,634	1.70
14	Somatropin	8,980	2.43	6,442,636	2.31
15	Interferon beta-1b	8,766	2.37	10,329,522	3.70
16	Goserelin	6,361	1.72	2,180,924	0.78
17	Capecitabine	6,280	1.70	1,587,595	0.57
18	Cinacalcet	5,669	1.53	1,865,312	0.67
19	Glatiramer Acetate	4,906	1.33	5,992,555	2.14
20	Dornase alfa	4,437	1.20	4,286,258	1.53
21	Methoxy Polyethylene Glycol-Epoietin beta	4,312	1.17	975,412	0.35
22	Filgrastim	4,241	1.15	3,093,726	1.11
23	Follitropin beta	3,611	0.98	3,127,510	1.12
24	Choriogonadotropin alfa	3,460	0.94	187,192	0.07
25	Palivizumab	3,252	0.88	3,435,810	1.23
26	Imatinib	2,876	0.78	7,938,190	2.84
27	Octreotide	2,545	0.69	3,001,573	1.07
28	Ribavirin	2,434	0.66	1,449,229	0.52
29	Sildenafil	2,365	0.64	1,836,689	0.66
30	Temozolomide	2,043	0.55	2,286,281	0.82
31	Peginterferon alfa-2a	1,962	0.53	1,953,650	0.70
32	Riluzole	1,950	0.53	633,822	0.23
33	Bosentan	1,805	0.49	5,546,219	1.98
34	Follitropin alfa	1,763	0.48	1,877,592	0.67
35	Tobramycin	1,721	0.47	4,638,011	1.66

Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.

Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

	Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
36	Human Menopausal Gonadotrophin	1,674	0.45	1,093,959	0.39
37	Lenalidomide	1,401	0.38	9,766,472	3.49
38	Sirolimus	1,232	0.33	330,455	0.12
39	Linezolid	1,229	0.33	1,804,785	0.65
40	Anagrelide	1,218	0.33	649,717	0.23
41	Parathyroid Hormone	1,182	0.32	489,253	0.18
42	Thalidomide	1,179	0.32	819,342	0.29
43	Fulvestrant	1,130	0.31	591,669	0.21
44	Lamivudine	1,119	0.30	110,508	0.04
45	Erlotinib	1,070	0.29	2,402,891	0.86
46	Valganciclovir	1,025	0.28	1,654,167	0.59
47	Ganirelix	993	0.27	304,038	0.11
48	Paricalcitol	897	0.24	155,960	0.06
49	Peginterferon alfa-2b	890	0.24	538,317	0.19
50	Entecavir	869	0.24	502,035	0.18
51	Lanreotide	812	0.22	886,540	0.32
52	Nafarelin	801	0.22	132,531	0.05
53	Voriconazole	788	0.21	1,987,078	0.71
54	Sunitinib	778	0.21	2,794,283	1.00
55	Deferasirox	777	0.21	764,991	0.27
56	Lutropin alfa	725	0.20	417,424	0.15
57	Adefovir Dipivoxil	716	0.19	393,090	0.14
58	Ibandronic Acid	715	0.19	184,592	0.07
59	Sorafenib	672	0.18	2,313,418	0.83
60	Interferon alfa-2b	651	0.18	459,549	0.16
61	Clodronic Acid	544	0.15	149,392	0.05
62	Lapatinib	455	0.12	1,029,154	0.37
63	Flutamide	439	0.12	58,448	0.02
64	Posaconazole	415	0.11	721,853	0.26
65	Etoposide	410	0.11	40,869	0.01
66	Anakinra	392	0.11	396,072	0.14
67	Vinorelbine	390	0.11	152,846	0.05
68	Interferon alfa-2a	348	0.09	120,639	0.04
69	Sitaxentan	307	0.08	794,701	0.28
70	Dasatinib	298	0.08	1,331,190	0.48

Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.

Table 19.7 HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued

Name	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
71 Vancomycin Oral	273	0.07	55,814	0.02
72 Pegvisomant	234	0.06	980,308	0.35
73 Fludarabine	227	0.06	178,641	0.06
74 Lenograstim	197	0.05	155,452	0.06
75 Nilotinib	182	0.05	841,888	0.30
76 Efalizumab	168	0.05	191,543	0.07
77 Iloprost	122	0.03	582,632	0.21
78 Risedronic Acid	115	0.03	26,999	0.01
79 Cetrorelix	98	0.03	27,448	0.01
80 Bexarotene	94	0.03	254,111	0.09
81 Sodium Oxybate	86	0.02	56,500	0.02
82 Buserelin	77	0.02	16,840	0.01
83 Topotecan	48	0.01	53,850	0.02
84 Idarubicin	31	0.01	20,901	0.01
85 Aldesleukin	30	0.01	26,702	0.01
86 Epoprostenol	29	0.01	231,451	0.08
87 Chorionic Gonadotrophin	18	0.00	149	0.00
88 Degarelix	15	0.00	4,118	0.00
89 Urofollitropin	11	0.00	7,587	0.00
90 Interferon gamma	10	0.00	9,975	0.00
91 Sodium Phenylbutyrate	6	0.00	5,423	0.00
92 Ambrisentan	4	0.00	11,489	0.00
93 Becaplermin	4	0.00	1,955	0.00
94 Follitropin alfa and Lutropin alfa	4	0.00	4,914	0.00
95 Everolimus	2	0.00	8,083	0.00
96 Miglustat	1	0.00	1,136	0.00
Total	369,674	100.00%	€279,613,031	100.00%

Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.

Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
1	Adalimumab	46,250,835	16.54	33,726	9.12
2	Etanercept	38,064,481	13.61	33,436	9.05
3	Interferon beta-1a	16,380,502	5.86	14,143	3.83
4	Pegfilgrastim	13,704,084	4.90	11,005	2.98
5	Interferon beta-1b	10,329,522	3.70	8,766	2.37
6	Erythropoietin	10,132,560	3.62	13,990	3.78
7	Lenalidomide	9,766,472	3.49	1,401	0.38
8	Darbepoetin alfa	8,047,667	2.88	16,842	4.56
9	Imatinib	7,938,190	2.84	2,876	0.78
10	Tacrolimus	7,150,988	2.56	26,352	7.13
11	Somatropin	6,442,636	2.31	8,980	2.43
12	Glatiramer Acetate	5,992,555	2.14	4,906	1.33
13	Leuprorelin	5,594,792	2.00	11,504	3.11
14	Bosentan	5,546,219	1.98	1,805	0.49
15	Mycophenolic Acid	5,512,786	1.97	25,738	6.96
16	Triptorelin	5,005,534	1.79	13,806	3.73
17	Teriparatide	4,752,634	1.70	10,390	2.81
18	Tobramycin	4,638,011	1.66	1,721	0.47
19	Dornase alfa	4,286,258	1.53	4,437	1.20
20	Palivizumab	3,435,810	1.23	3,252	0.88
21	Follitropin beta	3,127,510	1.12	3,611	0.98
22	Filgrastim	3,093,726	1.11	4,241	1.15
23	Octreotide	3,001,573	1.07	2,545	0.69
24	Sunitinib	2,794,283	1.00	778	0.21
25	Erlotinib	2,402,891	0.86	1,070	0.29
26	Sorafenib	2,313,418	0.83	672	0.18
27	Temozolomide	2,286,281	0.82	2,043	0.55
28	Ciclosporin	2,191,614	0.78	18,599	5.03
29	Goserelin	2,180,924	0.78	6,361	1.72
30	Bicalutamide	2,060,709	0.74	23,777	6.43
31	Voriconazole	1,987,078	0.71	788	0.21
32	Peginterferon alfa-2a	1,953,650	0.70	1,962	0.53
33	Follitropin alfa	1,877,592	0.67	1,763	0.48
34	Cinacalcet	1,865,312	0.67	5,669	1.53
35	Sildenafil	1,836,689	0.66	2,365	0.64

Note: Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.

Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost continued

	Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
36	Linezolid	1,804,785	0.65	1,229	0.33
37	Valganciclovir	1,654,167	0.59	1,025	0.28
38	Capecitabine	1,587,595	0.57	6,280	1.70
39	Ribavirin	1,449,229	0.52	2,434	0.66
40	Dasatinib	1,331,190	0.48	298	0.08
41	Human Menopausal Gonadotrophin	1,093,959	0.39	1,674	0.45
42	Lapatinib	1,029,154	0.37	455	0.12
43	Pegvisomant	980,308	0.35	234	0.06
44	Methoxy Polyethylene Glycol-Epoietin beta	975,412	0.35	4,312	1.17
45	Lanreotide	886,540	0.32	812	0.22
46	Nilotinib	841,888	0.30	182	0.05
47	Thalidomide	819,342	0.29	1,179	0.32
48	Sitaxentan	794,701	0.28	307	0.08
49	Deferasirox	764,991	0.27	777	0.21
50	Posaconazole	721,853	0.26	415	0.11
51	Anagrelide	649,717	0.23	1,218	0.33
52	Riluzole	633,822	0.23	1,950	0.53
53	Fulvestrant	591,669	0.21	1,130	0.31
54	Iloprost	582,632	0.21	122	0.03
55	Peginterferon alfa-2b	538,317	0.19	890	0.24
56	Entecavir	502,035	0.18	869	0.24
57	Parathyroid Hormone	489,253	0.18	1,182	0.32
58	Interferon alfa-2b	459,549	0.16	651	0.18
59	Lutropin alfa	417,424	0.15	725	0.20
60	Anakinra	396,072	0.14	392	0.11
61	Adefovir Dipivoxil	393,090	0.14	716	0.19
62	Sirolimus	330,455	0.12	1,232	0.33
63	Ganirelix	304,038	0.11	993	0.27
64	Bexarotene	254,111	0.09	94	0.03
65	Epoprostenol	231,451	0.08	29	0.01
66	Efalizumab	191,543	0.07	168	0.05
67	Choriogonadotropin alfa	187,192	0.07	3,460	0.94
68	Ibandronic Acid	184,592	0.07	715	0.19
69	Fludarabine	178,641	0.06	227	0.06
70	Paricalcitol	155,960	0.06	897	0.24

Note: Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.

Table 19.8 HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost continued

Name	Ingredient Cost €	% of Scheme Total	Prescribing Frequency	% of Scheme Total
71 Lenograstim	155,452	0.06	197	0.05
72 Vinorelbine	152,846	0.05	390	0.11
73 Clodronic Acid	149,392	0.05	544	0.15
74 Nafarelin	132,531	0.05	801	0.22
75 Interferon alfa-2a	120,639	0.04	348	0.09
76 Lamivudine	110,508	0.04	1,119	0.30
77 Flutamide	58,448	0.02	439	0.12
78 Sodium Oxybate	56,500	0.02	86	0.02
79 Vancomycin (Oral)	55,814	0.02	273	0.07
80 Topotecan	53,850	0.02	48	0.01
81 Etoposide	40,869	0.01	410	0.11
82 Cetorelix	27,448	0.01	98	0.03
83 Risedronic Acid	26,999	0.01	115	0.03
84 Aldesleukin	26,702	0.01	30	0.01
85 Idarubicin	20,901	0.01	31	0.01
86 Buserelin	16,840	0.01	77	0.02
87 Ambrisentan	11,489	0.00	4	0.00
88 Interferon gamma	9,975	0.00	10	0.00
89 Everolimus	8,083	0.00	2	0.00
90 Urofollitropin	7,587	0.00	11	0.00
91 Sodium Phenylbutyrate	5,423	0.00	6	0.00
92 Follitropin alfa and Lutropin alfa	4,914	0.00	4	0.00
93 Degarelix	4,118	0.00	15	0.00
94 Becaplermin	1,955	0.00	4	0.00
95 Miglustat	1,136	0.00	1	0.00
96 Chorionic Gonadotrophin	149	0.00	18	0.00
Total	€279,613,031	100.00%	369,674	100.00%

Note: Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.

Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
A	Alimentary Tract and Metabolism	6,823,109	13.45	156,444,358	16.07
A01	Stomatological Preparations	94,625	0.19	354,012	0.04
A02	Drugs for Acid Related Disorders	2,998,458	5.91	100,396,882	10.31
A03	Drugs for Functional Gastrointestinal Disorders	472,807	0.93	2,385,512	0.25
A04	Anti-emetics and Antinauseants	20,363	0.04	2,306,181	0.24
A05	Bile and Liver Therapy	13,859	0.03	716,000	0.07
A06	Laxatives	713,646	1.41	6,250,788	0.64
A07	Antidiarrheals, Intestinal Anti-inflammatory/ Anti-infective Agents	239,558	0.47	5,026,408	0.52
A08	Anti-obesity Preparations, excl. Diet Products	73,417	0.14	4,712,569	0.48
A09	Digestives, incl. Enzymes	13,307	0.03	1,197,653	0.12
A10	Drugs used in Diabetes	1,146,550	2.26	24,430,197	2.51
A11	Vitamins	77,186	0.15	923,022	0.09
A12	Mineral Supplements	959,332	1.89	7,745,125	0.80
A14	Anabolic Agents for Systemic Use	1	0.00	9	0.00
B	Blood and Blood Forming Organs	4,432,675	8.74	32,919,001	3.38
B01	Antithrombotic Agents	3,661,585	7.22	31,091,880	3.19
B02	Antihemorrhagics	13,175	0.03	166,926	0.02
B03	Anti-anemic Preparations	757,903	1.49	1,660,105	0.17
B05	Blood Substitutes and Perfusion Solutions	12	0.00	90	0.00

Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
C	Cardiovascular System	12,321,274	24.29	226,213,848	23.24
C01	Cardiac Therapy	789,086	1.55	8,134,343	0.84
C02	Antihypertensives	308,676	0.61	8,623,756	0.89
C03	Diuretics	1,732,681	3.42	5,248,436	0.54
C04	Peripheral Vasodilators	51,957	0.10	846,580	0.09
C05	Vasoprotectives	121,485	0.24	839,740	0.09
C07	Beta Blocking Agents	1,911,958	3.77	14,239,792	1.46
C08	Calcium Channel Blockers	1,275,172	2.51	17,271,187	1.77
C09	Agents Acting on the Renin-Angiotensin System	2,921,226	5.76	54,842,291	5.63
C10	Lipid Modifying Agents	3,209,033	6.33	116,167,723	11.93
D	Dermatologicals	1,359,233	2.68	13,257,482	1.36
D01	Antifungals for Dermatological Use	319,460	0.63	2,943,463	0.30
D02	Emollients and Protectives	207,339	0.41	582,987	0.06
D03	Preparations for Treatment of Wounds and Ulcers	662	0.00	16,242	0.00
D05	Antipsoriatics	65,290	0.13	3,688,185	0.38
D06	Antibiotics and Chemotherapeutics for Dermatological Use	134,619	0.27	1,224,789	0.13
D07	Corticosteroids, Dermatological Preparations	563,489	1.11	3,075,790	0.32
D10	Anti-Acne Preparations	52,659	0.10	906,580	0.09
D11	Other Dermatological Preparations	15,715	0.03	819,446	0.08
G	Genito Urinary System and Sex Hormones	1,768,748	3.49	38,309,216	3.94
G01	Gynecological Anti-infectives and Antiseptics	24,707	0.05	134,971	0.02
G02	Other Gynecologicals	21,821	0.04	1,681,502	0.17
G03	Sex Hormones and Modulators of the Genital System	892,906	1.76	7,890,023	0.81
G04	Urologicals	829,314	1.64	28,602,720	2.94

Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
H	Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins	1,604,245	3.16	5,230,939	0.54
H01	Pituitary, Hypothalamic Hormones and Analogues	13,175	0.03	760,126	0.08
H02	Corticosteroids for Systemic Use	549,069	1.08	2,151,208	0.22
H03	Thyroid Therapy	1,035,243	2.04	2,111,145	0.22
H04	Pancreatic Hormones	6,603	0.01	202,008	0.02
H05	Calcium Homeostasis	155	0.00	6,452	0.00
J	Anti-infectives for Systemic Use	2,490,998	4.91	27,033,298	2.78
J01	Antibacterials for Systemic Use	2,362,181	4.66	22,344,481	2.30
J02	Antimycotics for Systemic Use	79,573	0.16	1,381,761	0.14
J04	Antimycobacterials	2,900	0.00	73,162	0.01
J05	Antivirals for Systemic Use	46,338	0.09	3,233,830	0.33
J07	Vaccines	6	0.00	64	0.00
L	Antineoplastic and Immunomodulating Agents	248,563	0.49	9,967,100	1.03
L01	Antineoplastic Agents	20,479	0.04	668,392	0.07
L02	Endocrine Therapy	95,477	0.19	7,664,951	0.79
L04	Immunosuppressive Agents	132,607	0.26	1,633,757	0.17

Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
M	Musculo-Skeletal System	3,224,421	6.36	55,518,015	5.71
M01	Anti-inflammatory and Antirheumatic Products	1,634,156	3.22	22,026,552	2.26
M02	Topical Products for Joint and Muscular Pain	557,064	1.10	4,349,790	0.45
M03	Muscle Relaxants	43,980	0.09	1,333,210	0.14
M04	Antigout Preparations	195,508	0.39	955,978	0.10
M05	Drugs for treatment of Bone Diseases	735,261	1.44	26,117,973	2.68
M09	Other Drugs for Disorders of the Musculo-Skeletal System	58,452	0.12	734,512	0.08
N	Nervous System	9,639,420	19.00	211,746,442	21.76
N01	Anesthetics	3,119	0.01	20,907	0.00
N02	Analgesics	2,377,371	4.69	30,167,025	3.10
N03	Anti-epileptics	930,816	1.83	40,134,381	4.12
N04	Antiparkinson Drugs	241,828	0.48	8,208,274	0.84
N05	Psycholeptics	3,524,727	6.95	55,715,039	5.73
N06	Psychoanaleptics	2,194,696	4.32	67,412,648	6.93
N07	Other Nervous System Drugs	366,863	0.72	10,088,168	1.04
P	Antiparasitic Products, Insecticides and Repellents	75,524	0.15	641,448	0.06
P01	Antiprotozoals	54,909	0.11	505,852	0.05
P02	Anthelmintics	8,585	0.02	23,661	0.00
P03	Ectoparasiticides, incl. Scabicides, Insecticides and Repellents	12,030	0.02	111,935	0.01

Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
R	Respiratory System	3,750,446	7.39	98,264,490	10.10
R01	Nasal Preparations	298,437	0.59	3,340,128	0.34
R02	Throat Preparations	11,595	0.02	26,803	0.00
R03	Drugs for Obstructive Airway Diseases	2,733,416	5.39	90,480,098	9.30
R05	Cough and Cold Preparations	352,058	0.69	1,396,577	0.15
R06	Antihistamines for Systemic Use	354,500	0.70	3,009,095	0.31
R07	Other Respiratory System Products	440	0.00	11,789	0.00
S	Sensory Organs	1,214,434	2.40	13,177,562	1.35
S01	Ophthalmologicals	1,128,761	2.23	12,844,628	1.32
S02	Otologicals	39,663	0.08	205,943	0.02
S03	Ophthalmological and Otological Preparations	46,010	0.09	126,991	0.01
V	Various	1,768,829	3.49	84,626,045	8.69
V01	Allergens	99	0.00	8,802	0.00
V03	Other Therapeutic Products	14,579	0.03	2,578,263	0.26
V04	Diagnostic Products	425,437	0.84	16,387,335	1.68
V06	Clinical Nutritional Products	553,149	1.09	41,382,430	4.25
V07	All Other Non-Therapeutic Products	775,565	1.53	24,269,215	2.50
	<i>Needles/Syringes/Lancets</i>	231,985	0.46	3,259,767	0.33
	<i>Ostomy Requisites</i>	70,784	0.14	12,619,818	0.69
	<i>Urinary Requisites</i>	25,856	0.05	6,670,509	0.11
	<i>Dressings</i>	122,742	0.24	1,079,813	1.30
	<i>Miscellaneous</i>	324,198	0.64	639,308	0.07
	TOTAL	50,721,919	100.00%	€973,349,244	100.00%

Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
A	Alimentary Tract and Metabolism	1,559,672	11.66	43,595,868	15.20
A01	Stomatological Preparations	22,687	0.17	84,793	0.03
A02	Drugs for Acid Related Disorders	851,403	6.37	30,592,032	10.66
A03	Drugs for Functional Gastrointestinal Disorders	111,518	0.83	647,285	0.23
A04	Anti-emetics and Antinauseants	9,090	0.07	846,281	0.30
A05	Bile and Liver Therapy	6,533	0.05	405,799	0.14
A06	Laxatives	80,688	0.60	736,273	0.26
A07	Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents	102,717	0.77	4,405,527	1.54
A08	Anti-obesity Preparations, excl. Diet Products	40,992	0.30	2,601,804	0.91
A09	Digestives, incl. Enzymes	2,095	0.01	114,387	0.04
A10	Drugs used in Diabetes	58,613	0.44	787,424	0.27
A11	Vitamins	16,850	0.13	241,199	0.08
A12	Mineral Supplements	256,451	1.92	2,130,409	0.74
A14	Anabolic Agents for Systemic Use	3	0.00	58	0.00
A16	Other Alimentary Tract/Metabolism Products	32	0.00	2,597	0.00
B	Blood and Blood Forming Organs	1,037,575	7.76	9,336,007	3.26
B01	Antithrombotic Agents	911,988	6.82	8,997,610	3.14
B02	Antihemorrhagics	4,169	0.03	54,459	0.02
B03	Anti-anemic Preparations	121,413	0.91	283,846	0.10
B05	Blood Substitutes and Perfusion Solutions	5	0.00	92	0.00

Note: The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.

Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
C	Cardiovascular System	3,601,729	26.94	78,796,091	27.47
C01	Cardiac Therapy	101,663	0.76	1,559,963	0.55
C02	Antihypertensives	81,109	0.61	2,316,295	0.81
C03	Diuretics	259,023	1.94	1,122,128	0.39
C04	Peripheral Vasodilators	3,666	0.03	60,236	0.02
C05	Vasoprotectives	42,434	0.32	295,155	0.10
C07	Beta Blocking Agents	554,996	4.15	4,284,219	1.49
C08	Calcium Channel Blockers	336,512	2.51	4,479,268	1.56
C09	Agents Acting on the Renin-Angiotensin System	973,422	7.28	19,382,914	6.76
C10	Lipid Modifying Agents	1,248,904	9.34	45,295,913	15.79
D	Dermatologicals	442,876	3.31	9,199,328	3.21
D01	Antifungals for Dermatological Use	104,088	0.78	1,401,726	0.49
D02	Emollients and Protectives	27,833	0.21	90,140	0.03
D03	Preparations for Treatment of Wounds and Ulcers	428	0.00	60,858	0.02
D04	Antipruritics including Antihistamines, Anesthetics, etc.	588	0.00	35,397	0.01
D05	Antipsoriatics	46,827	0.35	3,813,304	1.33
D06	Antibiotics and Chemotherapeutics for Dermatological Use	35,747	0.27	533,248	0.19
D07	Corticosteroids Dermatological Preparations	166,717	1.25	975,390	0.34
D08	Antiseptics and Disinfectants	11	0.00	38	0.00
D10	Anti-Acne Preparations	48,280	0.36	1,539,238	0.54
D11	Other Dermatological Preparations	12,357	0.09	749,989	0.26
G	Genito Urinary System and Sex Hormones	593,570	4.44	16,480,453	5.74
G01	Gynecological Anti-infectives and Antiseptics	6,136	0.05	36,147	0.01
G02	Other Gynecologicals	19,312	0.14	1,949,954	0.68
G03	Sex Hormones and Modulators of the Genital System	345,434	2.58	7,116,609	2.48
G04	Urologicals	222,688	1.67	7,377,743	2.57

Note: The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.

Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
H	Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins	524,685	3.92	1,923,714	0.67
H01	Pituitary, Hypothalamic Hormones and Analogues	6,368	0.05	470,058	0.17
H02	Corticosteroids for Systemic Use	171,292	1.28	725,638	0.25
H03	Thyroid Therapy	346,784	2.59	719,965	0.25
H04	Pancreatic Hormones	186	0.00	5,679	0.00
H05	Calcium Homeostasis	55	0.00	2,374	0.00
J	Anti-infectives for Systemic Use	723,985	5.42	10,441,739	3.64
J01	Antibacterials for Systemic Use	657,941	4.92	7,298,678	2.55
J02	Antimycotics for Systemic Use	35,829	0.27	699,435	0.24
J04	Antimycobacterials	2,450	0.02	85,040	0.03
J05	Antivirals for Systemic Use	27,760	0.21	2,358,548	0.82
J07	Vaccines	5	0.00	38	0.00
L	Antineoplastic and Immunomodulating Agents	115,518	0.86	4,342,207	1.51
L01	Antineoplastic Agents	8,342	0.06	423,646	0.15
L02	Endocrine Therapy	32,279	0.24	2,845,698	0.99
L04	Immunosuppressive Agents	74,897	0.56	1,072,863	0.37

Note: The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.

Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
M	Musculo-Skeletal System	953,952	7.13	17,299,093	6.03
M01	Anti-inflammatory and Antirheumatic Products	559,410	4.18	8,411,887	2.93
M02	Topical Products for Joint and Muscular Pain	98,786	0.74	780,695	0.27
M03	Muscle Relaxants	5,295	0.04	131,692	0.05
M04	Antigout Preparations	68,672	0.51	370,582	0.13
M05	Drugs for treatment of Bone Diseases	212,305	1.59	7,400,175	2.58
M09	Other Drugs for Disorders of the Musculo-Skeletal System	9,484	0.07	204,062	0.07
N	Nervous System	2,002,641	14.97	47,020,936	16.39
N01	Anesthetics	3,074	0.02	671,318	0.23
N02	Analgesics	429,273	3.21	7,043,093	2.46
N03	Anti-epileptics	174,170	1.30	9,099,790	3.17
N04	Antiparkinson Drugs	24,207	0.18	963,804	0.34
N05	Psycholeptics	680,876	5.09	9,272,962	3.23
N06	Psychoanaleptics	631,896	4.73	17,633,721	6.15
N07	Other Nervous System Drugs	59,145	0.44	2,336,248	0.81
P	Antiparasitic Products, Insecticides and Repellents	39,365	0.30	1,068,892	0.37
P01	Antiprotozoals	37,539	0.28	1,050,625	0.37
P02	Anthelmintics	795	0.01	6,480	0.00
P03	Ectoparasiticides, incl. Scabicides, Insecticides and Repellents	1,031	0.01	11,787	0.00

Note: The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.

Table 20.1 DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
R	Respiratory System	1,281,721	9.58	33,158,341	11.56
R01	Nasal Preparations	166,948	1.25	1,979,040	0.69
R02	Throat Preparations	2,825	0.02	6,109	0.00
R03	Drugs for Obstructive Airway Diseases	914,645	6.84	29,618,540	10.33
R05	Cough and Cold Preparations	51,593	0.38	224,557	0.08
R06	Antihistamines for Systemic Use	145,683	1.09	1,329,459	0.46
R07	Other Respiratory System Products	27	0.00	636	0.00
S	Sensory Organs	261,519	1.96	2,767,866	0.97
S01	Ophthalmologicals	228,340	1.71	2,654,864	0.93
S02	Otologicals	11,397	0.09	61,522	0.02
S03	Ophthalmological and Otological Preparations	21,782	0.16	51,480	0.02
V	Various	233,717	1.75	11,421,362	3.98
V01	Allergens	853	0.01	72,749	0.03
V03	Other Therapeutic Products	2,045	0.02	324,846	0.11
V04	Diagnostic Products	19,386	0.14	678,577	0.24
V06	Clinical Nutritional Products	117,317	0.88	5,119,221	1.78
V07	All Other Non-Therapeutic Products	94,116	0.70	5,225,969	1.82
	<i>Ostomy Requisites</i>	38,497	0.29	3,520,075	1.23
	<i>Needles/Syringes/Lancets</i>	22,325	0.17	131,383	0.05
	<i>Dressings</i>	8,896	0.06	226,846	0.08
	<i>Urinary Requisites</i>	9,937	0.07	1,219,839	0.42
	<i>Miscellaneous</i>	14,461	0.11	127,826	0.04
	TOTAL	13,372,525	100.00%	286,851,897	100.00%

Note: The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.

Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
A	Alimentary Tract and Metabolism	740,528	25.93	23,252,100	27.59
A01	Stomatological Preparations	589	0.02	3,356	0.00
A02	Drugs for Acid Related Disorders	23,708	0.83	866,735	1.03
A03	Drugs for Functional Gastrointestinal Disorders	1,997	0.07	51,966	0.06
A04	Anti-emetics and Antinauseants	1,436	0.05	56,581	0.07
A05	Bile and Liver Therapy	923	0.03	48,719	0.06
A06	Laxatives	8,062	0.28	78,754	0.09
A07	Antidiarrheals, Intestinal Anti-inflammatory/ Anti-infective Agents	1,192	0.04	33,177	0.04
A08	Anti-obesity Preparations, excl. Diet Products	3,975	0.14	251,915	0.30
A09	Digestives, incl. Enzymes	7,896	0.28	867,294	1.03
A10	Drugs Used in Diabetes	668,001	23.40	20,214,746	23.99
A11	Vitamins	13,247	0.46	345,861	0.41
A12	Mineral Supplements	7,419	0.26	67,580	0.08
A13	Tonics	27	0.00	239	0.00
A14	Anabolic Agents for Systemic Use	1	0.00	284	0.00
A16	Other Alimentary Tract and Metabolism Products	2,055	0.07	364,893	0.43
B	Blood and Blood Forming Organs	305,410	10.70	1,657,098	1.97
B01	Antithrombotic Agents	284,409	9.96	1,557,092	1.85
B02	Antihemorrhagics	1,063	0.04	13,536	0.02
B03	Anti-anemic Preparations	19,537	0.69	32,625	0.04
B05	Blood Substitutes and Perfusion Solutions	401	0.01	53,845	0.06

Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
C	Cardiovascular System	851,765	29.83	19,641,325	23.30
C01	Cardiac Therapy	12,221	0.43	138,225	0.16
C02	Antihypertensives	25,809	0.90	835,189	0.99
C03	Diuretics	45,970	1.61	206,678	0.24
C04	Peripheral Vasodilators	767	0.03	15,998	0.02
C05	Vasoprotectives	193	0.01	1,508	0.00
C07	Beta Blocking Agents	89,798	3.14	720,866	0.86
C08	Calcium Channel Blockers	77,979	2.73	1,106,558	1.31
C09	Agents Acting on the Renin-Angiotensin System	294,214	10.30	5,469,682	6.49
C10	Lipid Modifying Agents	304,814	10.68	11,146,621	13.23
D	Dermatologicals	6,397	0.22	79,430	0.09
D01	Antifungals for Dermatological Use	2,298	0.08	25,274	0.03
D02	Emollients and Protectives	1,221	0.04	7,519	0.01
D03	Preparations for Treatment of Wounds and Ulcers	21	0.00	364	0.00
D04	Antipruritics, incl. Antihistamines, Anesthetics, etc.	80	0.00	2,019	0.00
D05	Antipsoriatics	292	0.01	23,586	0.03
D06	Antibiotics and Chemotherapeutics for Dermatological Use	365	0.01	3,751	0.00
D07	Corticosteroids, Dermatological Preparations	1,263	0.04	7,062	0.01
D08	Antiseptics and Disinfectants	438	0.02	2,930	0.00
D10	Anti-Acne Preparations	140	0.01	1,571	0.00
D11	Other Dermatological Preparations	279	0.01	5,354	0.01
G	Genito Urinary System and Sex Hormones	33,446	1.17	1,079,176	1.28
G01	Gynecological Anti-infectives and Antiseptics	98	0.00	18,648	0.02
G02	Other Gynecologicals	93	0.00	6,622	0.01
G03	Sex Hormones and Modulators of the Genital System	2,215	0.08	44,721	0.05
G04	Urologicals	31,040	1.09	1,009,185	1.20

Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
H	Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins	34,015	1.20	437,979	0.52
H01	Pituitary, Hypothalamic Hormones and Analogues	2,162	0.08	150,361	0.18
H02	Corticosteroids for Systemic Use	3,402	0.12	20,462	0.02
H03	Thyroid Therapy	20,828	0.73	47,322	0.06
H04	Pancreatic Hormones	7,606	0.27	218,679	0.26
H05	Calcium Homeostasis	17	0.00	1,155	0.00
J	Anti-infectives for Systemic Use	19,046	0.67	1,160,726	1.38
J01	Antibacterials for Systemic Use	17,961	0.63	1,106,848	1.31
J02	Antimycotics for Systemic Use	647	0.02	28,419	0.03
J04	Antimycobacterials	103	0.01	3,565	0.01
J05	Antivirals for Systemic Use	319	0.01	21,735	0.03
J07	Vaccines	16	0.00	159	0.00
L	Antineoplastic and Immunomodulating Agents	1,578	0.05	54,774	0.06
L01	Antineoplastic Agents	352	0.01	27,081	0.03
L02	Endocrine Therapy	82	0.00	8,176	0.01
L04	Immunosuppressive Agents	1,144	0.04	19,517	0.02

Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
M	Musculo-Skeletal System	19,798	0.69	413,344	0.49
M01	Anti-inflammatory and Antirheumatic Products	5,751	0.20	77,796	0.09
M02	Topical Products for Joint and Muscular Pain	641	0.02	4,830	0.00
M03	Muscle Relaxants	6,322	0.22	207,493	0.25
M04	Antigout Preparations	3,712	0.13	22,220	0.03
M05	Drugs for treatment of Bone Diseases	2,732	0.10	94,359	0.11
M09	Other Drugs for Disorders of the Musculo-Skeletal System	640	0.02	6,646	0.01
N	Nervous System	308,905	10.82	13,236,034	15.71
N01	Anesthetics	285	0.01	25,756	0.03
N02	Analgesics	10,017	0.35	109,124	0.13
N03	Anti-epileptics	229,761	8.05	8,991,184	10.67
N04	Antiparkinson Drugs	29,869	1.05	2,966,229	3.52
N05	Psycholeptics	20,585	0.72	453,011	0.54
N06	Psychoanaleptics	16,606	0.58	586,989	0.70
N07	Other Nervous System Drugs	1,782	0.06	103,741	0.12
P	Antiparasitic Products, Insecticides and Repellents	126	0.00	1,377	0.00
P01	Antiprotozoals	118	0.00	1,280	0.00
P02	Anthelmintics	4	0.00	48	0.00
P03	Ectoparasitocides, incl. Scabicides, Insecticides and Repellents	4	0.00	49	0.00

Table 20.2 LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
R	Respiratory System	16,074	0.56	443,749	0.53
R01	Nasal Preparations	1,569	0.05	19,107	0.03
R02	Throat Preparations	40	0.00	273	0.00
R03	Drugs for Obstructive Airway Diseases	11,583	0.41	363,755	0.43
R05	Cough and Cold Preparations	1,088	0.04	41,588	0.05
R06	Antihistamines for Systemic Use	1,794	0.06	19,026	0.02
S	Sensory Organs	9,568	0.34	154,189	0.18
S01	Ophthalmologicals	9,307	0.33	153,297	0.18
S02	Otologicals	89	0.00	451	0.00
S03	Ophthalmological and Otological Preparations	172	0.01	441	0.00
V	Various	508,705	17.82	22,668,344	26.90
V03	Other Therapeutic Products	363	0.01	60,599	0.07
V04	Diagnostic Products	289,993	10.16	13,137,046	15.59
V06	Clinical Nutritional Products	34,323	1.20	4,287,817	5.09
V07	All Other Non-Therapeutic Products	184,026	6.45	5,182,882	6.15
	<i>Needles/Syringes/Lancets/Swabs</i>	158,723	5.56	3,678,601	4.36
	<i>Urinary Requisites</i>	6,850	0.24	790,351	0.94
	<i>Dressings</i>	2,107	0.08	115,545	0.14
	<i>Nutritional/Ancillary Devices</i>	2,230	0.08	329,525	0.39
	<i>Ostomy Requisites</i>	1,236	0.04	115,441	0.14
	<i>Miscellaneous</i>	12,880	0.45	153,419	0.18
	TOTAL	2,855,361	100.00%	€84,279,645	100.00%

Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
A	Alimentary Tract and Metabolism	1,177	0.32	218,333	0.08
A07A	Intestinal Anti-infectives	273	0.08	55,814	0.02
AIICC	Vitamin D and Analogues	897	0.24	155,960	0.06
AI6AX	Other Alimentary Tract and Metabolism Products	7	0.00	6,559	0.00
B	Blood and Blood Forming Organs	35,295	9.55	19,969,722	7.14
B01	Antithrombotic Agents	151	0.04	814,083	0.29
B03	Anti-anemic Preparations	35,144	9.51	19,155,639	6.85
C	Cardiovascular System	4,481	1.21	8,189,098	2.93
C02	Antihypertensives	4,481	1.21	8,189,098	2.93
D	Dermatologicals	4	0.00	1,955	0.00
D03A	Cicatrizants	4	0.00	1,955	0.00
G	Genito Urinary System and Sex Hormones	11,266	3.05	6,716,327	2.40
G03GA	Gonadotropins	11,266	3.05	6,716,327	2.40

Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.

Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
H	Systemic Hormonal Preparations, Excl.Sex Hormones and Insulins	31,704	8.58	18,882,273	6.75
H01	Pituitary and Hypothalamic Hormones and Analogues	14,463	3.91	11,775,074	4.21
H05	Calcium Homeostasis	17,241	4.67	7,107,199	2.54
J	Anti-infectives for Systemic Use	13,568	3.67	16,696,567	5.98
J01	Antibacterials for Systemic Use	2,950	0.80	6,442,796	2.31
J02	Antimycotics for Systemic Use	1,203	0.32	2,708,931	0.97
J05	Antivirals for Systemic Use	6,163	1.67	4,109,030	1.47
J06	Immune Sera and Immunoglobulins	3,252	0.88	3,435,810	1.23
L	Antineoplastic and Immunomodulating Agents	263,555	71.29	202,836,203	72.54
L01	Antineoplastic Agents	17,074	4.62	23,883,907	8.54
L02	Endocrine Therapy	57,109	15.45	15,513,034	5.55
L03	Immunostimulants	47,149	12.75	52,764,673	18.87
L04	Immunosuppressive Agents	142,223	38.47	110,674,589	39.58

Note: Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.

Table 20.3 HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued

ATC Class	Product Category	Prescribing Frequency	% of Scheme Total	Ingredient Cost €	% of Scheme Total
M	Musculo-Skeletal System	1,374	0.37	360,983	0.13
M05	Drugs for treatment of Bone Diseases	1,374	0.37	360,983	0.13
N	Nervous System	2,036	0.55	690,322	0.25
N07XX	Other Nervous System Drugs	2,036	0.55	690,322	0.25
R	Respiratory System	4,437	1.20	4,286,257	1.53
R05CB	Mucolytics (Inhaled)	4,437	1.20	4,286,257	1.53
V	Various	777	0.21	764,991	0.27
V03AC	Iron Chelating Agents	777	0.21	764,991	0.27
	TOTAL	369,674	100.00%	€279,613,031	100.00%

Note: Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.

Table 21 GMS: Average Payment to Doctors in Panel Ranges

Health Service Executive	Average Panel Ranges in 2009							
	0-100 €	101-250 €	251-500 €	501-1,000 €	1,001-1,500 €	1,501-2,000 €	2,001 and Over €	
East Coast Area	15,279 (77)	85,593 (31)	157,384 (51)	234,237 (60)	361,501 (11)	-	-	
South Western Area	15,478 (63)	63,515 (23)	121,898 (36)	227,180 (95)	328,271 (46)	425,877 (21)	483,482 (3)	
Northern Area	16,066 (56)	65,371 (22)	122,413 (42)	239,768 (68)	346,588 (45)	459,716 (11)	532,054 (3)	
Midland	23,735 (21)	76,830 (3)	109,937 (14)	252,787 (44)	364,918 (34)	448,608 (12)	-	
Mid-Western	22,823 (35)	57,632 (6)	132,646 (36)	245,785 (81)	338,927 (32)	472,387 (12)	457,692 (1)	
North Eastern	6,198 (15)	41,519 (7)	142,990 (16)	220,634 (69)	305,788 (51)	411,289 (11)	467,314 (3)	
North Western	6,813 (11)	66,783 (7)	140,139 (21)	227,026 (49)	361,607 (39)	452,381 (15)	582,575 (3)	
South Eastern	5,770 (25)	65,410 (8)	117,993 (22)	225,532 (119)	338,593 (56)	460,045 (19)	482,765 (1)	
Southern	16,632 (72)	61,304 (49)	134,834 (61)	242,880 (155)	382,304 (63)	450,553 (10)	639,191 (3)	
Western	11,961 (38)	62,857 (13)	135,449 (42)	255,667 (106)	364,080 (51)	512,633 (9)	509,750 (1)	
National 2009	€15,285 (413)	€66,456 (169)	€133,757 (341)	€237,477 (846)	€348,688 (428)	€451,852 (120)	€531,336 (18)	
National 2008	€20,917 (235)	€74,466 (173)	€145,290 (367)	€246,041 (846)	€351,858 (375)	€465,472 (82)	€530,293 (7)	

Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.

(ii) The number of Doctors in each range is shown in brackets.

(iii) The average payment to Doctors in each panel range is the gross payments divided by the number of Doctors in that range.

(iv) Doctors payment is exclusive of superannuation paid to retired DMOs.

Table 21.1 GMS: Number of Doctors in Payment Ranges

2009 (2008 in brackets)

Health Service Executive	Up to €30,000	€30,001-€60,000	€60,001-€90,000	€90,001-€120,000	€120,001-€150,000	€150,001-€180,000	€180,001-€210,000	€210,001-€240,000	€240,001-€270,000	€270,001-€370,000	€370,001-€470,000	€470,001 and Over
East Coast Area	24 (17)	15 (9)	19 (14)	20 (22)	19 (9)	16 (21)	11 (19)	21 (14)	17 (8)	18 (36)	2 (8)	1 (2)
South Western Area	21 (29)	21 (18)	16 (19)	13 (20)	25 (17)	18 (20)	22 (18)	17 (12)	20 (19)	47 (48)	20 (25)	5 (8)
Northern Area	21 (28)	11 (8)	21 (23)	14 (12)	11 (12)	17 (21)	15 (13)	18 (13)	22 (13)	40 (41)	13 (21)	6 (11)
Midland	9 (15)	3 (6)	5 (7)	8 (2)	4 (4)	5 (8)	6 (6)	13 (10)	12 (11)	35 (32)	13 (21)	4 (3)
Mid-Western	17 (21)	7 (5)	6 (7)	11 (11)	15 (12)	16 (13)	16 (15)	22 (24)	18 (18)	37 (34)	17 (18)	4 (6)
North Eastern	9 (4)	3 (5)	8 (7)	5 (6)	14 (15)	10 (7)	18 (18)	16 (17)	17 (16)	47 (41)	13 (10)	2 (4)
North Western	5 (6)	4 (2)	5 (5)	8 (6)	11 (8)	7 (6)	11 (15)	13 (11)	13 (11)	31 (38)	23 (19)	7 (6)
South Eastern	9 (8)	4 (3)	8 (13)	12 (10)	10 (8)	19 (24)	28 (29)	30 (22)	19 (24)	66 (63)	15 (15)	10 (8)
Southern	33 (45)	30 (32)	30 (28)	24 (21)	22 (19)	27 (28)	28 (23)	38 (34)	35 (34)	63 (75)	33 (28)	9 (11)
Western	20 (19)	8 (13)	14 (13)	17 (10)	15 (20)	15 (16)	19 (15)	24 (18)	21 (20)	53 (59)	24 (25)	9 (10)
National	168 (192)	106 (101)	132 (136)	132 (120)	146 (124)	150 (164)	174 (171)	212 (175)	194 (174)	437 (467)	173 (190)	57 (69)

Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.

(ii) Above table relates to the payments listed in Table 3.

(iii) Doctors payment is exclusive of superannuation paid to retired DMOs.

Table 22 GMS: Number of Pharmacists in Dispensing Fee Ranges

2009 (2008 in brackets)

Health Service Executive	Up to €20,000	€20,001-€40,000	€40,001-€60,000	€60,001-€80,000	€80,001-€100,000	€100,001-€120,000	€120,001-€140,000	€140,001-€160,000	€160,001-€180,000	€180,001-€200,000	€200,001-€220,000	€220,001-€240,000	€240,001 and over
East Coast Area	6 (9)	5 (7)	12 (13)	16 (17)	15 (14)	20 (13)	8 (11)	15 (10)	7 (7)	5 (5)	7 (2)	6 (4)	10 (12)
South Western Area	5 (17)	13 (21)	20 (16)	15 (16)	22 (24)	17 (16)	17 (19)	15 (8)	8 (12)	18 (9)	7 (11)	7 (6)	36 (25)
Northern Area	6 (6)	9 (18)	17 (12)	17 (19)	16 (15)	13 (13)	15 (12)	18 (14)	12 (13)	8 (5)	6 (4)	7 (7)	38 (30)
Midland	- (2)	1 (4)	4 (6)	5 (4)	7 (7)	7 (9)	4 (3)	6 (6)	12 (11)	6 (8)	9 (4)	4 (6)	27 (19)
Mid-Western	2 (3)	5 (9)	12 (15)	9 (4)	5 (15)	12 (16)	14 (16)	14 (10)	11 (11)	10 (7)	10 (10)	13 (9)	25 (20)
North Eastern	3 (8)	8 (13)	11 (8)	11 (9)	7 (11)	15 (16)	14 (14)	13 (17)	14 (10)	11 (5)	8 (8)	4 (1)	26 (19)
North Western	- (4)	5 (5)	4 (2)	3 (9)	6 (6)	11 (9)	8 (10)	6 (6)	9 (9)	6 (6)	9 (3)	2 (2)	21 (17)
South Eastern	2 (4)	2 (7)	8 (10)	7 (3)	4 (17)	18 (18)	17 (14)	15 (12)	10 (14)	15 (9)	11 (11)	16 (11)	45 (35)
Southern	4 (7)	10 (10)	11 (12)	16 (25)	19 (18)	22 (19)	20 (23)	27 (21)	15 (27)	29 (7)	8 (9)	10 (10)	46 (32)
Western	2 (4)	4 (6)	13 (13)	10 (13)	12 (13)	12 (16)	15 (11)	12 (11)	13 (9)	7 (9)	9 (9)	11 (5)	38 (34)
National	30 (64)	62 (100)	112 (107)	109 (119)	113 (140)	147 (145)	132 (133)	141 (115)	111 (123)	115 (70)	84 (71)	80 (61)	312 (243)

Note: Pharmacies that entered or left the Scheme during the year are not included in the above table.

Table 23 DP: Number of Eligible Persons and Number and Cost of Pharmacists Claims

Health Service Executive	*Number of Persons Covered	Unique Number of Claimants	Number of Items	Cost per Item €	Gross Cost €	Net Cost per Claimant €	Paid by HSE €
Eastern Areas	539,188	243,837	5,294,426	34.43	182,280,180	442.50	107,898,970
Midland	101,708	42,258	846,125	32.73	27,689,784	377.56	15,954,793
Mid-Western	159,029	57,404	1,080,867	33.00	35,665,144	349.58	20,067,259
North Eastern	147,811	60,618	1,172,765	32.86	38,537,405	358.62	21,739,038
North Western	63,000	24,967	461,296	33.64	15,520,255	349.37	8,722,729
South Eastern	149,983	69,556	1,421,492	32.21	45,785,782	364.80	25,373,805
Southern	266,122	104,524	2,038,348	34.44	70,198,945	383.07	40,040,494
Western	160,607	59,963	1,057,206	34.08	36,029,819	335.73	20,131,101
National 2009	1,587,448	663,127	13,372,525	€33.78	€451,707,314	€391.97	€259,928,189
National 2008	1,624,413	687,587	13,907,438	€36.44	€506,805,684	€453.61	€311,898,446

Note: *As at 31st December 2009

Table 23.1 DP: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges

2009 (2008 in brackets)

Health Service Executive	Up to €20,000	€20,001-€40,000	€40,001-€60,000	€60,001-€80,000	€80,001-€100,000	€100,001-€120,000	€120,001-€140,000	€140,001-€160,000	€160,001-€180,000	€180,001-€200,000	€200,001-€220,000	€220,001-€240,000	€240,001 and over
East Coast Area	14 (14)	34 (19)	21 (23)	23 (19)	15 (13)	8 (13)	6 (6)	3 (7)	6 (2)	- (2)	2 (2)	1 (3)	- (4)
South Western Area	27 (19)	47 (44)	37 (23)	25 (29)	13 (17)	15 (15)	16 (10)	10 (8)	3 (7)	1 (10)	2 (7)	1 (3)	3 (8)
Northern Area	29 (21)	42 (26)	33 (21)	11 (21)	23 (14)	16 (12)	5 (11)	5 (16)	6 (6)	5 (1)	1 (8)	1 (3)	5 (10)
Midland	11 (6)	25 (17)	23 (15)	13 (18)	4 (8)	8 (5)	4 (9)	2 (3)	2 (2)	- (3)	- (1)	-	- (2)
Mid-Western	24 (20)	47 (28)	36 (32)	19 (23)	7 (17)	4 (10)	2 (5)	2 (4)	1 (1)	- (3)	- (1)	- (1)	-
North Eastern	30 (20)	45 (26)	26 (29)	13 (20)	10 (12)	9 (9)	7 (5)	5 (6)	- (5)	- (3)	- (4)	-	- (1)
North Western	33 (21)	30 (26)	18 (14)	3 (14)	4 (4)	1 (3)	- (2)	1 (1)	-	-	- (1)	-	-
South Eastern	35 (22)	42 (28)	42 (31)	24 (26)	15 (21)	5 (16)	5 (5)	1 (6)	- (6)	- (2)	-	1 (-)	- (2)
Southern	28 (16)	66 (39)	58 (45)	40 (36)	17 (34)	11 (17)	7 (7)	3 (6)	3 (7)	3 (3)	- (3)	- (2)	1 (6)
Western	44 (24)	43 (41)	33 (26)	18 (22)	11 (15)	6 (10)	3 (7)	- (5)	- (3)	-	- (1)	-	-
National	275 (183)	421 (294)	327 (259)	189 (228)	119 (155)	83 (110)	55 (67)	32 (62)	21 (39)	9 (25)	5 (28)	4 (12)	9 (33)

Note: (i) Pharmacies that entered or left the Scheme during the year are not included in the above table.

(ii) The above figures do not include the monthly co-payment of €100 paid by an individual or family to the Pharmacist.

Table 24 LTI: Number of Eligible Persons and Number and Cost of Pharmacists Claims

Health Service Executive	*Number of Eligible Persons	Unique Number of Claimants	Number of Items	Cost per Item €	Total Cost €	Cost per Claimant €
Eastern Areas	63,906	27,154	1,211,460	50.29	60,923,738	2,243.64
Midland	7,453	3,981	172,423	46.42	8,003,509	2,010.43
Mid-Western	8,647	4,640	188,257	45.73	8,608,387	1,855.26
North Eastern	10,241	5,956	265,117	48.84	12,947,603	2,173.88
North Western	7,207	4,065	184,643	48.71	8,994,083	2,212.57
South Eastern	13,602	7,014	313,172	45.26	14,174,555	2,020.89
Southern	9,259	7,891	328,991	50.39	16,577,276	2,100.78
Western	7,321	5,030	191,298	49.82	9,530,021	1,894.64
National 2009	127,636	65,731	2,855,361	€48.95	€139,759,172	€2,126.23
National 2008	120,407	62,934	2,643,424	€52.17	€137,898,995	€2,191.17

Note: * As at 31st December 2009

Table 24.1 LTI: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges

2009 (2008 in brackets)

Health Service Executive	Up to €10,000	€10,001 - €20,000	€20,001 - €30,000	€30,001 - €40,000	€40,001 - €50,000	€50,001 - €60,000	€60,001 and over
East Coast Area	12 (16)	28 (20)	31 (21)	17 (20)	12 (12)	10 (11)	23 (26)
South Western Area	19 (26)	40 (31)	47 (41)	23 (24)	17 (15)	20 (15)	34 (47)
Northern Area	23 (13)	36 (32)	29 (28)	29 (20)	16 (18)	20 (17)	29 (40)
Midland	15 (14)	27 (21)	15 (18)	15 (14)	9 (7)	5 (4)	6 (11)
Mid-Western	42 (37)	46 (39)	37 (38)	7 (15)	5 (4)	2 (6)	3 (6)
North Eastern	31 (30)	33 (24)	32 (34)	12 (16)	15 (11)	5 (9)	17 (15)
North Western	18 (19)	16 (14)	19 (13)	11 (16)	7 (5)	11 (8)	8 (11)
South Eastern	40 (34)	33 (25)	35 (34)	34 (31)	13 (20)	9 (9)	6 (12)
Southern	51 (41)	77 (70)	54 (45)	31 (36)	10 (9)	10 (6)	4 (11)
Western	52 (45)	50 (47)	25 (25)	22 (17)	5 (10)	2 (6)	2 (3)
National	303 (275)	386 (323)	324 (297)	201 (209)	109 (111)	94 (91)	132 (182)

Note: Pharmacies that entered or left the Scheme during the year are not included in the above table.

Table 25 EEA: Number and Cost of Pharmacists Claims

Health Service Executive	Number of Items	Cost per Item €	Total Cost €
East Coast Area	3,069	23.49	72,098
South Western Area	5,111	21.98	112,322
Northern Area	3,509	20.92	73,396
Midland	4,609	23.00	106,003
Mid-Western	10,139	22.87	231,847
North Eastern	5,407	25.72	139,049
North Western	10,878	22.29	242,507
South Eastern	8,732	22.90	199,920
Southern	19,539	22.20	433,731
Western	14,527	23.87	346,740
National 2009	85,520	€22.89	€1,957,613
National 2008	91,822	€24.46	€2,245,995

Table 26 DTS: Number of Treatments

Health Service Executive	Above the Line	Below the Line	Total
Eastern Areas	402,760	29,986	432,746
Midland	89,879	10,060	99,939
Mid-Western	119,984	15,466	135,450
North Eastern	127,435	14,711	142,146
North Western	84,965	6,108	91,073
South Eastern	177,103	23,680	200,783
Southern	258,768	24,635	283,403
Western	178,537	20,521	199,058
National 2009	1,439,431	145,167	1,584,598
National 2008	1,084,517	111,428	1,195,945

Table 26.1 DTS: Number of Dentists in Payment Ranges

2009 (2008 in brackets)

Health Service Executive	Up to €10,000	€10,001-€20,000	€20,001-€30,000	€30,001-€40,000	€40,001-€50,000	€50,001-€60,000	€60,001-€70,000	€70,001-€80,000	€80,001-€90,000	€90,001-€100,000	€100,001-€110,000	€110,001-€120,000	€120,001 and over
Eastern Areas	14 (15)	17 (22)	23 (17)	16 (16)	21 (21)	10 (7)	20 (12)	7 (12)	14 (14)	12 (16)	19 (6)	10 (3)	51 (40)
Midland	6 (1)	- (1)	2 (4)	- (1)	3 (2)	1 (2)	3 (5)	- (6)	3 (3)	4 (2)	2 (3)	6 (2)	19 (12)
Mid-Western	8 (8)	6 (9)	8 (8)	8 (8)	6 (8)	10 (6)	3 (7)	7 (7)	7 (2)	4 (5)	6 (2)	2 (3)	18 (13)
North Eastern	- (4)	3 (6)	3 (5)	- (2)	6 (8)	3 (4)	4 (3)	7 (3)	10 (9)	5 (2)	1 (3)	3 (1)	21 (14)
North Western	4 (3)	2 (1)	1 (1)	1 (2)	-	1 (1)	3 (1)	1 (-)	2 (4)	2 (2)	1 (4)	- (1)	17 (7)
South Eastern	6 (5)	1 (2)	1 (3)	4 (6)	3 (6)	9 (6)	5 (5)	8 (4)	2 (2)	5 (4)	5 (3)	3 (8)	36 (23)
Southern	18 (19)	21 (24)	30 (29)	24 (25)	17 (19)	15 (16)	19 (21)	17 (13)	17 (11)	10 (10)	13 (5)	7 (5)	26 (17)
Western	22 (14)	7 (6)	3 (5)	7 (7)	4 (2)	8 (8)	3 (3)	6 (7)	8 (4)	4 (3)	5 (4)	4 (7)	41 (22)
National	78 (69)	57 (71)	71 (72)	60 (67)	60 (66)	57 (50)	60 (57)	53 (52)	63 (49)	46 (44)	52 (30)	35 (30)	229 (148)

Note: Dentists who entered or left the Scheme during the year are not included in the above table.

Table 27 HSE-COS: Number of Treatments and Cost of Claims

Health Service Executive	Number of Treatments	Cost of Claims €
Eastern Areas	152,370	6,204,743
Midland	40,553	1,647,247
Mid-Western	54,305	2,111,555
North Eastern	40,353	1,553,308
North Western	44,020	1,638,602
South Eastern	85,279	3,247,259
Southern	87,626	3,464,502
Western	60,100	2,317,325
National 2009	564,606	€22,184,541
National 2008	530,282	€20,997,766

Note: Optometrists/Ophthalmologists were also paid in respect of: Health (Amendment) Act 1996 €72,238; Optical services for Teenagers €195,744; Optical services for Children €1,348,185.

Table 27.1 HSE-COS: Number of Optometrists/Ophthalmologists in Payment Ranges

2009 (2008 in brackets)

Health Service Executive	Up to €10,000	€10,001-€20,000	€20,001-€30,000	€30,001-€40,000	€40,001-€50,000	€50,001-€60,000	€60,001-€70,000	€70,001-€80,000	€80,001-€90,000	€90,001-€100,000	€100,001-€110,000	€110,001-€120,000	€120,001 and over
Eastern Areas	52 (48)	29 (28)	17 (20)	12 (13)	6 (6)	3 (5)	7 (4)	- (1)	1 (1)	1 (-)	2 (3)	- (2)	7 (5)
Midland	9 (12)	5 (2)	2 (3)	2 (5)	7 (6)	1 (2)	2 (1)	1 (-)	- (1)	-	-	1 (-)	1 (1)
Mid-Western	11 (10)	6 (3)	6 (7)	2 (2)	2 (4)	1 (1)	2 (1)	-	1 (-)	-	-	-	3 (3)
North Eastern	22 (19)	12 (10)	4 (6)	3 (2)	2 (3)	2 (2)	-	- (1)	2 (1)	-	-	-	-
North Western	6 (5)	4 (6)	5 (3)	1 (4)	5 (5)	3 (3)	1 (2)	-	1 (-)	-	-	-	1 (1)
South Eastern	13 (14)	12 (11)	5 (5)	3 (4)	4 (-)	2 (6)	3 (1)	2 (4)	3 (2)	2 (2)	- (1)	1 (-)	4 (2)
Southern	11 (13)	16 (19)	11 (9)	3 (6)	7 (6)	5 (4)	- (4)	2 (-)	-	-	1 (-)	-	3 (3)
Western	11 (11)	10 (16)	15 (8)	9 (12)	4 (-)	-	-	-	-	-	1 (-)	-	1 (2)
National	135 (132)	94 (95)	65 (61)	35 (48)	37 (30)	17 (23)	15 (13)	5 (6)	8 (5)	3 (2)	4 (4)	2 (2)	20 (17)

Note: Optometrists/Ophthalmologists who entered or left the Scheme during the year are not included in the above table.

Table 28 GMS: Investment in General Practice Development

Health Service Executive	2009 €	2008 €
Eastern Areas	1,285,694	1,816,863
Midland	71,214	303,491
Mid-Western	191,193	347,771
North Eastern	110,980	372,795
*North Western	-	-
South Eastern	209,684	262,712
Southern	247,531	394,323
Western	767,437	1,127,692
National	€2,883,733	€4,625,647

Note: The above are payments from the Indicative Drug Target Savings.

* No funds available to draw down in 2009.

